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Preamble
It is essential that the medical profession play a central role
in critically evaluating the evidence related to drugs, devices,
and procedures for the detection, management, or preven-
tion of disease. Properly applied, rigorous, expert analysis of
the available data documenting absolute and relative bene-
fits and risks of these therapies and procedures can improve
the effectiveness of care, optimize patient outcomes, and
favorably affect the cost of care by focusing resources on the
most effective strategies. One important use of such data is
the production of clinical practice guidelines that, in turn,
can provide a foundation for a variety of other applications
such as performance measures, appropriate use criteria,
clinical decision support tools, and quality improvement
tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly engaged in the production of guidelines in the area of
cardiovascular disease since 1980. The ACCF/AHA Task
Force on Practice Guidelines (Task Force) is charged withdeveloping, updating, and revising practice guidelines for
cardiovascular diseases and procedures, and the Task Force
directs and oversees this effort. Writing committees are
charged with assessing the evidence as an independent
group of authors to develop, update, or revise recommen-
dations for clinical practice.
Experts in the subject under consideration have been
selected from both organizations to examine subject-specific
data and write guidelines in partnership with representatives
from other medical practitioner and specialty groups. Writ-
ing committees are specifically charged to perform a formal
literature review; weigh the strength of evidence for or
against particular tests, treatments, or procedures; and
include estimates of expected health outcomes where data
exist. Patient-specific modifiers, comorbidities, and issues of
patient preference that may influence the choice of tests or
therapies are considered. When available, information from
studies on cost is considered, but data on efficacy and clinical
outcomes constitute the primary basis for recommendations
in these guidelines.
In analyzing the data and developing the recommenda-
tions and supporting text, the writing committee used
evidence-based methodologies developed by the Task Force
that are described elsewhere (1). The committee reviewed
and ranked evidence supporting current recommendations
with the weight of evidence ranked as Level A if the data
were derived from multiple randomized clinical trials or
meta-analyses. The committee ranked available evidence as
Level B when data were derived from a single randomized
trial or nonrandomized studies. Evidence was ranked as
Level C when the primary source of the recommendation
was consensus opinion, case studies, or standard of care. In
the narrative portions of these guidelines, evidence is gen-
erally presented in chronological order of development.
Studies are identified as observational, retrospective, pro-
spective, or randomized when appropriate. For certain
conditions for which inadequate data are available, recom-
mendations are based on expert consensus and clinical
experience and ranked as Level C. An example is the use of
penicillin for pneumococcal pneumonia, for which there are
no randomized trials and treatment is based on clinical
experience. When recommendations at Level C are sup-
ported by historical clinical data, appropriate references
(including clinical reviews) are cited if available. For issues
where sparse data are available, a survey of current practice
among the clinicians on the writing committee was the basis
for Level C recommendations, and no references are cited.
The schema for Classification of Recommendations and
Level of Evidence is summarized in Table 1, which also
illustrates how the grading system provides an estimate of
the size and the certainty of the treatment effect. A new
addition to the ACCF/AHA methodology is a separation of
the Class III recommendations to delineate whether the
recommendation is determined to be of “no benefit” or
associated with “harm” to the patient. In addition, in view of
the increasing number of comparative effectiveness studies,
nical co
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mendations for the comparative effectiveness of one treat-
ment/strategy with respect to another for Class of Recom-
mendation I and IIa, Level of Evidence A or B only have
been added.
The Task Force makes every effort to avoid actual,
potential, or perceived conflicts of interest that may arise as
a result of relationships with industry or other entities
(RWI) among the writing committee. Specifically, all mem-
bers of the writing committee, as well as peer reviewers of
the document, are asked to disclose all current relationships
and those 24 months before initiation of the writing effort
that may be perceived as relevant. All guideline recommen-
dations require a confidential vote by the writing committee
and must be approved by a consensus of the members
voting. Any writing committee member who develops a new
RWI during his or her tenure is required to notify guideline
Table 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpopulat
and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recom
to clinical trials. Even though randomized trials are not available, there may be a very clear cli
recommendations (Class I and IIa; Level of Evidence: A and B only), studies that support the use ostaff in writing. These statements are reviewed by the TaskForce and all members during each conference call and/or
meeting of the writing committee and are updated as
changes occur. For detailed information about guideline
policies and procedures, please refer to the ACCF/AHA
methodology and policies manual (1). Authors’ and peer
reviewers’ RWI pertinent to this guideline are disclosed in
Appendixes 1 and 2, respectively. Disclosure information
for the Task Force is available online at www.cardiosource.org/
ACC/About-ACC/Leadership/Guidelines-and-Documents-
Task-Forces.aspx. The work of the writing committee was
supported exclusively by the ACCF and AHA (and the
other partnering organizations) without commercial sup-
port. Writing committee members volunteered their time
for this effort.
The ACCF/AHA practice guidelines address patient pop-
ulations (and healthcare providers) residing in North America.
As such, drugs that are currently unavailable in North America
vidence
ch as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure,
tion is weak. Many important clinical questions addressed in the guidelines do not lend themselves
nsensus that a particular test or therapy is useful or effective. †For comparative effectiveness
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outside of North America, each writing committee reviews the
potential impact of different practice patterns and patient
populations on the treatment effect and the relevance to the
ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to
assist healthcare providers in clinical decision making by
describing a range of generally acceptable approaches for the
diagnosis, management, and prevention of specific diseases
or conditions. These practice guidelines represent a consen-
sus of expert opinion after a thorough review of the available
current scientific evidence and are intended to improve
patient care. The guidelines attempt to define practices that
meet the needs of most patients in most circumstances. The
ultimate judgment regarding care of a particular patient
must be made by the healthcare provider and patient in light
of all the circumstances presented by that patient. Thus,
there are situations in which deviations from these guide-
lines may be appropriate. Clinical decision making should
consider the quality and availability of expertise in the area
where care is provided. When these guidelines are used as
the basis for regulatory or payer decisions, the goal should be
improvement in quality of care. The Task Force recognizes
that situations arise for which additional data are needed to
better inform patient care; these areas will be identified
within each respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed.
Because lack of patient understanding and adherence may
adversely affect outcomes, physicians and other healthcare
providers should make every effort to engage the patient’s
active participation in prescribed medical regimens and
lifestyles.
The guidelines will be reviewed annually by the Task
Force and considered current unless they are updated,
revised, or withdrawn from distribution. The executive
summary and recommendations are published in the Journal
of the American College of Cardiology, Circulation, Catheter-
ization and Cardiovascular Interventions, the Journal of
ardiovascular Computed Tomography, the Journal of Neuro-
nterventional Surgery, Stroke, and Vascular Medicine.
Alice K. Jacobs, MD, FACC, FAHA, Chair,
ACCF/AHA Task Force on Practice Guidelines
Sidney C. Smith, Jr, MD, FACC, FAHA, Immediate Past Chair,
ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
The ACCF/AHA writing committee to create the 2011
Guideline on the Management of Patients With Extracra-
nial Carotid and Vertebral Artery Disease (ECVD) con-ducted a comprehensive review of the literature relevant to
carotid and vertebral artery interventions through May
2010.
The recommendations listed in this document are, when-
ever possible, evidence-based. Searches were limited to
studies, reviews, and other evidence conducted in human
subjects and published in English. Key search words in-
cluded but were not limited to angioplasty, atherosclerosis,
carotid artery disease, carotid endarterectomy (CEA), carotid
revascularization, carotid stenosis, carotid stenting, carotid
artery stenting (CAS), extracranial carotid artery stenosis,
stroke, transient ischemic attack (TIA), and vertebral artery
disease. Additional searches cross-referenced these topics
with the following subtopics: acetylsalicylic acid, antiplatelet
therapy, carotid artery dissection, cerebral embolism, cerebral
protection, cerebrovascular disorders, complications, comorbidi-
ties, extracranial atherosclerosis, intima-media thickness
(IMT), medical therapy, neurological examination, noninva-
sive testing, pharmacological therapy, preoperative risk, primary
closure, risk factors, and vertebral artery dissection. Addition-
ally, the committee reviewed documents related to the
subject matter previously published by the ACCF and AHA
(and other partnering organizations). References selected
and published in this document are representative and not
all-inclusive.
To provide clinicians with a comprehensive set of data,
whenever deemed appropriate or when published in the
article, data from the clinical trials were used to calculate the
absolute risk difference and number needed to treat (NNT)
or harm; data related to the relative treatment effects are also
provided, such as odds ratio (OR), relative risk (RR), hazard
ratio (HR), or incidence rate ratio, along with confidence
interval (CI) when available.
The committee used the evidence-based methodologies
developed by the Task Force and acknowledges that adju-
dication of the evidence was complicated by the timing of
the evidence when 2 different interventions were contrasted.
Despite similar study designs (e.g., randomized controlled
trials), research on CEA was conducted in a different era
(and thus, evidence existed in the peer-reviewed literature
for more time) than the more contemporary CAS trials.
Because evidence is lacking in the literature to guide many
aspects of the care of patients with nonatherosclerotic
carotid disease and most forms of vertebral artery disease, a
relatively large number of the recommendations in this
document are based on consensus.
The writing committee chose to limit the scope of this
document to the vascular diseases themselves and not to the
management of patients with acute stroke or to the detec-
tion or prevention of disease in individuals or populations at
risk, which are covered in another guideline (2). The
full-text guideline is based on the presumption that readers
will search the document for specific advice on the manage-
ment of patients with ECVD at different phases of illness.
Following the typical chronology of the clinical care of patients
with ECVD, the guideline is organized in sections that address
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management of patients with ECVD, including prevention of
recurrent ischemic events. The text, recommendations, and
supporting evidence are intended to assist the diverse array of
clinicians who provide care for patients with ECVD. In
particular, they are designed to aid primary care clinicians,
medical and surgical cardiovascular specialists, and trainees in
the primary care and vascular specialties, as well as nurses and
other healthcare personnel who seek clinical tools to promote
the proper evaluation and management of patients with
ECVD in both inpatient and outpatient settings. Application
of the recommended diagnostic and therapeutic strategies,
combined with careful clinical judgment, should improve
diagnosis of each syndrome, enhance prevention, and decrease
rates of stroke and related long-term disability and death. The
ultimate goal of the guideline statement is to improve the
duration and quality of life for people with ECVD.
1.2. Organization of the Writing Committee
The writing committee to develop the 2011 ASA/ACCF/
AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/
SIR/SNIS/SVM/SVS Guideline on the Management of
Patients With Extracranial Carotid and Vertebral Artery
Disease was composed of experts in the areas of medicine,
surgery, neurology, cardiology, radiology, vascular surgery,
neurosurgery, neuroradiology, interventional radiology,
noninvasive imaging, emergency medicine, vascular medi-
cine, nursing, epidemiology, and biostatistics. The commit-
tee included representatives of the American Stroke Asso-
ciation (ASA), ACCF, AHA, American Academy of
Neurology (AAN), American Association of Neuroscience
Nurses (AANN), American Association of Neurological
Surgeons (AANS), American College of Emergency Phy-
sicians (ACEP), American College of Radiology (ACR),
American Society of Neuroradiology (ASNR), Congress of
Neurological Surgeons (CNS), Society of Atherosclerosis
Imaging and Prevention (SAIP), Society for Cardiovascular
Angiography and Interventions (SCAI), Society of Cardio-
vascular Computed Tomography (SCCT), Society of Inter-
ventional Radiology (SIR), Society of NeuroInterventional
Surgery (SNIS), Society for Vascular Medicine (SVM), and
Society for Vascular Surgery (SVS).
1.3. Document Review and Approval
The document was reviewed by 55 external reviewers,
including individuals nominated by each of the ASA,
ACCF, AHA, AANN, AANS, ACEP, American College
of Physicians, ACR, ASNR, CNS, SAIP, SCAI, SCCT,
SIR, SNIS, SVM, and SVS, and by individual content
reviewers, including members from the ACCF Catheteriza-
tion Committee, ACCF Interventional Scientific Council,
ACCF Peripheral Vascular Disease Committee, ACCF
Surgeons’ Scientific Council, ACCF/SCAI/SVMB/SIR/
ASITN Expert Consensus Document on Carotid Stenting,
ACCF/AHA Peripheral Arterial Disease Guideline Writ-
ing Committee, AHA Peripheral Vascular Disease Steering sCommittee, AHA Stroke Leadership Committee, and in-
dividual nominees. All information on reviewers’ RWI was
distributed to the writing committee and is published in this
document (Appendix 2).
This document was reviewed and approved for publica-
tion by the governing bodies of the ASA, ACCF, and AHA
and endorsed by the AANN, AANS, ACR, ASNR, CNS,
SAIP, SCAI, SCCT, SIR, SNIS, SVM, and SVS. The
AAN affirms the value of this guideline.
1.4. Anatomy and Definitions
The normal anatomy of the aortic arch and cervical arteries
that supply the brain is subject to considerable variation (3).
Three aortic arch morphologies are distinguished on the
basis of the relationship of the brachiocephalic (innominate)
arterial trunk to the aortic arch (Figure 1). The Type I aortic
arch is characterized by the origin of all 3 major vessels in
the horizontal plane defined by the outer curvature of the
arch. In Type II, the brachiocephalic artery originates between
the horizontal planes of the outer and inner curvatures of the
arch. In Type III, it originates below the horizontal plane of
the inner curvature of the arch. In addition to aortic arch
anatomy, the configuration of the great vessels varies. Most
commonly, the brachiocephalic artery, left common carotid
artery, and left subclavian artery originate separately from the
aortic arch (4). The term bovine aortic arch refers to a frequent
ariant of human aortic arch branching in which the brachio-
ephalic and left common carotid arteries share a common
rigin. This anatomy is not generally found in cattle, so the
erm bovine arch is a misnomer (5,6).
The distal common carotid artery typically bifurcates into
he internal and external carotid arteries at the level of the
hyroid cartilage, but anomalous bifurcations may occur up
o 5 cm higher or lower. The carotid bulb, a dilated portion
t the origin of the internal carotid artery, usually extends
uperiorly for a distance of approximately 2 cm, where the
iameter of the internal carotid artery becomes more uni-
orm. The length and tortuosity of the internal carotid
rtery are additional sources of variation, with undulation,
oiling, or kinking in up to 35% of cases, most extensively in
lderly patients.
The intracranial portion of each carotid artery begins at
he base of the skull, traverses the petrous bone, and enters
he subarachnoid space near the level of the ophthalmic
rtery. There, the artery turns posteriorly and superiorly,
iving rise to the posterior communicating artery, which
onnects through the circle of Willis with the posterior
erebral artery that arises from the vertebrobasilar circula-
ion. The internal carotid artery then bifurcates into the
nterior cerebral and middle cerebral arteries. The anterior
erebral arteries connect with the circle of Willis through
he anterior communicating artery. Among the most im-
ortant collateral pathways are those from the external
arotid artery to the internal carotid artery (via the internal
axillary branch of the external carotid artery and theuperficial temporal artery to the ophthalmic branches of the
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the vertebral artery (via the occipital branch of the external
carotid artery), from the vertebrobasilar arterial system to
the internal carotid artery (via the posterior communicating
artery), and between the left and right internal carotid
arteries (via the interhemispheric circulation through the
anterior communicating artery). The configuration of the
circle of Willis is also highly variable, with a complete circle
in fewer than 50% of individuals. Variations due to tortu-
osity, calcification, intracranial arterial stenosis, collateral
circulation, aneurysms, and arteriovenous malformation
have important implications that must be considered in
applying treatment recommendations to individual patients.
Extracranial cerebrovascular disease encompasses several
disorders that affect the arteries that supply the brain and is
Figure 1. Aortic Arch Types
Panel A. The most common aortic arch branching pattern found in humans has sepa
he second most common pattern of human aortic arch branching has a common o
een referred to as a “bovine arch.” Panel C. In this variant of aortic arch branching,
ern has also been erroneously referred to as a “bovine arch.” Panel D. The aortic ar
he aortic arch that eventually splits into the bilateral subclavian arteries and a bicaan important cause of stroke and transient cerebral ischemicattack. The most frequent cause is atherosclerosis, but other
causes include fibromuscular dysplasia (FMD), cystic medial
necrosis, arteritis, and dissection. Atherosclerosis is a sys-
temic disease, and patients with ECVD typically face an
escalated risk of other adverse cardiovascular events, includ-
ing myocardial infarction (MI), peripheral arterial disease
(PAD), and death. To improve survival, neurological and
functional outcomes, and quality of life, preventive and
therapeutic strategies must address both cerebral and sys-
temic risk.
1.5. Epidemiology of Extracranial
Cerebrovascular Disease and Stroke
When considered separately from other cardiovascular dis-
eases, stroke is the third-leading cause of death in industri-
igins for the innominate, left common carotid, and left subclavian arteries. Panel B.
r the innominate and left common carotid arteries. This pattern has erroneously
ft common carotid artery originates separately from the innominate artery. This pat-
nching pattern found in cattle has a single brachiocephalic trunk originating from
unk. a indicates artery. Reprinted with permission from Layton et al. (6).rate or
rigin fo
the le
ch braalized nations, behind heart disease and cancer, and a
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of stroke involve mainly regional populations, and the
results may not be generalizable across the nation because of
geographic variations. Data from the Greater Cincinnati/
Northern Kentucky Stroke Study suggest an annual inci-
dence of approximately 700,000 stroke events, of which
approximately 500,000 are new and 200,000 are recurrent
strokes (8). In 2003, the Centers for Disease Control and
Prevention reported a higher prevalence in the “stroke belt”
of 10 southeastern states (9). Among persons younger than
65 years of age, excess deaths caused by stroke occur in most
racial/ethnic minority groups compared with whites (10). In
NOMASS (Northern Manhattan Stroke Study), the age-
adjusted incidence of first ischemic stroke per 100,000
population was 191 among blacks (95% CI 160 to 221), 149
among Hispanics (95% CI 132 to 165), and 88 (95% CI 75
to 101) among whites (11). The average annual age-
adjusted overall (initial and recurrent) stroke incidence per
100,000 for those 20 years old was 223 for blacks, 196 for
Hispanics, and 93 for whites, which represents a 2.4-fold
RR for blacks and a 2-fold increase for Hispanics compared
with whites (12). On a national level, however, a large
number of strokes apparently go unreported. The prevalence
of silent cerebral infarction between ages 55 and 64 years is
approximately 11%, increasing to 22% between ages 65 and
69, 28% between ages 70 and 74, 32% between ages 75 and
79, 40% between ages 80 and 85, and 43% beyond age 85.
The application of these rates to 1998 US population
estimates yielded an estimated 13 million people with silent
stroke (13).
Most (54%) of the 167,366 deaths attributed to stroke in
1999 were not specified by International Classification of
Disease, 9th Revision codes for hemorrhage or infarction
(14). On the basis of data from the Framingham Heart
Study (15), the ARIC (Atherosclerosis Risk in Communi-
ties) study (16,17), and the Greater Cincinnati/Northern
Kentucky Stroke Study (8), approximately 88% of all strokes
are ischemic, 9% are intracerebral hemorrhages, and 3% are
subarachnoid hemorrhages (18–22).
In the Framingham Heart Study population, the prev-
alence of 50% carotid stenosis was 7% in women and
9% in men ranging in age from 66 to 93 years (23). In the
Cardiovascular Health Study of subjects older than 65
years of age, 7% of men and 5% of women had moderate
(50% to 74%) carotid stenosis; severe (75% to 100%)
stenosis was detected in 2.3% of men and 1.1% of women
(24). In NOMASS, a population-based study of people
older than 40 years of age who lived in northern Man-
hattan, New York, 62% had carotid plaque thickness of
0.9 mm by sonography, and 39% had minimal or no (0.0
to 0.9 mm) carotid plaque (25). In those with subclinical
disease, mean plaque thickness was 1.0 mm for whites,
1.7 mm for blacks, and 1.2 mm for Hispanics (25). In a
population-based study of patients in Texas with TIA,
10% of those undergoing carotid ultrasonography had
70% stenosis of at least 1 internal carotid artery (26).Even subclinical carotid disease is associated with future
stroke, as in the ARIC study, in which the IMT of the
carotid artery walls of people 45 to 64 years old without
ulcerated or hemodynamically significant plaque at base-
line predicted stroke (16).
Carotid stenosis or occlusion as a cause of stroke has
been more difficult to determine from population studies.
For the NOMASS population, cerebral infarction attrib-
uted to ECVD was defined as clinical stroke with
evidence of infarction on brain imaging associated with
60% stenosis or occlusion of an extracranial carotid or
vertebral artery documented by noninvasive imaging or
angiography. Between 1993 and 1997, the incidence of
cerebral infarction attributable to ECVD was 17 per
100,000 (95% CI 8 to 26) for blacks, 9 per 100,000 (95%
CI 5 to 13) for Hispanics, and 5 per 100,000 (95% CI 2
to 8) for whites (11). Approximately 7% of all first
ischemic strokes were associated with extracranial carotid
stenosis of 60% or more (11). From a Mayo Clinic study
of the population of Rochester, Minn, for the period
1985 to 1989, 18% of all first ischemic strokes were
attributed to extracranial or intracranial large-vessel dis-
ease (27), but the report did not separately classify those
with extracranial or intracranial vascular disease.
Beyond the impact on individual patients, ECVD and its
consequences create a substantial social and economic bur-
den in the United States and are increasingly recognized as
a major drain on health resources worldwide. Stroke is the
most frequent neurological diagnosis that requires hospital-
ization (21), amounting to more than half a million hospi-
talizations annually (18). From the 1970s to the latest
figures available, the number of noninstitutionalized stroke
survivors in the United States increased from an estimated
1.5 million to 6 million (19). Survivors face risks of
recurrent stroke as high as 4% to 15% within a year after
incident stroke and 25% by 5 years (20,28). The direct and
indirect cost for acute and convalescent care for stroke
victims in the United States was estimated at $68.9 billion
in 2009. The economic burden and lifetime cost vary
considerably by type of stroke, averaging $103,576 across all
stroke types, with costs associated with first strokes esti-
mated as $228,030 for subarachnoid hemorrhage, $123,565
for intracerebral hemorrhage, and $90,981 for ischemic
stroke (22).
2. Atherosclerotic Disease of the
Extracranial Carotid and Vertebral Arteries
The pathobiology of carotid and vertebral artery atheroscle-
rosis is similar in most respects to atherosclerosis that affects
other arteries. Early lesion development is initiated by
intimal accumulation of lipoprotein particles. These parti-
cles undergo oxidative modification and elaborate cytokines
that cause expression of adhesion molecules and chemoat-
tractants that facilitate uptake and migration of monocytes
23
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macrophages, or foam cells, as a consequence of accumula-
tion of modified lipoproteins and subsequently release
additional cytokines, oxidants, and matrix metalloprotei-
nases. Smooth muscle cells migrate from the media to the
intima, proliferate, and elaborate extracellular matrix as
extracellular lipid accumulates in a central core surrounded
by a layer of connective tissue, the fibrous cap, which in
many advanced plaques becomes calcified. Initially, the
atherosclerotic lesion grows in an outward direction, a
process designated “arterial remodeling.” As the plaque
continues to grow, however, it encroaches on the lumen and
causes stenosis. Plaque disruption and thrombus formation
contribute to progressive narrowing of the lumen and to
clinical events. The mechanisms that account for plaque
disruption in the extracranial carotid and vertebral arteries
are similar to those proposed for the coronary arteries (29).
These include rupture of the fibrous cap, superficial erosion,
and erosion of a calcium nodule. Contact of blood elements,
including platelets and coagulation proteins, with constitu-
ents of the atherosclerotic plaque, such as collagen and
tissue factor, promotes thrombosis. In addition, intraplaque
hemorrhage caused by friable microvessels at the base of the
plaque may contribute to plaque expansion.
Atherosclerotic plaques often develop at flow dividers and
branch points, where there is both turbulence and shifts in
shear stress. As such, there is a predilection for plaque
formation at the bifurcation of the common carotid artery
into the internal and external carotid arteries. Stroke and
transient cerebrovascular ischemia may arise as a conse-
quence of several mechanisms that originate in the extracra-
nial cerebral arteries, including 1) artery-to-artery embolism
of thrombus formed on an atherosclerotic plaque, 2) athe-
roembolism of cholesterol crystals or other atheromatous
debris (e.g., Hollenhorst plaque), 3) acute thrombotic oc-
clusion of an extracranial artery resulting from plaque
rupture, 4) structural disintegration of the arterial wall
resulting from dissection or subintimal hematoma, and 5)
reduced cerebral perfusion resulting from critical stenosis or
occlusion caused by progressive plaque growth. For neuro-
logical symptoms to result from arterial stenosis or occlu-
sion, the intracranial collateral circulation must also be
deficient, and this represents the cause of a relatively small
proportion of clinical ischemic events.
2.1. Evaluation of Asymptomatic Patients at
Risk of Extracranial Carotid Artery Disease
2.1.1. Recommendations for Duplex Ultrasonography
to Evaluate Asymptomatic Patients With Known or
Suspected Carotid Stenosis
CLASS I
1. In asymptomatic patients with known or suspected carotid stenosis,
duplex ultrasonography, performed by a qualified technologist in a
certified laboratory, is recommended as the initial diagnostic test to
detect hemodynamically significant carotid stenosis. (Level of Evi-
dence: C)CLASS IIa
1. It is reasonable to perform duplex ultrasonography to detect hemo-
dynamically significant carotid stenosis in asymptomatic patients
with carotid bruit. (Level of Evidence: C)
2. It is reasonable to repeat duplex ultrasonography annually by a
qualified technologist in a certified laboratory to assess the progres-
sion or regression of disease and response to therapeutic interven-
tions in patients with atherosclerosis who have had stenosis greater
than 50% detected previously. Once stability has been established
over an extended period or the patient’s candidacy for further
intervention has changed, longer intervals or termination of surveil-
lance may be appropriate. (Level of Evidence: C)
CLASS IIb
1. Duplex ultrasonography to detect hemodynamically significant ca-
rotid stenosis may be considered in asymptomatic patients with
symptomatic PAD, coronary artery disease (CAD), or atherosclerotic
aortic aneurysm, but because such patients already have an indica-
tion for medical therapy to prevent ischemic symptoms, it is unclear
whether establishing the additional diagnosis of ECVD in those
without carotid bruit would justify actions that affect clinical out-
comes. (Level of Evidence: C)
2. Duplex ultrasonography might be considered to detect carotid ste-
nosis in asymptomatic patients without clinical evidence of athero-
sclerosis who have 2 or more of the following risk factors: hyperten-
sion, hyperlipidemia, tobacco smoking, a family history in a first-
degree relative of atherosclerosis manifested before age 60 years,
or a family history of ischemic stroke. However, it is unclear whether
establishing a diagnosis of ECVD would justify actions that affect
clinical outcomes. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Carotid duplex ultrasonography is not recommended for routine
screening of asymptomatic patients who have no clinical manifes-
tations of or risk factors for atherosclerosis. (Level of Evidence: C)
. Carotid duplex ultrasonography is not recommended for routine
evaluation of patients with neurological or psychiatric disorders
unrelated to focal cerebral ischemia, such as brain tumors, familial
or degenerative cerebral or motor neuron disorders, infectious and
inflammatory conditions affecting the brain, psychiatric disorders,
or epilepsy. (Level of Evidence: C)
. Routine serial imaging of the extracranial carotid arteries is not
recommended for patients who have no risk factors for develop-
ment of atherosclerotic carotid disease and no disease evident on
initial vascular testing. (Level of Evidence: C)
Although there is evidence from randomized trials that
referred patients with asymptomatic hemodynamically sig-
nificant carotid stenosis benefit from therapeutic interven-
tion, no screening program aimed at identifying people with
asymptomatic carotid stenosis has been shown to reduce
their risk of stroke. Hence, there is no consensus on which
patients should undergo screening tests for detection of
carotid disease. Auscultation of the cervical arteries for
bruits is a standard part of the physical examination of
adults, but detection of a bruit correlates more closely with
systemic atherosclerosis than with significant carotid steno-
sis (30). In the largest reported study of screening in
asymptomatic patients, the prevalence of carotid stenosis
35% in those without a bruit was 6.6%, and the prevalence
of 75% carotid stenosis was 1.2% (31). Because the
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predictive value for hemodynamically significant carotid
stenosis are relatively low, however, ultrasonography may be
appropriate in some high-risk asymptomatic patients irre-
spective of findings on auscultation (32).
Because carotid ultrasonography is a widely available
technology associated with negligible risk and discomfort,
the issue becomes one of appropriate resource utilization.
Lacking data from health economic studies to support mass
screening of the general adult population, our recommen-
dations are based on consensus and driven by awareness that
resources are limited and as a result favor targeted screening
of patients at greatest risk of developing carotid stenosis.
Additional pertinent considerations are that the stroke
reduction that accrues from screening asymptomatic pa-
tients and treating them with specific interventions is
unknown, that the benefit is limited by the low overall
prevalence of disease amenable to specific therapy in asymp-
tomatic patients, and that revascularization procedures are
associated with tangible risks.
2.1.2. Recommendations From Other Panels
The AHA/ASA guideline for primary prevention of
ischemic stroke recommended against screening the gen-
eral population for asymptomatic carotid stenosis on the
basis of concerns about lack of cost-effectiveness, the
potential adverse impact of false-positive and false-
negative results in the general population, and the small
absolute benefit of intervention (33). In addition, the
American Society of Neuroimaging recommended
against the screening of unselected populations but ad-
vised the screening of adults older than 65 years of age
who have 3 or more cardiovascular risk factors (34). The
ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Con-
sensus Panel on Carotid Stenting recommended the
screening of asymptomatic patients with carotid bruits
who are potential candidates for carotid revascularization
and the screening of those in whom coronary artery
bypass graft (CABG) surgery is planned (35). The US
Preventive Services Task Force recommended against
screening for asymptomatic carotid artery stenosis in the
general adult population (36).
2.2. Extracranial Cerebrovascular Disease as a
Marker of Systemic Atherosclerosis
Because atherosclerosis is a systemic disease, patients with
extracranial carotid or vertebral atherosclerosis frequently
have atherosclerosis elsewhere, notably in the aorta, coro-
nary arteries, and peripheral arteries (37–40). Patients with
ECVD are at increased risk of MI and death attributable to
cardiac disease (41–46), such that many patients with
carotid stenosis face a greater risk of death caused by MI
than of stroke (47,48). Coronary atherosclerosis is prevalent
in patients with fatal stroke of many origins and occurs more
frequently in those with carotid or vertebral artery athero-
sclerosis. In 803 autopsies of consecutive patients withneurological disease (49), the prevalences of atherosclerotic
coronary plaque, 50% coronary artery stenosis, and path-
ological evidence of MI were 72%, 38%, and 41%, respec-
tively, among the 341 patients with a history of stroke
compared with 27%, 10%, and 13%, respectively, of the 462
patients with neurological diseases other than stroke (all
p0.001). Two thirds of the cases of MI found at autopsy
had been clinically silent. The frequency of coronary ath-
erosclerosis and MI was similar in patients with various
stroke subtypes, but the severity of coronary atherosclerosis
was related to the severity of ECVD (adjusted linear p for
trend 0.005). Risk factors associated with ECVD, such as
cigarette smoking, hypercholesterolemia, diabetes, and hy-
pertension, are the same as for atherosclerosis elsewhere,
although differences exist in their relative contribution to
risk in the various vascular beds. A more detailed description
of risk factors and their management appears in Section 6.
The IMT of the carotid artery wall, a measurement
obtained by carotid ultrasound, is also a marker of systemic
atherosclerosis. Carotid IMT is a marker of risk for coro-
nary events and stroke in patients without clinical cardio-
vascular disease (50,51), although in the Framingham Heart
Study coefficients of correlation between carotid IMT and
coronary calcification were typically 0.3 (52–55). Data
from the ARIC study suggest that carotid IMT data may
enhance cardiovascular risk assessment, particularly among
individuals classified as being at intermediate risk by use of
conventional risk factors (56,57). In epidemiological studies
(58–62), IMT progresses at an average rate of 0.03 mm
per year. Progression can be retarded by 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor drugs
(statins), the combination of colestipol and niacin, and risk
factor modifications (58–62). The use of IMT measure-
ments to guide treatment based on outcomes of specific
interventions for patients has not been documented.
Measurement of IMT has not yet become a routine or
certified element of carotid ultrasound examinations in the
United States and is not currently recognized as a screening
method for atherosclerotic risk (63,64). There is no indica-
tion for measurement of IMT in patients with carotid
plaque or stenosis. For specific recommendations for screen-
ing for atherosclerosis by measurement of carotid IMT in
asymptomatic patients, the reader is referred to the 2010
ACCF/AHA Guidelines for Assessment of Cardiovascular
Risk in Asymptomatic Adults (65).
2.2.1. Screening for Coronary or Lower-Extremity
Peripheral Arterial Disease in Patients With
Atherosclerosis of the Carotid or Vertebral Arteries
Whether symptomatic or asymptomatic, individuals with
carotid atherosclerosis are more likely to have atherosclerosis
that involves other vascular beds, although the associations
are quantitatively modest. Specific recommendations for
screening for CAD and PAD in patients with ECVD are
beyond the scope of this document, and the reader is
referred to the ACC/AHA 2005 Guidelines for the Man-
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and the AHA/ASA scientific statement on coronary risk
evaluation in patients with TIA and ischemic stroke (67).
3. Clinical Presentation
3.1. Natural History of Atherosclerotic
Carotid Artery Disease
Extracranial atherosclerotic disease accounts for up to 15%
to 20% of all ischemic strokes (68,69). The progression of
carotid atherosclerosis may be similar to that in other
arterial beds, but the relationship between plaque growth,
increasing stenosis, and TIA or stroke is complex. There
was a clear correlation between the degree of stenosis and
the risk of stroke in the NASCET (North American
Symptomatic Carotid Endarterectomy Trial) (70), but the
relationship between stroke risk and severity of stenosis in
asymptomatic patients was less clear in other studies. After
18 months of medical therapy without revascularization,
stroke rates were 19% in those with 70% to 79% initial
stenosis, 28% in those with 80% to 89% stenosis, and 33%
in the 90% to 99% stenosis group, and the risk diminished
with near-occlusion (70). In ACAS (Asymptomatic Carotid
Atherosclerosis Study) and ACST (Asymptomatic Carotid
Surgery Trial), asymptomatic patients with 60% to 80%
stenosis had higher stroke rates than those with more severe
stenosis (71,72). However, medical therapy in the era during
which these trials were conducted was considerably limited
compared with today’s standards.
The natural history of asymptomatic carotid disease in
patients with cervical bruits or other risk factors for stroke
has been reported in case series, population-based studies,
and observational arms of randomized clinical trials. In the
Framingham Heart Study, the calculated age-adjusted in-
cidence of stroke in patients with cervical bruits was 2.6
times that of those without bruits (15). A number of early
natural history studies showing the incidence of stroke in
asymptomatic patients with 75% stenosis are summarized
in Table 2 (section on observational studies); the aggregate
nnual stroke rate exceeded 5% (73).
Table 2 (section on randomized trial cohorts) also sum-
arizes event rates in randomized trial cohorts. ACAS
emonstrated a rate of 11% during a 5-year period for
psilateral stroke or death in the group managed with
edical therapy, which consisted essentially of aspirin alone
neither the statin class of lipid-lowering drugs nor inhibi-
ors of the renin-angiotensin system were conventionally
sed) (74). In ACST, the risk of ipsilateral stroke or death
uring a 5-year period in patients with 70% stenosis
andomized to initial medical therapy was 4.7% (75). The
ifference in rates suggests that medical therapy has been
ssociated with diminishing event rates over time and that
symptomatic disease may follow a relatively benign course
n many individuals. Several other randomized trials have
lso documented a low rate of neurological events in bsymptomatic patients with moderate to severe internal
arotid artery stenosis (76,77).
3.2. Characterization of Atherosclerotic Lesions
in the Extracranial Carotid Arteries
Because the correlation between severity of stenosis and
ischemic events is imperfect, other characteristics have been
explored as potential markers of plaque vulnerability and
stroke risk. Among asymptomatic patients with carotid
bruit in the Framingham Heart Study cohort, fewer than
half of the stroke events affected the cerebral hemisphere
ipsilateral to the bruit and carotid stenosis (15).
Investigations of the relationship between cerebral symp-
toms and morphological characteristics of plaque defined by
ultrasound found an association of clinical cerebral ischemic
events with ulceration, echolucency, intraplaque hemor-
rhage, and high lipid content (86,87). Molecular and
cellular processes responsible for plaque composition (86–
88) may be more important than the degree of stenosis in
determining the risk of subsequent TIA and stroke, but the
degree of carotid stenosis estimated by ultrasonography
remains the main determinant of disease severity and forms
the basis for most clinical decision making. Quantitative
analysis of duplex ultrasound images correlates with histo-
logical findings of intraplaque hemorrhage, fibromuscular
hyperplasia, calcium, and lipid composition, and the feasi-
bility of identifying symptomatic and unstable plaques on
the basis of these features has been described (87).
Computer-generated measurements of carotid plaque echo-
genicity and surface characteristics (smooth, irregular, or
ulcerated) have been performed on images obtained from
patients with symptomatic or asymptomatic ipsilateral ce-
rebral infarction, but the prognostic value of these features
has not been established (89–92). Hypoechoic plaques are
associated with subcortical and cortical cerebral infarcts of
suspected embolic origin, and hyperechoic plaques are
associated with diffuse white matter infarcts of presumed
hemodynamic origin (including lacunar and basal ganglia
infarctions due to proximal arterial and distal intracranial
vascular disease) (93).
Contrast-enhanced magnetic resonance imaging (MRI)
at 1.5- and 3.0-Tesla field strengths, intravascular MRI, and
computed tomography (CT) have also been used to char-
acterize carotid atherosclerotic plaques. Thin or ruptured
fibrous caps, intraplaque hemorrhage, relatively large lipid-
rich or necrotic plaque cores, and overall plaque thickness
have been associated with subsequent ischemic brain events
in preliminary studies of asymptomatic patients with 50% to
79% carotid stenosis (94).
Metabolic activity in the vessel wall surrounding carotid
plaques can be detected by positron emission tomography
(PET) (95). Carotid plaques of symptomatic patients with
stroke demonstrate infiltration of the fibrous cap by inflamma-
tory cells including monocytes, macrophages, and lymphocytes
(96,97). Increased uptake of 18F-fluorodeoxyglucose measured
y PET imaging is believed to reflect inflammation (98,99).
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angiogenesis assessed by MRI have been observed in experi-
mental models (101). Biomarkers such as C-reactive protein
and certain matrix metalloproteinases with the potential to
Table 2. Event Rates in Patients With Carotid Artery Stenosis
Study
(Reference)
No. of
Patients
Symptom
Status Stenosis, % Follow
Observational studies
Hertzer et al.
(78)
290 Asymptomatic 50 33–38 m
Spence et al.
(79)
168 Asymptomatic 60 12 mo
Marquardt et
al. (80)
1,153 Asymptomatic 50 Mean 3
Abbott et al.
(81)
202 Asymptomatic 60–90 Mean 3
Goessens et
al. (82)
2,684 Asymptomatic 50 Mean 3
(SD 2
andomized trial cohorts
ECST (83) 3,024 Symptomatic 80 3 y
NASCET (84) 659 Symptomatic 70 2 y
VA 309 (85) 189 Symptomatic 50 1 y
NASCET (20) 858 Symptomatic 50–69 5 y
NASCET (20) 1,368 Symptomatic 50 5 y
ACAS (74) 1,662 Asymptomatic 60 5 y
ACST (75) 3,120 Asymptomatic 60 5 y
VA (76) 444 Asymptomatic 50 4 y
*Frequency based on Kaplan-Meier. †Risk event rate based on Kaplan-Meier. ‡Failure rate bas
AIIA indicates angiotensin II antagonist; ACAS, Asymptomatic Carotid Atherosclerosis Stu
ndarterectomy; CI, confidence interval; ECST, European Carotid Surgery Trial; n, number; N/
eviation; TIA, transient ischemic attack; VA 309, Veterans Affairs Cooperative Studies Program
Modified from Bates et al. (35).identify carotid plaque instability have also been investigated(102–104), but the reliability of biomarkers in predicting
clinical events has not been established. Several studies have
shown that plaque composition is modified by treatment with
statins (105–109). Despite these advances in understanding the
aged Without Revascularization
Medication Therapy Endpoint
Event Rate Over
Study Period (%)
Aspirin or dipyridamole
(n104); or anticoagulation
with warfarin (n9); or no
medical treatment (n82)
Death
TIA
Stroke
22.0, or 7.33
annualized
8.21, or 2.74
annualized
9.23, or 3.1
annualized
Multiple, including
antiplatelet, statins,
exercise, Mediterranean
diet, ACE inhibitors
Stroke 3.8, or 1.3
annualized
Multiple, including
antiplatelet,
anticoagulation, statin,
antihypertensive drugs
Ipsilateral stroke 0.34 (95% CI
0.01 to 1.87)
average annual
event rate
Multiple, including
antiplatelet, warfarin,
antihypertensive drugs,
cholesterol-lowering therapy
Ipsilateral stroke
or TIA;
ipsilateral
carotid
hemispheric
stroke
Ipsilateral stroke
or TIA or retinal
event:
3.1 (95% CI
0.7 to 5.5)
average annual
rate
Ipsilateral carotid
hemispheric
stroke:
1.0 (95% CI
0.4 to 2.4)
average annual
rate
Multiple, including
antiplatelet,
antihypertensive drugs,
lipid-lowering agents, ACE
inhibitors, and/or AIIA
Ischemic stroke;
death
Death:
9.0 or 2.5
annualized;
ischemic
stroke:
2.0 or 0.54
annualized
No surgery within 1 y or delay
of surgery
Major stroke or
death
26.5 over 3 y or
annualized
8.83 for 1 y*
Aspirin Ipsilateral stroke 26.0 over 2 y or
annualized
13.0 for 1 y†
Aspirin Ipsilateral stroke
or TIA or
surgical death
19.4 over
11.912 mo
Antiplatelet (usually aspirin) Ipsilateral stroke 22.2 over 5 y or
annualized
4.44 for 1 y‡
Antiplatelet (usually aspirin) Ipsilateral stroke 18.7 over 5 y or
annualized
3.74 for 1 y‡
Aspirin Ipsilateral
stroke,
surgical death
11.0 over 5 y or
annualized 2.2
for 1 y§
Indefinite deferral of any CEA Any stroke 11.8 over 5 y or
annualized
2.36 for 1 y§
Aspirin Ipsilateral stroke 9.4 over 4 y or
annualized
2.35 over 1 y
aplan-Meier. §Risk rate based on Kaplan-Meier.
E, angiotensin-converting enzyme; ACST, Asymptomatic Carotid Surgery Trial; CEA, carotid
pplicable; NASCET, North American Symptomatic Carotid Endarterectomy Trial; SD, standard
and VA, Veterans Affairs Cooperative Study Group.Man
-Up
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the occurrence of TIA, stroke, or other symptomatic manifes-
tations of ECVD has not been established clearly by prospec-
tive studies.
3.3. Symptoms and Signs of Transient Ischemic
Attack and Ischemic Stroke
TIA is conventionally defined as a syndrome of acute
neurological dysfunction referable to the distribution of a
single brain artery and characterized by symptoms that last
24 hours. With advances in brain imaging, many patients
with symptoms briefer than 24 hours are found to have
cerebral infarction. A revised definition has been developed
specifying symptoms that last 1 hour, and the typical
duration of symptoms is15 minutes (110), but this change
has not been accepted universally, and the 24-hour thresh-
old is still the standard definition (111). In patients with
acute ischemic stroke, symptoms and signs of neurological
deficit persist longer than 24 hours.
Symptoms and signs that result from ischemia or infarc-
tion in the distribution of the right internal carotid artery or
middle cerebral artery include but are not limited to left-
sided weakness, left-sided paresthesia or sensory loss, left-
sided neglect, abnormal visual-spatial ability, monocular
blindness that affects the right eye, and right homonymous
hemianopsia (visual loss that involves the right visual field).
Ischemia or infarction in the distribution of the left internal
carotid artery or middle cerebral artery may cause right-
sided weakness, right-sided paresthesia or sensory loss,
aphasia, and monocular blindness that affects the left eye or
left visual field. Aphasia may be a sign of ischemia or
infarction in the distribution of the right internal carotid
artery in ambidextrous or left-handed individuals. Symp-
toms and signs that result from ischemia or infarction in the
vertebrobasilar system include but are not limited to ataxia,
cranial nerve deficits, visual field loss, dizziness, imbalance,
and incoordination.
3.3.1. Public Awareness of Stroke Risk Factors and
Warning Indicators
The AHA and ASA have developed educational materials
for patients that emphasize recognition of the symptoms
and signs that warn of TIA and stroke and that encourage
those who observe these symptoms to seek immediate
medical attention, pointing out that rapid action could limit
disability and prevent death.
The joint Stroke Collaborative campaign of the AAN,
the ACEP, and the AHA/ASA seeks to increase stroke
symptom awareness among Americans (see http://
www.giveme5forstroke.org). A report from the region of
Cincinnati, Ohio (112), found significant improvement in
public knowledge of stroke warning signs as promulgated by
the ASA, National Stroke Association, and the National
Institute of Neurological Disorders and Stroke between
1995 and 2000 but less improvement in knowledge of stroke
risk factors during the same period.Patients with acute stroke face disease-specific causes of
delay in seeking medical treatment. In 1 study, 23% had
dysphasia, 77% had an upper-limb motor deficit, and 19%
had an altered level of consciousness (113). In addition to
clinical characteristics, demographic, cognitive, perceptual,
social, emotional, and behavioral factors affect the prehos-
pital delay in patients with ischemic stroke symptoms (114).
A gender analysis of the interval from symptom onset to
hospital arrival (115) found that nearly 4 times as many men
and 5 times as many women exceeded the goal of 3 hours
than those who did not.
4. Clinical Assessment of Patients With
Focal Cerebral Ischemic Symptoms
4.1. Acute Ischemic Stroke
The immediate management of a patient presenting with
a suspected acute focal neurological syndrome should
follow published guidelines for emergency stroke care (2).
Once the diagnosis of acute ischemic stroke is estab-
lished, the patient has been stabilized, thrombolytic
therapy has been administered to an eligible patient, and
initial preventive therapy has been implemented, further
evaluation is directed toward establishing the vascular ter-
ritory involved and the cause and pathophysiology of the
event (2,111,116,117). Risk stratification and secondary
prevention are important for all patients.
4.2. Transient Ischemic Attack
TIA is an important predictor of stroke; the risk is highest
in the first week, as high as 13% in the first 90 days after the
initial event, and up to 30% within 5 years (26,118–124).
On the basis of the conventional definition, an estimated
240,000 TIAs are diagnosed annually in the United States,
and the number of undiagnosed cases is likely considerably
greater (118). Early recognition of TIA, identification of
patients at risk, and risk factor modification (125) are
important stroke prevention measures.
In patients who display ischemic symptoms in the terri-
tory of a carotid artery that has high-grade stenosis, surgical
intervention reduces the risk of major neurological events
(20,75). The benefit of CEA in preventing stroke is greatly
diminished beyond 2 weeks after the onset of symptoms, in
large part because the risk of recurrent ischemic events is
highest in this early period. After 4 weeks in women and 12
weeks in men, the benefit of surgery in these symptomatic
patients is no more than that observed with surgery for
asymptomatic patients, and in some cases, surgery may be
harmful (126). Interventional decisions for a particular
patient should be based on balancing the risks of revascu-
larization against the risk of worsening symptoms and
disability with medical therapy alone.
4.3. Amaurosis Fugax
Transient monocular blindness (amaurosis fugax) is caused
by temporary reduction of blood flow to an eye with sudden
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downward over the field of view (127). The most common
cause is atherosclerosis of the ipsilateral internal carotid
artery, but other causes have been associated with this
syndrome as well. The mechanism may involve ophthalmic
artery embolism, observed as fibrin, cholesterol crystals
(Hollenhorst plaques), fat, or material arising from fibro-
calcific degeneration of the aortic or mitral valves. Causes of
transient monocular blindness follow:
• Carotid artery stenosis or occlusion
• Atherosclerosis
• Dissection
• Arteritis
• Radiation-induced arteriopathy
• Arterial embolism
• Cardiogenic embolism
• Atheroembolism
• Hypotension
• Intracranial hypertension
• Glaucoma
• Migraine
• Vasospastic or occlusive disease of the
ophthalmic artery
The risk of stroke was lower among patients with
transient monocular blindness than among those with
hemispheric TIA in the NASCET cohort (128). The 3-year
risk of stroke with medical treatment alone in patients with
transient monocular blindness was related to the number of
stroke risk factors (hypertension, hypercholesterolemia, di-
abetes, and cigarette smoking) and was specifically 1.8% in
those with 0 or 1 risk factor, 12.3% in those with 2 risk
factors, and 24.2% in those with 3 or 4 risk factors. In
addition to the risk of stroke, permanent blindness may
occur in the affected eye as a result of the initial or
subsequent episodes (128–130).
4.4. Cerebral Ischemia Due to Intracranial
Arterial Stenosis and Occlusion
Intracranial arterial stenosis may be caused by atherosclero-
sis, intimal fibroplasia, vasculitis, adventitial cysts, or vascu-
lar tumors; intracranial arterial occlusion may develop on the
basis of thrombosis or embolism arising from the cardiac
chambers, heart valves, aorta, proximal atheromatous dis-
ease of the carotid or vertebral arteries, or paradoxical
embolism involving a defect in cardiac septation or other
right-to-left circulatory shunt. The diagnosis and manage-
ment of these disorders are outside the scope of this
guideline, but evaluation of the intracranial vasculature may
be important in some patients with ECVD to exclude
high-grade tandem lesions that have implications for clini-
cal management.4.5. Atherosclerotic Disease of the Aortic Arch
as a Cause of Cerebral Ischemia
Atheromatous disease of the aortic arch is an independent
risk factor for ischemic stroke (131), but the diagnosis and
management of this disorder are outside the scope of this
guideline. See the 2010 ACCF/AHA/AATS/ACR/ASA/
SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis
and Management of Patients With Thoracic Aortic Disease
(132).
4.6. Atypical Clinical Presentations and
Neurological Symptoms Bearing an Uncertain
Relationship to Extracranial Carotid and
Vertebral Artery Disease
Most studies of the natural history and treatment of TIA
have included patients who experienced focal transient
ischemic events. The significance of nonfocal neurological
events, including transient global amnesia, acute confusion,
syncope, isolated vertigo, nonrotational dizziness, bilateral
weakness, or paresthesias, is less well studied. Brief, stereo-
typed, repetitive symptoms suggestive of transient cerebral
dysfunction raise the possibility of partial seizure, and
electroencephalography may be useful in such cases. When
symptoms are purely sensory (numbness, pain, or paresthesia),
then radiculopathy, neuropathy, microvascular cerebral or spi-
nal pathology, or lacunar stroke should be considered. A small
proportion of patients with critical (70% and usually 90%)
arotid stenosis present with memory, speech, and hearing
ifficulty related to hypoperfusion of the dominant cerebral
emisphere.
In a study from the Netherlands, patients with transient
eurological attacks of either focal or nonfocal neurological
ymptoms faced an increased risk of stroke compared with
hose without symptoms (HR 2.14 and 1.56, respectively)
133). The pathophysiological mechanism responsible for
ransient global amnesia has not been elucidated, and it is
ot clear whether, in fact, this syndrome is related to ECVD
t all (134). Vertigo (in contrast to nonrotational dizziness)
as associated with a risk of subsequent stroke in a
opulation-based study of patients 65 years of age or older,
ut a direct causative relationship to ECVD has not been
stablished (135).
5. Diagnosis and Testing
5.1. Recommendations for Diagnostic Testing
in Patients With Symptoms or Signs of
Extracranial Carotid Artery Disease
CLASS I
1. The initial evaluation of patients with transient retinal or hemi-
spheric neurological symptoms of possible ischemic origin should
include noninvasive imaging for the detection of ECVD. (Level of
Evidence: C)
2. Duplex ultrasonography is recommended to detect carotid stenosis
in patients who develop focal neurological symptoms corresponding
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(Level of Evidence: C)
3. In patients with acute, focal ischemic neurological symptoms cor-
responding to the territory supplied by the left or right internal
carotid artery, magnetic resonance angiography (MRA) or computed
tomography angiography (CTA) is indicated to detect carotid steno-
sis when sonography either cannot be obtained or yields equivocal
or otherwise nondiagnostic results. (Level of Evidence: C)
4. When extracranial or intracranial cerebrovascular disease is not
severe enough to account for neurological symptoms of suspected
ischemic origin, echocardiography should be performed to search
for a source of cardiogenic embolism. (Level of Evidence: C)
5. Correlation of findings obtained by several carotid imaging modali-
ties should be part of a programof quality assurance in each laboratory
that performs such diagnostic testing. (Level of Evidence: C)
CLASS IIa
1. When an extracranial source of ischemia is not identified in patients
with transient retinal or hemispheric neurological symptoms of
suspected ischemic origin, CTA, MRA, or selective cerebral angiog-
raphy can be useful to search for intracranial vascular disease.
(Level of Evidence: C)
2. When the results of initial noninvasive imaging are inconclusive,
additional examination by use of another imaging method is rea-
sonable. In candidates for revascularization, MRA or CTA can be
useful when results of carotid duplex ultrasonography are equivocal
or indeterminate. (Level of Evidence: C)
3. When intervention for significant carotid stenosis detected by ca-
rotid duplex ultrasonography is planned, MRA, CTA, or catheter-
based contrast angiography can be useful to evaluate the severity of
stenosis and to identify intrathoracic or intracranial vascular lesions
that are not adequately assessed by duplex ultrasonography. (Level
of Evidence: C)
. When noninvasive imaging is inconclusive or not feasible because
of technical limitations or contraindications in patients with tran-
sient retinal or hemispheric neurological symptoms of suspected
ischemic origin, or when noninvasive imaging studies yield discor-
dant results, it is reasonable to perform catheter-based contrast
angiography to detect and characterize extracranial and/or intracra-
nial cerebrovascular disease. (Level of Evidence: C)
. MRA without contrast is reasonable to assess the extent of disease in
patients with symptomatic carotid atherosclerosis and renal insuffi-
ciency or extensive vascular calcification. (Level of Evidence: C)
. It is reasonable to use MRI systems capable of consistently gener-
ating high-quality images while avoiding low-field systems that do
not yield diagnostically accurate results. (Level of Evidence: C)
. CTA is reasonable for evaluation of patients with clinically suspected
significant carotid atherosclerosis who are not suitable candidates
for MRA because of claustrophobia, implanted pacemakers, or
other incompatible devices. (Level of Evidence: C)
CLASS IIb
1. Duplex carotid ultrasonography might be considered for patients
with nonspecific neurological symptoms when cerebral ischemia is
a plausible cause. (Level of Evidence: C)
2. When complete carotid arterial occlusion is suggested by duplex
ultrasonography, MRA, or CTA in patients with retinal or hemi-
spheric neurological symptoms of suspected ischemic origin,
catheter-based contrast angiography may be considered to deter-
mine whether the arterial lumen is sufficiently patent to permit
carotid revascularization. (Level of Evidence: C)3. Catheter-based angiography may be reasonable in patients with
renal dysfunction to limit the amount of radiographic contrast
material required for definitive imaging for evaluation of a single
vascular territory. (Level of Evidence: C)
Carotid ultrasonography, CTA, and MRA can provide the
information needed to guide the choice of medical, endo-
vascular, or surgical treatment in most cases. The severity of
stenosis is defined according to angiographic criteria by the
method used in NASCET (70), but it corresponds as well to
assessment by sonography (136) and other accepted meth-
ods of measurement such as CTA and MRA, although the
latter may overestimate the severity of stenosis. It is impor-
tant to bear in mind that 75% diameter stenosis of a vessel
corresponds to 90% reduction in the cross-sectional area
of the lumen.
Catheter-based angiography may be necessary in some
cases for definitive diagnosis or to resolve discordance
between noninvasive imaging findings. These advanced
imaging techniques generally do not replace carotid duplex
ultrasonography for initial evaluation of suspected carotid
stenosis in those with symptomatic manifestations of isch-
emia (or in asymptomatic individuals at risk), either as a
solitary diagnostic method or as a confirmatory test to assess
the severity of known stenosis. Indications for carotid
duplex sonography follow (137,138):
• Cervical bruit in an asymptomatic patient
• Follow-up of known stenosis (20%) in asymptomatic
individuals
• Vascular assessment in a patient with multiple risk
factors for atherosclerosis
• Stroke risk assessment in a patient with CAD or PAD
• Amaurosis fugax
• Hemispheric TIA
• Stroke in a candidate for carotid revascularization
• Follow-up after a carotid revascularization procedure
• Intraoperative assessment during CEA or stenting
Each imaging modality has strengths and weaknesses,
and because the quality of images produced by each nonin-
vasive modality differs from one institution to another, no
single modality can be recommended as uniformly superior.
In general, correlation of findings obtained by multiple
modalities should be part of a program of quality assurance
in every laboratory and institution. It is most important that
data obtained in patients undergoing catheter-based angiog-
raphy for evaluation of ECVD be compared with noninva-
sive imaging findings to assess and improve the accuracy of
noninvasive vascular testing. The following discussion per-
tains mainly to evaluation of the cervical carotid arteries for
atherosclerotic disease. There is a paucity of literature
addressing evaluation of the vertebral arteries and of both
the carotid and vertebral arteries for nonatherosclerotic
disorders such as traumatic injury (139–141). The relative
roles of noninvasive imaging and conventional angiography
for these indications have not been defined.
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essential to the selection of appropriate patients for surgical
or endovascular intervention, and imaging of the extracra-
nial carotid arteries should be performed whenever cerebral
ischemia is a suspected mechanism of neurological symp-
toms in a viable patient. Choosing among the available
vascular imaging modalities, deciding when to combine
multiple modalities, and judicious application of angiogra-
phy are challenging aspects of evaluation in patients with
ECVD. Imaging of the aortic arch, proximal cervical
arteries, and the artery distal to the site of stenosis is
required before endovascular therapy to ascertain the feasi-
bility of intervention. Less anatomic information is neces-
sary before surgical intervention at the carotid bifurcation
because the procedure entails direct exposure of the target
artery.
5.2. Carotid Duplex Ultrasonography
Duplex ultrasound modalities combine 2-dimensional real-
time imaging with Doppler flow analysis to evaluate vessels
of interest (typically the cervical portions of the common,
internal, and external carotid arteries) and measure blood
flow velocity. The method does not directly measure the
diameter of the artery or stenotic lesion. Instead, blood flow
velocity is used as an indicator of the severity of stenosis
(Figure 2). Several schemes have been developed for
assessment of carotid stenosis by duplex ultrasound
(136,143,144). The peak systolic velocity in the internal
carotid artery and the ratio of the peak systolic velocity in
the internal carotid artery to that in the ipsilateral common
carotid artery appear to correlate best with angiographically
determined arterial stenosis.
Ultrasonography is an accurate method for measuring the
severity of stenosis, with the caveat that subtotal arterial
occlusion may sometimes be mistaken for total occlusion.
Typically, 2 categories of internal CAS severity are defined
by ultrasound, one (50% to 69% stenosis) that represents the
Figure 2. Peak Systolic Flow Velocity
s a Measure of Internal Carotid Stenosis
The relationship between peak systolic flow velocity in the internal carotid artery
and the severity of stenosis as measured by contrast angiography is illustrated.
Note the considerable overlap between adjacent categories of stenosis. Error bars
indicate 1 standard deviation about the mean values. Reprinted with permission
from Grant et al. (142).inflection point at which flow velocity accelerates abovenormal because of atherosclerotic plaque and the other (70%
to 99% stenosis) representing more severe nonocclusive
disease, although the correlation with angiographic stenosis
is approximate and varies among laboratories. According to
a consensus document (136), when ultrasound is used, 50%
to 69% stenosis of the internal carotid artery is associated
with sonographically visible plaque and a peak systolic
velocity of 125 to 230 cm/s in this vessel. Additional criteria
include a ratio of internal to common carotid artery peak
systolic velocities between 2 and 4 and an end-diastolic
velocity of 40 to 100 cm/s in the internal carotid artery.
Nonocclusive stenosis 70% in the internal carotid artery is
associated with a peak systolic velocity 230 cm/s in this
vessel and plaque and luminal narrowing visualized by
gray-scale and color Doppler sonography. Additional crite-
ria include a ratio of internal to common carotid artery peak
systolic velocity4 and end-diastolic velocity100 cm/s in
the internal carotid artery. The considerable overlap of
velocities associated with stenosis of varying severities may
make it difficult to distinguish 70% stenosis from less severe
stenosis and supports the use of corroborating vascular
imaging methods for more accurate assessment in equivocal
or uncertain cases. The ratio of flow velocities in the internal
and common carotid arteries may help distinguish between
increased compensatory flow through collaterals and true
contralateral internal carotid stenosis or occlusion.
Among the pitfalls in velocity-based estimation of inter-
nal carotid artery stenosis are higher velocities in women
than in men and elevated velocities in the presence of
contralateral carotid artery occlusion (145,146). Severe ar-
terial tortuosity, high carotid bifurcation, obesity, and ex-
tensive vascular calcification reduce the accuracy of ultra-
sonography. Furthermore, in situ carotid stents decrease
compliance of the vessel wall and can accelerate flow velocity
(147). Ultrasonography may fail to differentiate between sub-
total and complete arterial occlusion, although the distinction
is of critical clinical importance. In such cases, intravenous
administration of sonographic contrast agents may improve
diagnostic accuracy (148,149), but the safety of these agents
has been questioned (150). In addition to these technical
factors, variability in operator expertise greatly affects the
quality of examinations and reliability of results (Table 3)
(151–153). Despite these limitations, ultrasonography per-
formed by well-trained, experienced technologists provides
accurate and relatively inexpensive assessment of the cervical
carotid arteries (151–153,162–164). The technique is truly
noninvasive and does not involve venipuncture or exposure to
ionizing radiation or potentially nephrotoxic contrast material.
Although results vary greatly between laboratories and opera-
tors, the sensitivity and specificity for detection or exclusion
of 70% stenosis of the internal carotid artery are 85% to
90% compared with conventional angiography (Table 4)
(141,165,166).
Every vascular laboratory should have a quality assurance
program that compares estimates of stenosis by color Dopp-
ler ultrasound imaging with angiographic measurements.
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adherence to stringent quality assurance programs, as re-
quired for accreditation by the Intersocietal Commission for
the Accreditation of Vascular Laboratories, have been asso-
ciated with superior results (Standards for Accreditation in
Noninvasive Vascular Testing, Part II, Vascular Laboratory
Operations: Extracranial Cerebrovascular Testing; available
at http://www.icavl.org). Characterization of plaque mor-
phology is possible in some cases and may have therapeutic
implications (181), but this is not yet widely used in
practice. Future technological advances may bring about less
operator-dependent 3-dimensional, high-resolution arterial
imaging.
5.3. Magnetic Resonance Angiography
MRA can generate high-resolution noninvasive images of
the cervical arteries. The radiofrequency signal characteris-
tics of flowing blood are sufficiently distinct from surround-
ing soft tissue to allow imaging of the arterial lumen (182).
However, there is an increasing shift to contrast-enhanced
Table 3. Variability of Doppler Ultrasonography
Author/Type of Study (Reference) Study Parame
ariability between different centers
Perkins et al./survey (154) Questionnaire on carotid duple
73 vascular laboratories
Robless et al./survey (155) Questionnaire on carotid duple
71 vascular laboratories
Alexandrov et al./prospective (156) 2 Vascular laboratories in 2 ho
same equipment
Schwartz et al./prospective (157) 10 Systems, 9 hospitals
Fillinger et al./consecutive (158) 2 Vascular laboratories, 4 syste
Howard (151) 37 Centers, 63 Doppler devices
Howard/prospective (100) 19 Centers, 30 Doppler devices
nterequipment variability
Ranke/prospective (159) 20 ICA, 10 patients, 2 different
same observer
Wolstenhulme/prospective (160) 2 Systems, 43 patients, same
Daigle/in vitro (161) 6 Systems, velocity-calibrated s
nterobserver and intraobserver variability
Ranke/prospective (159) 20 ICA, 11 patients, same syst
olstenhulme/prospective (160) 20 Patients, 2 systems, 1 obse
CI indicates confidence interval; and ICA, internal carotid artery.
Reprinted with permission from Long et al. (167).MRA to amplify the relative signal intensity of flowingblood compared with surrounding tissues and allow more
detailed evaluation of the cervical arteries (183–188). Slowly
flowing blood is also better imaged with contrast-enhanced
MRA, which is sensitive to both the velocity and direction
of blood flow. Despite artifacts and other limitations,
high-quality MRA can provide accurate anatomic imaging
of the aortic arch and the cervical and cerebral arteries (167)
and may be used to plan revascularization without exposure
to ionizing radiation.
Technological advancements have reduced image acqui-
sition time, decreased respiratory and other motion-based
artifacts, and greatly improved the quality of MRA to rival
that of conventional angiography for many applications,
including evaluation of patients with ECVD. Higher-field-
strength systems, such as the 3-Tesla apparatus, more
powerful gradients, and sophisticated software are associ-
ated with better MRA image quality than systems with
lower field strengths. Although popular with patients, low-
field-strength, open MRI systems are rarely capable of
Conclusions
tice; Diversity in diagnostic criteria; diversity in method of
stenosis grading
tice; Diversity in method of stenosis grading; diversity
concerning the Doppler angle used
; A definite velocity criterion does not have the same
validity and predictive value to grade carotid stenosis
at different laboratories
Predictive ability of different parameters to quantify
stenosis was different from 1 device to another
60 bifurcations Most accurate duplex criteria for a 60% ICA stenosis
were machine specific
Performance of Doppler ultrasound was heterogeneous
between devices
Performance relates to the device-sonographer-reader
system. Cut point for the peak systolic flow to ensure
a positive predictive value of 90% in predicting a
60% stenosis ranged from 151 to 390 cm/s or
from 5,400 to 11,250 Hz
ms, Intrastenotic peak flow velocity values were significantly
higher with 1 system
er Limits of agreements (within 95% of different lie)
between systems: 0.47 to 0.45 m/s
flow phantom Five of 6 systems: overestimation of all peak velocities
compared with the calibrated string flow phantom
observers Interobserver variation expressed as 95% CI for
predicted stenosis between 2 observers was 13.6%
with peak systolic velocity and 15.4% with mean
velocity ratio
Intraobserver reproducibility coefficient for both
machines was 0.48 cm/sters
x prac
x prac
spitals
ms, 3
syste
observ
tring
em, 2
rverproducing high-quality MRA. Correlations with angiogra-
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sensitivity that ranges from 97% to 100% and a specificity
that ranges from 82% to 96% (183–186,189), although these
estimates may be subject to reporting bias.
Pitfalls in MRA evaluation of ECVD include overesti-
mation of stenosis (more so with noncontrast examinations)
and inability to discriminate between subtotal and complete
arterial occlusion. More problematic is the inability to
examine the substantial fraction of patients who have
claustrophobia, extreme obesity, or incompatible implanted
devices such as pacemakers or defibrillators, many of whom
are at high risk for atherosclerotic ECVD. On the other
hand, among the notable strengths of MRA relative to
carotid ultrasound and CTA is its relative insensitivity to
arterial calcification. Like sonography, MRI may be used to
assess atheromatous plaque morphology (190,191), but the
utility of this application in clinical practice requires further
validation.
Gadolinium-based compounds used as magnetic reso-
nance contrast agents are associated with a much lower
incidence of nephrotoxicity and allergic reactions than the
iodinated radiographic contrast materials used for CTA and
conventional angiography. However, exposure of patients
with preexisting renal dysfunction to high doses of
gadolinium-based contrast agents in conjunction with
MRA has been associated with nephrogenic systemic fibro-
sis. This poorly understood disorder causes cutaneous scle-
rosis, subcutaneous edema, disabling joint contractures, and
Table 4. Sensitivity and Specificity of Duplex Ultrasonography
Study, Year (Reference) Degree of Stenosis
erfaty et al., 2000 (168) Occlusion
ood et al., 1996 (169) Occlusion
hite et al., 1994 (170) Occlusion
urnipseed et al., 1993 (171) Occlusion
iles et al., 1992 (172) Occlusion
iles et al., 1992 (172) Stenosis 80%
ohnson et al., 2000 (173) Stenosis 70%
erfaty et al., 2000 (168) Stenosis 70%
uston et al., 1998 (174) Stenosis 70%
ink et al., 1997 (175) Stenosis 70%
ood et al., 1996 (169) Stenosis 70%
ray et al., 1995 (176) Stenosis 70%
atel et al., 1995 (177) Stenosis 70%
urnipseed et al., 1993 (171) Stenosis 70%
luth et al., 2000 (178) Stenosis 60%
ackson et al., 1998 (179) Stenosis 60%
hite et al., 1994 (170) Stenosis 60%
alters et al., 1993 (180) Stenosis 60%
erfaty et al., 2000 (168) Stenosis 50%
ood et al., 1996 (169) Stenosis 50%
ray et al., 1995 (176) Stenosis 50%
iles et al., 1992 (172) Stenosis 50%
Modified from Long et al. (167).injury to internal organs (192).5.4. Computed Tomographic Angiography
Multiplanar reconstructed CTA may be obtained from thin,
contiguous axial images acquired after intravenous admin-
istration of radiographic contrast material. Rapid image
acquisition and processing, continuous image acquisition
(“spiral CT”), and multiple-detector systems have made
high-resolution CTA clinically practical (193–199). Like
MRA, CTA provides anatomic imaging from the aortic
arch through the circle of Willis. Multiplanar reconstruction
and analysis allows evaluation of even very tortuous vessels.
Unlike ultrasonography or MRA, CTA provides direct
imaging of the arterial lumen suitable for evaluation of stenosis.
With severe stenosis, volume averaging affects the accuracy of
measurement as the diameter of the residual vessel lumen
approaches the resolution limit of the CT system.
Like MRA, CTA is undergoing rapid technological
evolution. Increasing the number of detector rows facilitates
faster, higher-resolution imaging and larger fields of view,
and 16-, 32-, 64-, 256-, and 320-row detector and dual-
source systems are in clinical use (200,201). Slower image
acquisition by equipment with fewer detector rows allows
the intravenous contrast bolus to traverse the arteries and
enter the capillaries and veins before imaging is complete,
degrading images by competing enhancement of these
structures. Conversely, scanners with a greater number of
detector rows offer faster acquisition during the arterial
phase, reduce motion and respiratory artifacts, and lessen
the volume of contrast required. Equipment, imaging pro-
Function of Degree of Carotid Stenosis
Carotids, n Sensitivity, % Specificity, %
46 100 90
457 100 99
120 80 100
34 100 100
75 100 100
75 85 80
76 65 95
46 64 97
100 97 75
56 87 98
457 86 97
128 85 96–97
171 94 83
34 94 89
40 62 100
99 89 92
120 73 88
102 88 88
46 94 83
457 99.5 89
128 87–95 96
75 98 69as atocols, and interpreter experience factor heavily into the
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CTA has compared favorably with catheter angiography for
evaluation of patients with ECVD, with 100% sensitivity
and 63% specificity (95% CI 25% to 88%); the negative
predictive value of CTA demonstrating70% carotid artery
stenosis was 100% (206) (Table 5). However, on the basis of
study that compared sonography, CTA, and MRA per-
ormed with and without administration of intravenous
ontrast material, the accuracy of noninvasive imaging for
valuation of cervical carotid artery stenosis may be generally
verestimated in the literature (215).
The need for relatively high volumes of iodinated contrast
edia restricts the application of CTA to patients with
dequate renal function. Although several strategies have
een evaluated, discussion of medical therapies designed to
educe the risk of contrast-induced nephropathy is beyond
he scope of this document. Faster imaging acquisition and
greater number of detector rows ameliorate this problem.
s with sonography, heavily calcified lesions are difficult to
ssess for severity of stenosis, and the differentiation of
ubtotal from complete arterial occlusion can be problematic
216). Metallic dental implants or surgical clips in the neck
enerate artifacts that may obscure the cervical arteries.
bese or uncooperative (moving) patients are difficult to scan
ccurately, but pacemakers and defibrillators implanted in the
hest are not impediments to CTA of the cervical arteries.
Other perfusion-based CT imaging techniques can provide
dditional information about cerebral blood flow and help
etermine the hemodynamic significance of stenotic lesions in
Table 5. Sensitivity and Specificity of Computed Tomographic
Study, Year (Reference) Degree of Stenosis
Anderson et al., 2000 (207) Occlusion
Leclerc et al., 1999 (208) Occlusion
Marcus et al., 1999 (209) Occlusion
Verhoek et al., 1999 (210) Occlusion
Magarelli et al., 1998 (211) Occlusion
Link et al., 1997 (175) Occlusion
Leclerc et al., 1995 (212) Occlusion
Dillon et al., 1993 (213) Occlusion
Schwartz et al., 1992 (214) Occlusion
Stenosis 80%
Anderson et al., 2000 (207) Stenosis 70%
Leclerc et al., 1999 (208) Stenosis 70%
Marcus et al., 1999 (209) Stenosis 70%
Verhoek et al., 1999 (210) Stenosis 70%
Magarelli et al., 1998 (211) Stenosis 70%
Link et al., 1997 (175) Stenosis 70%
Leclerc et al., 1995 (212) Stenosis 70%
Dillon et al., 1993 (213) Stenosis 70%
Schwartz et al., 1992 (214) Stenosis 70%
Stenosis 60%
Anderson et al., 2000 (207) Stenosis 50%
NA indicates not available.
Modified from Long et al. (167).he extracranial and intracranial arteries that supply the brain.s is the case with carotid duplex sonography, transcranial
oppler sonography, MRI, and radionuclide imaging to assess
erebral perfusion, there is no convincing evidence that avail-
ble imaging methods reliably predict the risk of subsequent
troke, and there is no adequate foundation on which to
ecommend the broad application of these techniques for
valuation of patients with cervical arterial disease.
5.5. Catheter-Based Contrast Angiography
Conventional digital angiography remains the standard
against which other methods of vascular imaging are com-
pared in patients with ECVD. There are several methods for
measuring stenosis in the internal carotid arteries that yield
markedly different measurements in vessels with the same
degree of anatomic narrowing (Figure 3), but the method used
in NASCET is dominant and has been used in most modern
clinical trials. It is essential to specify the methodology used
both in the evaluation of individual patients with ECVD and
in the assessment of the accuracy of noninvasive imaging
techniques. Among the impediments to angiography as a
screening modality are its costs and associated risks. The most
feared complication is stroke, the incidence of which is 1%
when the procedure is performed by experienced physicians
(218–225). Substantially higher rates of stroke have been
reported with diagnostic angiography in some series, most
notably in ACAS (71), in which the incidence was 1.2%
because of unusually frequent complications at a few centers.
Complication rates in other studies have been substantially
lower (226), and most authorities regard a stroke rate 1%
graphy as a Function of Degree of Carotid Stenosis
Carotids, n Sensitivity, % Specificity, %
80 69–100 98
44 100 100
46 100 100
38 66–75 87–100
40 100 100
56 100 100
39 100 100
50 81–87.5 97–100
40 100 100
NA NA NA
80 67–77 84–92
44 67–100 94–97
46 85–93 93–97
38 80–100 95–100
40 92 98.5
56 100 100
39 87.5–100 96–100
50 81–82 94–95
40 100 100
NA NA NA
80 85–90 82–91Angiowith diagnostic angiography as unacceptable (227). Angiogra-
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when obesity, renal dysfunction, or indwelling ferromagnetic
material renders CTA or MRA technically inadequate or
impossible, and angiography is appropriate when noninvasive
imaging studies produce conflicting results. In practice, how-
ever, catheter-based angiography is unnecessary for diagnostic
evaluation of most patients with ECVD and is used increas-
ingly as a therapeutic revascularization maneuver in conjunc-
tion with stent deployment.
5.6. Selection of Vascular Imaging Modalities
for Individual Patients
Because of its widespread availability and relatively low cost,
carotid duplex ultrasonography is favored for screening patients
at moderate risk of disease. When this method does not
suggest significant stenosis in a symptomatic patient, further
anatomic assessment should be considered by use of other
modalities capable of detecting more proximal or distal disease.
If ultrasound imaging results are equivocal or indeterminate,
MRA or CTA may be performed to confirm the extent of
atherosclerotic disease and provide additional anatomic infor-
mation. Conversely, patients with a high pretest probability of
disease may be studied initially by MRA or CTA to more
completely evaluate the cerebral vessels distal to the aortic arch,
because sonographic imaging alone does not provide assess-
ment of intrathoracic or intracranial lesions beyond the limited
range of the ultrasound probe. Moreover, duplex ultrasonog-
raphy may overestimate the severity of stenosis contralateral to
internal carotid occlusion. This is an important consideration
during the selection of asymptomatic patients for carotid
revascularization, and in such cases, confirmation of the sono-
graphic findings by another modality is recommended. Pa-
Figure 3. Angiographic Methods for
etermining Carotid Stenosis Severity
ECST indicates European Carotid Surgery Trial; and NASCET, North American Symp-
tomatic Carotid Endarterectomy Trial. Reprinted with permission from Osborn (217).tients poorly suited to MRA because of claustrophobia, im-planted pacemakers, or other factors may be evaluated by
CTA, whereas those with extensive calcification should un-
dergo MRA. In patients with renal insufficiency, for whom
exposure to iodinated radiographic contrast stands as a relative
contraindication to CTA, the relatively rare occurrence of
nephrogenic systemic fibrosis has reduced the use of gadolin-
ium contrast-enhanced MRA as well.
Because high-quality imaging potentially can be obtained by
any of the recommended modalities, these are simply general
suggestions. Given the variation in image quality and resource
availability at one facility compared with another, other factors
may govern the selection of the optimum testing modality for
a particular patient. In general, though, conventional angiog-
raphy is usually reserved for patients in whom adequate
delineation of disease cannot be obtained by other methods,
when noninvasive imaging studies have yielded discordant
results, or for those with renal dysfunction in whom evaluation
of a single vascular territory would limit exposure to contrast
material. A patient presenting with a left hemispheric stroke or
TIA, for instance, might best be evaluated by selective angiog-
raphy of the left common carotid artery, which entails a small
volume of contrast that is unlikely to exacerbate renal insuffi-
ciency while providing definitive images of the culprit vessel
and its branches.
6. Medical Therapy for Patients
With Atherosclerotic Disease of the
Extracranial Carotid or Vertebral Arteries
6.1. Recommendations for the
Treatment of Hypertension
CLASS I
1. Antihypertensive treatment is recommended for patients with hy-
pertension and asymptomatic extracranial carotid or vertebral ath-
erosclerosis to maintain blood pressure below 140/90 mm Hg
(111,228–231). (Level of Evidence: A)
CLASS IIa
1. Except during the hyperacute period, antihypertensive treatment is
probably indicated in patients with hypertension and symptomatic
extracranial carotid or vertebral atherosclerosis, but the benefit of
treatment to a specific target blood pressure (e.g., below 140/90
mm Hg) has not been established in relation to the risk of exacer-
bating cerebral ischemia. (Level of Evidence: C)
Hypertension increases the risk of stroke, and the relation-
ship between blood pressure and stroke is continuous
(232–234). For each 10-mm Hg increase in blood pressure,
the risk of stroke increases by 30% to 45% (235). Con-
versely, antihypertensive therapy reduces the risk of stroke
(230); meta-analysis of more than 40 trials and 188,000
patients found a 33% decreased risk of stroke for each
10-mm Hg reduction in systolic blood pressure to 115/75
mm Hg (230,231). A systematic review of 7 randomized
trials found that antihypertensive therapy reduced the risk of
recurrent stroke by 24% (228). The type of therapy appears
less important than the response (230). For these reasons,
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Patients With Ischemic Stroke or Transient Ischemic At-
tack recommend antihypertensive treatment beyond the
hyperacute period for patients who have experienced isch-
emic stroke or TIA (111).
Epidemiological studies, including the ARIC study (17),
Cardiovascular Health Study (236), Framingham Heart
Study (237), and MESA (Multi-Ethnic Study of Athero-
sclerosis) (238), among others, found an association be-
tween hypertension and the risk of developing carotid
atherosclerosis (17,236,238 –240). In the Framingham
eart Study, for example, there was a 2-fold greater risk of
arotid stenosis 25% for each 20-mm Hg increase in
ystolic blood pressure (237). In SHEP (Systolic Hyperten-
ion in the Elderly Program), systolic blood pressure 160
m Hg was the strongest independent predictor of carotid
tenosis (241). Meta-analysis of 17 hypertension treatment
rials involving approximately 50,000 patients found a 38%
eduction in risk of stroke and 40% reduction in fatal stroke
ith antihypertensive therapy (242). These beneficial effects
ere shared among whites and blacks across a wide age
ange (242). In patients who had experienced ischemic
troke, administration of a combination of the angiotensin-
onverting enzyme inhibitor perindopril and a diuretic
indapamide) significantly reduced the risk of recurrent
schemic events compared with placebo among 6105 par-
icipants randomized in the PROGRESS (Preventing
trokes by Lowering Blood Pressure in Patients With
erebral Ischemia) trial (RR reduction 28%, 95% CI 17% to
8%; p0.0001) (229). The protective value of blood
ressure lowering extends even to patients without hyper-
ension, as demonstrated in the HOPE (Heart Outcomes
rotection Evaluation) trial, in which patients with systemic
therosclerosis randomized to treatment with ramipril dis-
layed a significantly lower risk of stroke than those given a
lacebo (RR 0.68; p0.001) (243).
In symptomatic patients with severe carotid artery steno-
is, however, it is not known whether antihypertensive
herapy is beneficial or confers harm by reducing cerebral
erfusion. In some patients with severe carotid artery
tenosis, impaired cerebrovascular reactivity may be associ-
ted with an increased risk of ipsilateral ischemic events
244). The Seventh Report of the Joint National Commit-
ee for the Prevention, Detection, Evaluation, and Treat-
ent of High Blood Pressure (JNC-7) recommends blood
ressure lowering for patients with ischemic heart disease or
AD but offers no specific recommendation for treatment
f hypertension in patients with ECVD (245).
6.2. Cessation of Tobacco Smoking
6.2.1. Recommendation for Cessation of
Tobacco Smoking
CLASS I
1. Patients with extracranial carotid or vertebral atherosclerosis whosmoke cigarettes should be advised to quit smoking and offeredsmoking cessation interventions to reduce the risks of atheroscle-
rosis progression and stroke (246–250). (Level of Evidence: B)
Smoking increases the RR of ischemic stroke by 25% to
50% (247–253). Stroke risk decreases substantially within 5
years in those who quit smoking compared with continuing
smokers (248,250). In large epidemiological studies, ciga-
rette smoking has been associated with extracranial carotid
artery IMT and the severity of carotid artery stenosis
(23,254–257). In the ARIC study, current and past ciga-
rette smoking, respectively, were associated with 50% and
25% increases in the progression of carotid IMT over 3
years compared with nonsmokers (252). In the Framingham
Heart Study, extracranial carotid artery stenosis correlated
with the quantity of cigarettes smoked over time (237). In
the Cardiovascular Health Study, the severity of carotid
artery stenosis was greater in current smokers than in former
smokers, and there was a significant relationship between
the severity of carotid stenosis and pack-years of exposure to
tobacco (239). The RRs of finding 60% carotid stenosis
were 1.5 and 3.9 among cigarette smokers with cerebral
ischemia in the NOMASS and the BCID (Berlin Cerebral
Ischemia Databank) studies, respectively (258).
6.3. Control of Hyperlipidemia
6.3.1. Recommendations for Control of
Hyperlipidemia
CLASS I
1. Treatment with a statin medication is recommended for all
patients with extracranial carotid or vertebral atherosclerosis to
reduce low-density lipoprotein (LDL) cholesterol below 100
mg/dL (111,259,260). (Level of Evidence: B)
CLASS IIa
1. Treatment with a statin medication is reasonable for all patients
with extracranial carotid or vertebral atherosclerosis who sustain
ischemic stroke to reduce LDL-cholesterol to a level near or below
70 mg/dL (259). (Level of Evidence: B)
2. If treatment with a statin (including trials of higher-dose statins and
higher-potency statins) does not achieve the goal selected for a
patient, intensifying LDL-lowering drug therapy with an additional
drug from among those with evidence of improving outcomes (i.e.,
bile acid sequestrants or niacin) can be effective (261–264). (Level
of Evidence: B)
3. For patients who do not tolerate statins, LDL-lowering therapy with
bile acid sequestrants and/or niacin is reasonable (261,263,265).
(Level of Evidence: B)
The relationship between cholesterol and ischemic stroke is
not as evident as that between cholesterol and MI, and
findings from population-based studies are inconsistent. In
the MR FIT (Multiple Risk Factor Intervention Trial),
comprising more than 350,000 men, the RR of death
increased progressively with serum cholesterol, exceeding
2.5 in those with the highest levels (266). An analysis of 45
prospective observational cohorts involving approximately
450,000 individuals, however, found no association of hy-
percholesterolemia with stroke (267). In the ARIC study,
the relationships between lipid values and incident ischemic
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a prospective cohort study among 27,937 U.S. women 45
years of age and older, total and LDL cholesterol levels were
strongly associated with increased risk of ischemic stroke
(269). The RR of a future ischemic stroke in the highest
quintile of non–high-density lipoprotein (HDL) choles-
terol levels compared with the lowest quintile was 2.25. In
a meta-analysis of 61 prospective observational studies, most
conducted in western Europe or North America, consisting
of almost 900,000 adults between the ages of 40 and 89
years without previous disease and nearly 12 million person-
years at risk, total cholesterol was only weakly related to
ischemic stroke mortality in the general population between
ages 40 and 59 years, and this was largely accounted for by
the association of cholesterol with hypertension (270).
Moreover, in those with below-average blood pressures, a
positive relation was seen only in middle age. At older ages
(70 to 89 years) and for those with systolic blood pressure
145 mm Hg, total serum cholesterol was inversely related
to hemorrhagic and total stroke mortality (270). Epidemi-
ological studies, however, have consistently found an asso-
ciation between cholesterol and carotid artery atherosclero-
sis as determined by measurement of IMT (25,255,271). In
the Framingham Heart Study, the RR of carotid artery
stenosis 25% was approximately 1.1 for every 10-mg/dL
increase in total cholesterol (237). In the MESA study,
carotid plaque lipid core detected by MRI was strongly
associated with total cholesterol (272).
Lipid-lowering therapy with statins reduces the risk of
stroke in patients with atherosclerosis (273). Two large
meta-analyses examined the effect of statins on the risk of
stroke among patients with CAD or other manifestations of
atherosclerosis or at high risk for atherosclerosis (274,275).
One such analysis of 26 trials comprising 90,000 patients
found that statins reduced the risk of all strokes by approx-
imately 21% (274), with stroke risk decreasing 15.6% for
each 10% reduction in serum LDL cholesterol (274).
Another meta-analysis of 9 trials comprising more than
65,000 patients found a 22% reduction in ischemic stroke
per 1-mmol/L (40 mg/dL) reduction in serum LDL
cholesterol (275). There was no effect in either meta-
analysis of lowering LDL cholesterol on the risk of hem-
orrhagic stroke.
A randomized trial, SPARCL (Stroke Prevention by
Aggressive Reduction in Cholesterol Levels), prospectively
compared the effect of atorvastatin (80 mg daily) against
placebo on the risk of stroke among patients with recent
stroke or TIA (259). Statin therapy reduced the absolute
risk of stroke at 5 years by 2.2%, the RR of all stroke by
16%, and the RR of ischemic stroke by 22% (206).
There are multiple causes of ischemic stroke, and only a
limited number of studies have specifically examined the
effect of statins on stroke in patients with ECVD; the
available data suggest that statins are beneficial. In a
secondary subgroup analysis of the trial data, there was no
heterogeneity in the treatment effect for the primary end-point (fatal and nonfatal stroke) or for secondary endpoints
between patients with and without carotid stenosis (276). In
those with carotid stenosis, greater benefit occurred in terms
of reduction of all cerebrovascular and cardiovascular events
combined, and treatment with atorvastatin was associated
with a 33% reduction in the risk of any stroke (HR 0.67,
95% CI 0.47 to 0.94; p0.02) and a 43% reduction in risk
of major coronary events (HR 0.57, 95% CI 0.32 to 1.00;
p0.05). Subsequent carotid revascularization was reduced
by 56% (HR 0.44, 95% CI 0.24 to 0.79; p0.006) in the
group randomized to atorvastatin (276). Hence, consistent
with the overall results of the trial, lipid lowering with
high-dose atorvastatin reduced the risk of cerebrovascular
events in particular and cardiovascular events in general in
patients with and without carotid stenosis, yet those with
carotid stenosis derived greater benefit (276).
Statins reduce the risk of MI by 23% and cardiovascular
death by 19% in patients with CAD (275). Moreover, statin
therapy reduces progression or induces regression of carotid
atherosclerosis. In the Heart Protection Study, there was a
50% reduction in CEA in patients randomized to statin
therapy (277). A meta-analysis of 9 trials of patients
randomized to statin treatment or control found the statin
effect to be closely associated with LDL cholesterol reduc-
tion. Each 10% reduction in LDL cholesterol reduced the
risk of all strokes by 15.6% (95% CI 6.7 to 23.6) and of
carotid IMT by 0.73% per year (95% CI 0.27 to 1.19) (274).
METEOR (Measuring Effects on Intima-Media Thick-
ness: An Evaluation of Rosuvastatin) found that compared
with placebo, rosuvastatin reduced progression of carotid
IMT over 2 years in patients with low Framingham risk
scores and elevated serum LDL cholesterol levels (278).
Two of the trials included in the meta-analysis compared
greater- to lesser-intensity statin therapy. In the ARBITER
(Arterial Biology for the Investigation of the Treatment Effects
of Reducing Cholesterol) trial, carotid IMT regressed after
12 months of treatment with atorvastatin (80 mg daily) but
remained unchanged after treatment with pravastatin (40
mg daily) (279). The LDL cholesterol levels in the atorva-
statin and pravastatin treatment groups were 7623 and
11030 mg/dL, respectively. In the ASAP (Atorvastatin
versus Simvastatin on Atherosclerosis Progression) trial of
patients with familial hypercholesterolemia, carotid IMT
decreased after 2 years of treatment with 80 mg of atorva-
statin daily but increased in patients randomized to 40 mg
of simvastatin daily (280).
It is less clear whether lipid-modifying therapies other
than high-dose statins reduce the risk of ischemic stroke or
the severity of carotid artery disease. Among patients
participating in the Coronary Drug Project, niacin reduced
the 15-year mortality rate (9 years after study completion),
primarily by decreasing the incidence of death caused by
coronary disease, with a relatively small beneficial trend in
the risk of death caused by cerebrovascular disease (281). In
the Veterans Affairs HDL Intervention trial of men with
CAD and low serum HDL cholesterol levels, gemfibrozil
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ischemic strokes (282). Fenofibrate did not reduce the
stroke rate in the FIELD (Fenofibrate Intervention and
Event Lowering in Diabetes) study of patients with diabetes
mellitus (283). In the CLAS (Cholesterol Lowering Ath-
erosclerosis) trial, the combination of colestipol and niacin
reduced progression of carotid IMT (58). In the
ARBITER-2 study of patients with CAD and low levels of
HDL cholesterol, carotid IMT progression did not differ
significantly after the addition of extended-release niacin to
statin therapy compared with statin therapy alone, although
there was a trend favoring the dual therapy (284). In the
ENHANCE (Effect of Combination Ezetimibe and High-
Dose Simvastatin vs. Simvastatin Alone on the Atheroscle-
rotic Process in Patients with Heterozygous Familial Hy-
percholesterolemia) study, in patients with familial
hypercholesterolemia, the addition of ezetimibe to simva-
statin did not affect progression of carotid IMT more than
the use of simvastatin alone (285).
6.4. Management of Diabetes Mellitus
6.4.1. Recommendations for Management of
Diabetes Mellitus in Patients With Atherosclerosis
of the Extracranial Carotid or Vertebral Arteries
CLASS IIa
1. Diet, exercise, and glucose-lowering drugs can be useful for patients
with diabetes mellitus and extracranial carotid or vertebral artery
atherosclerosis. The stroke prevention benefit, however, of intensive
glucose-lowering therapy to a glycosylated hemoglobin A1c level
less than 7.0% has not been established (286,287). (Level of
Evidence: A)
2. Administration of statin-type lipid-lowering medication at a dosage
sufficient to reduce LDL cholesterol to a level near or below 70
mg/dL is reasonable in patients with diabetesmellitus and extracra-
nial carotid or vertebral artery atherosclerosis for prevention of
ischemic stroke and other ischemic cardiovascular events (288).
(Level of Evidence: B)
The risk of ischemic stroke in patients with diabetes
mellitus is increased 2- to 5-fold (289–291) compared with
patients without diabetes. The Cardiovascular Health Study
investigators reported that elevated fasting and postchal-
lenge glucose levels were associated with an increased risk of
stroke (292), and diabetes was associated with carotid IMT
and the severity of carotid artery stenosis (24). In the Insulin
Resistance Atherosclerosis Study, diabetes and fasting glu-
cose levels were associated with carotid IMT, and carotid
IMT progressed twice as rapidly in patients with diabetes as
in those without diabetes (293–295). Similarly, in the ARIC
study, diabetes was associated with progression of carotid
IMT (254,291,296), and in the Rotterdam study, diabetes
predicted progression to severe carotid obstruction (297). In
the EDIC (Epidemiology of Diabetes Interventions and
Complications) study, the progression of carotid IMT was
greater in patients with diabetes than in those without
diabetes (298) and less in patients with diabetes treated with
intensive insulin therapy than in those managed moreconventionally. In several randomized studies, pioglitazone
caused less progression or induced regression of carotid
IMT compared with glimepiride (299,300).
Several trials examined the effect of intensive glucose
control on vascular events, with stroke included as a sec-
ondary outcome. In the United Kingdom Prospective Dia-
betes study, intensive treatment of blood glucose, compared
with conventional management, did not affect the risk of
stroke in patients with type 2 diabetes mellitus (301). In the
ACCORD (Action to Control Cardiovascular Risk in
Diabetes) (286) and ADVANCE (Action in Diabetes and
Vascular Disease: Preterax and Diamicron MR Controlled
Evaluation) (287) trials, intensive treatment to achieve
glycosylated hemoglobin levels 6.0% and 6.5%, respec-
tively, did not reduce the risk of stroke in patients with type
2 diabetes mellitus compared with conventional treatment.
In patients with type 1 diabetes mellitus, intensive insulin
treatment reduced rates of nonfatal MI, stroke, or death due
to cardiovascular disease by 57% during the long-term
follow-up phase of the DDCT (Diabetes Control and
Complications Trial)/EDIC study, but the absolute risk
reduction was 1% during 17 years of follow-up. These
observations suggest that it would be necessary to treat 700
patients for 17 years to prevent cardiovascular events in 19
patients; the NNT per year to prevent a single event equals
626, a relatively low return on effort for prevention of stroke
(302). Effects on fatal and nonfatal strokes were not re-
ported separately (302).
At least as important as treatment of hyperglycemia is
aggressive control of other modifiable risk factors in patients
with diabetes. In the UK-TIA (United Kingdom Transient
Ischemic Attack) trial, treatment of hypertension was more
useful than blood glucose control in reducing the rate of
recurrent stroke (303). In patients with type 2 diabetes
mellitus who had normal serum levels of LDL cholesterol,
administration of 10 mg of atorvastatin daily was safe and
effective in reducing the risk of cardiovascular events by 37%
and of stroke by 48% (288). Although the severity of carotid
atherosclerosis was not established in the trial cohort, the
findings suggest that administration of a statin may be
beneficial in patients with diabetes even when serum lipid
levels are not elevated. Other agents, such as those of the
fibrate class, do not appear to offer similar benefit in this
situation (283,304).
6.5. Hyperhomocysteinemia
Hyperhomocysteinemia increases the risk of stroke. Meta-
analysis of 30 studies comprising more than 16,000 patients
found a 25% difference in plasma homocysteine concentra-
tion, which corresponded to approximately 3 micromoles
per liter, to be associated with a 19% difference in stroke risk
(305). The risk of developing 25% extracranial carotid
stenosis is increased 2-fold among elderly patients with
elevated homocysteine levels (306), and plasma concentra-
tions of folate and pyridoxal 5= phosphate are inversely
associated with carotid stenosis (306). In the ARIC study,
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among participants with the highest than the lowest quintile
of homocysteine (307), and findings were similar in the
Perth Carotid Ultrasound Disease Assessment study (308),
ut adjustment for renal function eliminated or attenuated
he relationship between homocysteine levels and carotid
MT (309).
Stroke rates decreased and average plasma homocysteine
oncentrations fell after folic acid fortification of enriched
rain products in the United States and Canada, but not in
ngland and Wales, where fortification did not occur (310).
eta-analysis of 8 randomized primary prevention trials
ound that folic acid supplementation reduced the risk of
troke by 18% (311). Despite these observations, studies of
atients with established vascular disease have not con-
rmed a benefit of homocysteine lowering by B-complex
itamin therapy on cardiovascular outcomes, including
troke. In the VISP (Vitamin Intervention for Stroke
revention) study, a high-dose formulation of pyridoxine
B6), cobalamin (B12), and folic acid lowered the plasma
homocysteine level 2 micromoles per liter more than a
low-dose formulation of these vitamins but did not reduce
the risk of recurrent ischemic stroke (312). Among patients
with established vascular disease or diabetes, a combination
of vitamins B6, B12, and folic acid lowered plasma homo-
cysteine by 2.4 micromoles per liter without effects on the
composite endpoint of cardiovascular death, MI, or stroke
or its individual components (313). Similarly, this combi-
nation of B-complex vitamins lowered plasma homocysteine
concentration by more than 2 micromoles per liter (18.5%)
in women with established cardiovascular disease or 3 or
more risk factors but did not alter rates of the primary
composite endpoint of MI, stroke, coronary revasculariza-
tion, or cardiovascular death or the secondary endpoint of
stroke (314).
Given that in patients with CAD, hyperhomocysteinemia
is a marker of risk but not a target for treatment and that
vitamin supplementation does not appear to affect clinical
outcomes, the writing committee considers the evidence
insufficient to justify a recommendation for or against
routine therapeutic use of vitamin supplements in patients
with ECVD.
6.6. Obesity and the Metabolic Syndrome
The metabolic syndrome, defined by the World Health
Organization and the National Cholesterol Education Pro-
gram on the basis of blood glucose, hypertension, dyslipi-
demia, body mass index, waist/hip ratio, and urinary albu-
min excretion, is associated with carotid atherosclerosis after
adjustment for other risk factors in men and women across
several age strata and ethnic groups (315–324). This rela-
tionship to carotid atherosclerosis is strengthened in pro-
portion to the number of components of metabolic syn-
drome present (p0.001) (325–327). With regard to the
individual components, the relationship appears strongest
for hypertension (317,320,321,326,328,329), with hyper-cholesterolemia and obesity also related to carotid athero-
sclerosis in several reports (317,330). Abdominal adiposity
bears a graded association with the risk of stroke and TIA
independent of other vascular disease risk factors (331).
6.7. Physical Inactivity
Physical inactivity is a well-documented, modifiable risk
factor for stroke, with a prevalence of 25%, an attributable
risk of 30%, and an RR of 2.7, but the risk reduction
associated with treatment is unknown (33,332). Neverthe-
less, several meta-analyses and observational studies suggest
a lower risk of stroke among individuals engaging in
moderate to high levels of physical activity (333). The
relationship between physical activity and carotid IMT as a
marker of subclinical atherosclerosis has been inconsistent
(334–337). Furthermore, it is not clear whether exercise
alone is beneficial with respect to stroke risk in the absence
of effects on other risk factors, such as reduction of obesity
and improvements in serum lipid values and glycemic
control.
6.8. Antithrombotic Therapy
6.8.1. Recommendations for Antithrombotic Therapy
in Patients With Extracranial Carotid Atherosclerotic
Disease Not Undergoing Revascularization
CLASS I
1. Antiplatelet therapy with aspirin, 75 to 325 mg daily, is recom-
mended for patients with obstructive or nonobstructive atheroscle-
rosis that involves the extracranial carotid and/or vertebral arteries
for prevention of MI and other ischemic cardiovascular events,
although the benefit has not been established for prevention of
stroke in asymptomatic patients (33,260,305,338). (Level of Evi-
dence: A)
2. In patients with obstructive or nonobstructive extracranial carotid or
vertebral atherosclerosis who have sustained ischemic stroke or
TIA, antiplatelet therapy with aspirin alone (75 to 325 mg daily),
clopidogrel alone (75 mg daily), or the combination of aspirin plus
extended-release dipyridamole (25 and 200 mg twice daily, respec-
tively) is recommended (Level of Evidence: B) and preferred over the
combination of aspirin with clopidogrel (260,305,339–342) (Level
of Evidence: B). Selection of an antiplatelet regimen should be
individualized on the basis of patient risk factor profiles, cost,
tolerance, and other clinical characteristics, as well as guidance
from regulatory agencies.
3. Antiplatelet agents are recommended rather than oral anticoagula-
tion for patients with atherosclerosis of the extracranial carotid or
vertebral arteries with (343,344) (Level of Evidence: B) or without
(Level of Evidence: C) ischemic symptoms. (For patients with allergy
or other contraindications to aspirin, see Class IIa recommendation
#2, this section.)
CLASS IIa
1. In patients with extracranial cerebrovascular atherosclerosis who
have an indication for anticoagulation, such as atrial fibrillation or a
mechanical prosthetic heart valve, it can be beneficial to administer
a vitamin K antagonist (such as warfarin, dose-adjusted to achieve
a target international normalized ratio [INR] of 2.5 [range 2.0 to
FC
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(Level of Evidence: C)
2. For patients with atherosclerosis of the extracranial carotid or
vertebral arteries in whom aspirin is contraindicated by factors
other than active bleeding, including allergy, either clopidogrel (75
mg daily) or ticlopidine (250 mg twice daily) is a reasonable
alternative. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Full-intensity parenteral anticoagulation with unfractionated hepa-
rin or low-molecular-weight heparinoids is not recommended for
patients with extracranial cerebrovascular atherosclerosis who de-
velop transient cerebral ischemia or acute ischemic stroke
(2,346,347). (Level of Evidence: B)
2. Administration of clopidogrel in combination with aspirin is not
recommended within 3 months after stroke or TIA (340). (Level of
Evidence: B)
Although antiplatelet drugs reduce the risk of stroke com-
pared with placebo in patients with TIA or previous stroke
(305) (Table 6), no adequately powered controlled studies
have demonstrated the efficacy of platelet-inhibitor drugs
for prevention of stroke in asymptomatic patients with
ECVD. The Asymptomatic Cervical Bruit Study compared
enteric-coated aspirin, 325 mg daily, against placebo in
neurologically asymptomatic patients with carotid stenosis
of 50% as determined by duplex ultrasonography. On the
basis of just under 2 years of follow-up, the annual rate of
ischemic events and death due to any cause was 12.3% in the
placebo group and 11.0% in the aspirin group (p0.61), but
the sample size of 372 patients may have been insufficient to
detect a clinically meaningful difference (348). In the
Table 6. American Heart Association/American Stroke
Association Guidelines for Antithrombotic Therapy in
Patients With Ischemic Stroke of Noncardioembolic Origin
(Secondary Prevention)
Guideline
Classification of
Recommendation,
Level of Evidence*
Antiplatelet agents recommended over oral
anticoagulants
I, A
or initial treatment, aspirin (50–325 mg/d),†
the combination of aspirin and extended-
release dipyridamole, or clopidogrel
I, A
ombination of aspirin and extended-release
dipyridamole recommended over aspirin
alone
I, B
lopidogrel may be considered instead of
aspirin alone
IIb, B
or patients hypersensitive to aspirin,
clopidogrel is a reasonable choice
IIa, B
ddition of aspirin to clopidogrel increases
risk of hemorrhage
III, A
*Recommendation: I indicates treatment is useful and effective; IIa, conflicting evidence or
divergence of opinion regarding treatment usefulness and effectiveness; IIb, usefulness/efficacy
of treatment is less well established; and III, treatment is not useful or effective. Level of
Evidence: A indicates data from randomized clinical trials; and B, data from a single randomized
clinical trial or nonrandomized studies. †Insufficient data are available to make evidence-based
recommendations about antiplatelet agents other than aspirin.
Modified with permission from Sacco et al. (111).Veterans Affairs Cooperative Study Group (76) and ACAS(74), the stroke rates were approximately 2% per year in
groups treated with aspirin alone (74,76,349). No controlled
studies of stroke have shown superior results with antiplate-
let agents other than aspirin in patients with asymptomatic
ECVD.
Randomized studies have compared aspirin with CEA in
symptomatic patients (111). In NASCET, patients with
70% stenosis had a stroke rate of 24% after 18 months, and
those with 50% to 69% stenosis had a stroke rate of 22% over
5 years with antiplatelet therapy (predominantly aspirin) and
without revascularization (84). WARSS (Warfarin-Aspirin
Recurrent Stroke Study) compared aspirin and warfarin for
stroke prevention in patients with recent stroke (343). In the
subgroup with severe large-artery stenosis or occlusion (259
patients), including ECVD, there was no benefit of warfarin
over aspirin after 2 years. Patients with carotid stenosis suffi-
ciently severe to warrant surgical intervention were excluded,
which limits application of the results.
The combination of clopidogrel and aspirin did not reduce
stroke risk compared with either treatment alone in the
MATCH (Management of Atherothrombosis With Clopi-
dogrel in High-Risk Patients) and CHARISMA (Clopidogrel
for High Atherothrombotic Risk and Ischemic Stabilization,
Management, and Avoidance) trials (340,350). However, in
ESPS-2 (Second European Stroke Prevention Study), the
combination of 25 mg of aspirin twice daily plus 200 mg of
extended-release dipyridamole twice daily was superior to the
use of only 50 mg of aspirin daily in patients with prior TIA or
stroke (341). Outcomes in a subgroup defined on the basis of
ECVD have not been reported.
The PROFESS (Prevention Regimen for Effectively
Avoiding Second Strokes) trial directly compared the combi-
nation of extended-release dipyridamole and aspirin versus
clopidogrel (342) in 20,332 patients with prior stroke. Over a
mean follow-up of 2.5 years, recurrent stroke occurred in 9% of
patients in the aspirin-plus-dipyridamole group and in 8.8% of
those assigned to clopidogrel (HR 1.01, 95% CI 0.92 to 1.11).
Neither treatment was superior for prevention of recurrent
stroke, and the risk of the composite outcome of stroke, MI, or
vascular death was identical in the 2 treatment groups (13.1%).
Major hemorrhagic events were more common in patients
assigned to extended-release dipyridamole plus aspirin (4.1%)
than in those assigned to clopidogrel (3.6%; HR 1.15, 95%
CI 1.00 to 1.32), including intracranial hemorrhage (HR
1.42, 95% CI 1.11 to 1.83). The net risk of recurrent stroke
or major hemorrhage was similar in the 2 groups (11.7%
with aspirin plus dipyridamole versus 11.4% with clopi-
dogrel; HR 1.03, 95% CI 0.95 to 1.11) (342). Accordingly,
although clopidogrel monotherapy was associated with
equal efficacy and lower risk of hemorrhage than the
combination of dipyridamole plus aspirin and no less effi-
cacy than the combination of clopidogrel plus aspirin,
variations in the response to clopidogrel based on genetic
factors and drug interactions make individualized treatment
selection appropriate for optimum stroke prophylaxis.
a
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bral ischemia during antiplatelet therapy has not been ad-
dressed in adequately powered randomized trials. Lacking firm
evidence, physicians choose an alternative antiplatelet regimen
in such cases. Aspirin or clopidogrel resistance, defined as the
inability of these agents to inhibit platelet function, is one
potential cause of failure in stroke prevention. There is no
agreement on which platelet function test should be used to
determine aspirin or clopidogrel resistance. In a study of 129
patients admitted with a diagnosis of stroke, TIA, or ECVD,
no antiplatelet effect of aspirin or clopidogrel was demonstrated
in 37% of cases. Aspirin resistance was more frequent in those
taking 81 mg daily than in those taking 325 mg daily and was
higher in those taking enteric-coated preparations of aspirin
than in those taking uncoated aspirin (351). Clopidogrel
resistance has also been described (352). Its effectiveness is
diminished when conversion into its active form by the
cytochrome P450 system, which depends primarily on the
function of CYP2C19, is inhibited either because of genetic
variations or owing to drugs that impede CYP2C19 activity,
which adversely affects clopidogrel metabolism. Whether vari-
ation in the response to aspirin or clopidogrel is associated with
a greater risk of stroke has not been established, and it is not
known whether testing for or treatment of drug resistance
improves outcomes.
In 2010, the U.S. Food and Drug Administration issued a
boxed warning to clinicians that addressed the use of pharma-
cogenomic testing to identify patients with altered clopidogrel
metabolism who were thus at risk of a suboptimal clinical
response to clopidogrel (353,354). Variability in response to
clopidogrel results from both clinical and genetic factors;
genotyping and measurement of platelet inhibition may be
appropriate in patients with cerebrovascular disease who have
experienced ischemic events despite compliance with clopi-
dogrel therapy or in those at high risk for such events. Genetic
variability in CYP enzymes that affect platelet function has
been associated with adverse outcomes. Although CYP2C19*2
is the most common genetic variant associated with impaired
response to clopidogrel, other genetic polymorphisms may also
contribute to the variable responsiveness of individual patients
to clopidogrel, and the specific role of individual genetic
polymorphisms remains uncertain.
Information about the predictive value of pharmacog-
enomic testing is the focus of ongoing studies, but data on
the role of genotyping in the selection of antiplatelet therapy
for patients with symptomatic or asymptomatic ECVD are
presently insufficient to justify specific or general recom-
mendations. New agents such as prasugrel and ticagrelor,
which are not affected by CYP2C19 genetic variants, may
prove to be more effective than clopidogrel in conventional
doses but have not been evaluated adequately in patients
with carotid or vertebral artery disease.
Early administration of unfractionated heparin or low-
molecular-weight heparin/danaparoid did not improve the out-
come of patients with acute ischemic stroke (355).
c
u6.8.2. Nonsteroidal Anti-Inflammatory Drugs
In a population-based stroke registry, nonsteroidal anti-
inflammatory drugs (NSAIDs) were not associated with either
an increased risk of hemorrhagic stroke or protection against
initial ischemic stroke (357). A systematic review and meta-
analysis of randomized trials involving cyclo-oxygenase type 2
inhibitors found no significant incremental risk of events
compared with placebo or nonselective NSAIDs (OR 1.03,
95% CI 0.71 to 1.50 and OR 0.86, 95% CI 0.64 to 1.16,
respectively) (358). Hence, in available data sets, the vascular
risk associated with NSAIDs in general and cyclo-oxygenase
type 2 inhibitors in particular is more apparent for MI than for
stroke. The writing committee makes no recommendation for
or against the use of NSAIDs because of a lack of evidence
specifically pertinent to patients with ECVD, except to note
the association of the use of these drugs with increased risks of
both MI and gastrointestinal bleeding.
7. Revascularization
7.1. Recommendations for Selection of Patients
for Carotid Revascularization*
CLASS I
1. Patients at average or low surgical risk who experience nondis-
abling ischemic stroke† or transient cerebral ischemic symptoms,
including hemispheric events or amaurosis fugax, within 6 months
(symptomatic patients) should undergo CEA if the diameter of the
lumen of the ipsilateral internal carotid artery is reduced more than
70%‡ as documented by noninvasive imaging (20,83) (Level of
Evidence: A) or more than 50% as documented by catheter angiog-
raphy (20,70,83,359) (Level of Evidence: B) and the anticipated rate
of perioperative stroke or mortality is less than 6%.
2. CAS is indicated as an alternative to CEA for symptomatic patients
at average or low risk of complications associated with endovascu-
lar intervention when the diameter of the lumen of the internal
carotid artery is reduced by more than 70% as documented by
noninvasive imaging or more than 50% as documented by catheter
angiography and the anticipated rate of periprocedural stroke or
mortality is less than 6% (360). (Level of Evidence: B)
3. Selection of asymptomatic patients for carotid revascularization
should be guided by an assessment of comorbid conditions, life
expectancy, and other individual factors and should include a
thorough discussion of the risks and benefits of the procedure with
an understanding of patient preferences. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to perform CEA in asymptomatic patients who have
more than 70% stenosis of the internal carotid artery if the risk of
perioperative stroke, MI, and death is low (74,76,359,361–363).
(Level of Evidence: A)
*Recommendations for revascularization in this section assume that operators are
experienced, having successfully performed the procedures in 20 cases with proper
technique and a low complication rate based on independent neurological evaluation
before and after each procedure.
†Nondisabling stroke is defined by a residual deficit associated with a score 2
ccording to the Modified Rankin Scale.
The degree of stenosis is based on catheter-based or noninvasive vascular imaging
ompared with the distal arterial lumen or velocity measurements by duplex
ltrasonography. See Section 7 for details.
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indicated in older patients, particularly when arterial pathoanatomy
is unfavorable for endovascular intervention (360,364–368). (Level
of Evidence: B)
3. It is reasonable to choose CAS over CEA when revascularization is
indicated in patients with neck anatomy unfavorable for arterial
surgery (369–373).§ (Level of Evidence: B)
4. When revascularization is indicated for patients with TIA or stroke
and there are no contraindications to early revascularization, inter-
vention within 2 weeks of the index event is reasonable rather than
delaying surgery (374). (Level of Evidence: B)
CLASS IIb
1. Prophylactic CAS might be considered in highly selected patients
with asymptomatic carotid stenosis (minimum 60% by angiogra-
phy, 70% by validated Doppler ultrasound), but its effectiveness
compared with medical therapy alone in this situation is not well
established (360). (Level of Evidence: B)
2. In symptomatic or asymptomatic patients at high risk of complica-
tions for carotid revascularization by either CEA or CAS because
of comorbidities, the effectiveness of revascularization versus
medical therapy alone is not well established (35,361,362,366,
369–372,375,376). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Except in extraordinary circumstances, carotid revascularization by
either CEA or CAS is not recommended when atherosclerosis nar-
rows the lumen by less than 50% (35,70,74,369,377). (Level of
Evidence: A)
2. Carotid revascularization is not recommended for patients with
chronic total occlusion of the targeted carotid artery. (Level of
Evidence: C)
3. Carotid revascularization is not recommended for patients with
severe disability¶ caused by cerebral infarction that precludes pres-
ervation of useful function. (Level of Evidence: C)
7.2. Carotid Endarterectomy
CEA dramatically reduces the incidence of ipsilateral stroke
beyond the 30-day perioperative period, but the risk of
periprocedural stroke must be considered in the assessment
of overall safety and efficacy. For symptomatic patients
undergoing surgical revascularization, the incidence of sub-
sequent stroke is approximately 1.1% per year, which
corresponds to stroke-free survival of approximately 93% at
5 years (Table 7). The actuarial 5-year survival in patients
with carotid stenosis is approximately 75%, with CAD
being the major cause of death. For asymptomatic patients,
the risk of ipsilateral stroke after CEA is 0.5% per year,
§Conditions that produce unfavorable neck anatomy include but are not limited to
arterial stenosis distal to the second cervical vertebra or proximal (intrathoracic)
arterial stenosis, previous ipsilateral CEA, contralateral vocal cord paralysis, open
tracheostomy, radical surgery, and irradiation.
Comorbidities that increase the risk of revascularization include but are not limited
to age 80 years, New York Heart Association class III or IV heart failure, left
entricular ejection fraction 30%, class III or IV angina pectoris, left main or
ultivessel CAD, need for cardiac surgery within 30 days, MI within 4 weeks, and
evere chronic lung disease.
In this context, severe disability refers generally to a Modified Rankin Scale score of
3, but individual assessment is required, and intervention may be appropriate ino
elected patients with considerable disability when a worse outcome is projected with
ontinued medical therapy alone.but this rate may not be significantly lower than that
currently associated with medical therapy alone.
7.2.1. Randomized Trials of Carotid Endarterectomy
7.2.1.1. CAROTID ENDARTERECTOMY IN SYMPTOMATIC PATIENTS
The NASCET (reported in 1991) was designed to test the
hypothesis that symptomatic patients with either TIA or
mild stroke and 30% to 99% ipsilateral carotid stenosis
would have fewer strokes after CEA and medical manage-
ment than those given medical therapy (including aspirin)
alone (70). Randomization was stratified according to the
severity of stenosis. The high-grade stenosis category was
70% to 99% diameter reduction measured by contrast
angiography by a method originally defined for an ECVD
disease study in the 1960s, in which the luminal diameter at
the point of greatest stenosis severity was compared with the
diameter of the distal internal carotid artery (Figure 3). The
lower-grade stenosis category included patients with 30% to
69% stenosis.
NASCET was stopped for the 70% to 99% stenosis
group after 18 months of follow-up because a significant
benefit for CEA was evident (70). In the 328 patients
assigned to surgical management, the cumulative risk of
ipsilateral stroke at 2 years, including perioperative events,
was 9%. For the 331 patients in the high-grade stenosis
category assigned to medical therapy alone, the cumulative
risk of ipsilateral stroke at 2 years was 26% (absolute risk
reduction 17% in favor of surgical management) (70).
Subsequently, the NASCET investigators also demon-
strated a benefit of CEA for patients with 50% to 69%
carotid stenosis but not for those with 50% stenosis.
Among patients in the surgical group with 50% to 69%
stenosis, the rate of operative mortality or stroke was 6.7%
at 30 days. Over longer-term follow-up, the rate of ipsilat-
eral stroke, including perioperative events, was 15.7% at 5
years compared with 22% for medically managed patients.
In other words, approximately 15 patients would have had
to undergo CEA to prevent 1 stroke over 5 years (NNT77
atients per year) (20,70,84,381).
The ECST (European Carotid Surgery Trial), performed
t about the same time as NASCET, randomized 2,518
atients over a 10-year period, yielding a mean follow-up of
years. Patients were stratified into 3 categories that
orresponded to mild (10% to 29%), moderate (30% to
9%), and severe (70% to 99%) carotid stenosis by a
ifferent method of measurement. According to the method
sed in ECST, the minimal residual lumen through the
one of stenosis was compared with the estimated diameter
f the carotid bulb rather than the distal internal carotid
rtery, which was the method used in NASCET (Figure 3,
able 8). The European study found a highly significant
enefit of CEA for patients with 70% to 99% stenosis but
o benefit in those with milder stenosis. When the angio-
rams of ECST participants were analyzed according to the
ethod used in NASCET, no benefit for surgical treatmentver medical treatment was found for those with 50% to
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No. of Patients Events, %
Trial, Year
(Reference)
Patient
Population Intervention Comparator
Treatment
Group
Comparator
Group
Treatment
Group
Comparator
Group Event Used to Calculate NNT ARR, % NNT*
Symptomatic CEA
NASCET (1991) (84) Symptomatic,
70% to 99%
stenosis
CEA Medical
therapy
328 321 9 26 Ipsilateral stroke 17.00 12
ECST (2003) (378) Symptomatic,
70% to 99%
stenosis
CEA Medical
therapy
Not
reported
Not
reported
Not
reported
Not
reported
Ipsilateral ischemic stroke and
surgical stroke or death;
ARR provided in study
18.70 27
ECST (2003) (378) Symptomatic,
70% to 99%
stenosis
CEA Medical
therapy
429 850 6.80 N/A Stroke or surgical death;
ARR provided in study
21.20 24
NASCET (1998) (20) Symptomatic,
50% to 69%
stenosis
CEA Medical
therapy
430 428 15.70 22.20 Ipsilateral stroke 6.50 77
ECST (2003) (378) Symptomatic,
50% to 69%
stenosis
CEA Medical
therapy
Not
reported
Not
reported
Not
reported
Not
reported
Ipsilateral ischemic stroke and
surgical stroke or death;
ARR provided in study
2.90 173
ECST (2003) (378) Symptomatic,
50% to 69%
stenosis
CEA Medical
therapy
646 850 10.00 N/A All stroke or surgical death;
ARR provided in study
5.70 88
Asymptomatic CEA
ACAS (1995) (74) Asymptomatic CEA Medical
therapy
825 834 5.10 11 Ipsilateral stroke and periprocedural
stroke or death
6 84
ACAS (1995) (74) Asymptomatic CEA Medical
therapy
825 834 13.40 13.60 Stroke or death 0.20 1,351
ACST (2004) (75) Asymptomatic Immediate
CEA
Deferred
CEA
1,560 1,560 3.80 3.97 Ipsilateral stroke in carotid artery
territory
0.17 2,000
ACST (2004) (75) Asymptomatic Immediate
CEA
Deferred
CEA
1,560 1,560 3.80 11.00 Stroke risks 7.20 70
Symptomatic
SPACE 2-y data
(2008) (364)
Symptomatic CEA CAS 589 607 8.80 9.50 All periprocedural strokes or deaths
and ipsilateral ischemic strokes up
to 2 y after the procedure
0.70 286
SPACE 2-y data
(2008) (364)
Symptomatic CEA CAS 589 607 1.90 2.20 Ipsilateral ischemic stroke within
31 d and 2 y
0.30 667
SPACE 2-y data
(2008) (364)
Symptomatic CEA CAS 589 607 10.10 10.90 All stroke 0.80 250
EVA-3S 4-y data
(2008) (379)
Symptomatic CEA CAS 262 265 1.50 1.50 Ipsilateral stroke 0 
EVA-3S 4-y data
(2008) (379)
Symptomatic CEA CAS 262 265 6.20 11.10 Composite of periprocedural stroke,
death, and nonprocedural ipsilateral
stroke during 4 y of follow-up
4.90 82
EVA-3S 4-y data
(2008) (379)
Symptomatic CEA CAS 262 265 3.40 9.10 All strokes 5.70 71
Mixed patient populations
SAPPHIRE 1-y data
(2004) (370)
Mixed
population:
Symptomatic,
50%
stenosis;
Asymptomatic,
80%
stenosis
CEA CAS 167 167 7.90 6.20 Stroke 1.70 58
SAPPHIRE 1-y data
(2004) (370)
Mixed
population:
Symptomatic,
50%
stenosis;
Asymptomatic,
80%
stenosis
CEA CAS 167 167 4.80 4.20 Ipsilateral stroke 0.60 167
SAPPHIRE 1-y data
(2004)† (370)
Mixed
population:
Symptomatic,
50%
stenosis;
Asymptomatic,
80%
stenosis
CEA CAS 167 167 20.10 12.20 Cumulative incidence of death, stroke,
or MI within 30 d after the
procedure or death or ipsilateral
stroke between 31 d and 1 y
7.90 13
SAPPHIRE 3-y data
(2008) (369)
Mixed
population:
Symptomatic,
50%
stenosis;
Asymptomatic,
80%
stenosis
CEA CAS 167 167 26.90 24.60 Composite of death, stroke, or MI
within 30 d after the procedure;
death or ipsilateral stroke between
31 d and 1,080 d; 1,080 d was
converted to 3 y for normalization
and NNT calculation
2.30 130
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adjusted for primary endpoints and duration of follow-up,
CEA had a similar benefit for symptomatic patients across
the NASCET and ESCT trials for both men and women
(383).
A U.S. Veterans Affairs trial of CEA, the VACS (Vet-
erans Affairs Cooperative Study), was stopped after 189
patients with symptomatic stenosis had been randomly
Table 7. Continued
No. of Patie
Trial, Year
(Reference)
Patient
Population Intervention Comparator
Treatment
Group
Co
SAPPHIRE 3-y data
(2008) (369)
Mixed
population:
Symptomatic,
50% stenosis;
Asymptomatic,
80%
stenosis
CEA CAS 167
SAPPHIRE 3-y data
(2008) (369)
Mixed
population:
Symptomatic,
50%
stenosis;
Asymptomatic,
80%
stenosis
CEA CAS 167
Symptomatic
ICSS (2010) (380) Symptomatic CEA CAS 858
ICSS (2010) (380) Symptomatic CEA CAS 858
CREST symptomatic
CREST 4-y data
(2010) (360)
Symptomatic CEA CAS 653
CREST 4-y data
(2010) (360)
Symptomatic CEA CAS 653
CREST 4-y data
(2010) (360)
Symptomatic CEA CAS 653
CREST asymptomatic
CREST 4-y data
(2010) (360)
Asymptomatic CEA CAS 587
CREST 4-y data
(2010) (360)
Asymptomatic CEA CAS 587
CREST 4-y data
(2010) (360)
Asymptomatic CEA CAS 587
CREST mixed population
CREST 4-y data
(2010) (360)
Patient
population
not separated
in table;
mixed patient
population
CEA CAS 1,240
*NNT indicates number of patients needed to treat over the course of 1 year with the indicated t
annualized. For details of methodology, please see Suissa (381a). †The 1-year data from the S
econdary endpoint. ‡Annualized data. Cannot be calculated because ARR is 0.
ACAS indicates Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid Surg
arotid Revascularization Endarterectomy versus Stenting Trial; ECST, European Carotid Surgery T
CSS, International Carotid Stenting Study; NASCET, North American Symptomatic Carotid Endart
ith Protection in Patients at High Risk for Endarterectomy; and SPACE, Stent-Protected Angiop
Table 8. Comparison of the Methods of Stenosis
Measurement Used in ECST and NASCET
European Stenosis Scale* North American Stenosis Scale*
65% Stenosis 30% Stenosis
70% Stenosis 40% Stenosis
90% Stenosis 80% Stenosis
*All values are approximations.
ECST indicates European Carotid Surgery Trial; and NASCET, North American Symptomatic
Carotid Endarterectomy Trial.allocated to surgery plus medication therapy versus medical
management alone (85). At that point, with mean follow-up
of 11.9 months, 7.7% of patients assigned to surgical
treatment had experienced death, stroke, or TIA compared
with 19.4% of those managed without surgery. Despite the
small number of patients and abbreviated follow-up, this
difference reached statistical significance (85), and the
implications of the interim analysis were strengthened by
the results of NASCET, which had become available
concurrently.
Pooled analysis of the 3 largest randomized trials (VACS,
NASCET, and ECST) involving more than 3,000 symp-
tomatic patients found a 30-day stroke and death rate of
7.1% after CEA (382) (Table 7). Differences between trials
in the method of measurement of carotid stenosis and
definitions of outcome events confound interpretation of the
meta-analysis. Analysis of individual patient-level data par-
Events, %
or Treatment
Group
Comparator
Group Event Used to Calculate NNT ARR, % NNT*
9.00 9.00 Stroke 0 
5.40 6.60 Ipsilateral stroke 1.20 250
4.10 7.70 All strokes within 120 d after
randomization‡
3.60 7
3.30 7.00 All strokes within 30 d after
randomization‡
3.70 2
8.40 8.60 All strokes, MIs, or deaths within
periprocedural period and
postprocedural ipsilateral strokes
0.20 2,000
6.40 8.00 All periprocedural strokes or deaths or
postprocedural ipsilateral strokes
1.60 250
6.40 7.60 All periprocedural strokes or
postprocedural ipsilateral strokes
1.20 333
4.90 5.60 All strokes, MIs, or deaths within
periprocedural period and
postprocedural ipsilateral strokes
0.70 571
2.70 4.50 All periprocedural strokes or
postprocedural ipsilateral strokes
1.80 223
2.70 4.50 All periprocedural strokes or deaths or
postprocedural ipsilateral strokes
1.80 223
7.90 10.20 All stroke 2.30 174
as opposed to the comparator to prevent the specified event(s). All NNT calculations have been
E trial included the primary endpoint; long-term data were used to calculate rates of the major
l; ARR, absolute risk reduction; CAS, carotid artery stenting; CEA, carotid endarterectomy; CREST,
A-3S, Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis;
y Trial; NNT, number needed to treat; N/A, not applicable; SAPPHIRE, Stenting and Angioplasty
rsus Carotid Endarterectomy.nts
mparat
Group
167
167
855
855
668
668
668
594
594
594
1,262
herapy
APPHIR
ery Tria
rial; EVtially overcomes these limitations, and such an analysis
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results of ECST and NASCET to be more consistent than
the originally reported results suggested. The lack of benefit
of CEA in patients with moderate stenosis reported by the
ECST investigators (83) can be explained by differences in
the method of measuring stenosis severity and definition of
outcome events. With the exception of patients with
chronic carotid occlusion or near-occlusion, surgery was
beneficial when the degree of stenosis was 50% as mea-
sured by the technique used in NASCET (70) and VACS
(85) (approximately equivalent to 65% stenosis by the
method used in ECST). In patients with 50% to 69%
stenosis by the method used in NASCET, the benefit was
modest but increased over time. Surgery was most effective
in patients with 70% carotid stenosis without occlusion or
near-occlusion (382). When the combined outcome of fatal
or disabling ipsilateral ischemic stroke, perioperative stroke,
or death was considered, the benefit of surgery was evident
only in patients with 80% to 99% stenosis. Surgery offered
little or no long-term benefit to patients with near-occlusion
of a carotid artery, in whom the risk of stroke was lower
among medically treated patients than in those with lesser
degrees of severe stenosis, perhaps as a result of collateral
blood flow (384,385).
7.2.1.2. CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS
The first major trial of CEA in asymptomatic patients was
conducted in 10 U.S. Veterans Affairs medical centers to
test the hypothesis that surgery in combination with aspirin
and risk factor modification would result in fewer TIAs,
strokes, and deaths than medical management alone (76).
Among 444 patients randomized over a 54-month period,
211 CEA procedures were performed and 233 patients were
treated medically. The 30-day mortality rate was 1.9% in
patients assigned to undergo surgery, and the incidence of
stroke was 2.4%, for a combined rate of 4.3%. By 5 years,
the differences in outcomes reached statistical significance,
with a 10% overall rate of adverse events in the surgical
group compared with 20% in the group given medical
therapy alone. Inclusion of TIA in the primary composite
endpoint was a source of controversy, because the study was
not powered to detect a difference in the composite end-
point of death and stroke without TIA (76,386,387).
The hypothesis that CEA plus aspirin and risk factor
control (albeit limited by modern standards) would reduce
the rate of TIA, stroke, and death compared with aspirin
and risk factor control without surgery was evaluated in
ACAS (74). In response to criticism of the VACS design,
the primary endpoint did not include TIA, which raised the
requisite recruitment. The trial was stopped before comple-
tion after randomization of 1,662 patients when an advan-
tage to CEA became apparent among patients with lesions
producing 60% stenosis as measured by the method used
in NASCET. After a mean follow-up of 2.7 years, the
projected 5-year rates of ipsilateral stroke, perioperative
stroke, and death were 5.1% for surgical patients and 11%for patients treated medically. The 30-day perioperative
death and stroke rate for patients undergoing CEA was
2.3%, but some patients assigned to the surgical group
experienced stroke during contrast angiography and did not
undergo surgery (74,388–391).
The ACST, sponsored by the Medical Research Council
of Great Britain, randomized 3,120 asymptomatic patients
with hemodynamically significant carotid artery stenosis to
immediate CEA versus delayed surgery on the basis of the
onset of symptoms (72). The 30-day risk of stroke or death
in either group, including the perioperative period, was
3.1%. Five-year rates, including perioperative events, were
6.4% for the early-surgery group versus 11.7% for the group
initially managed medically. The primary endpoint in
ACST differed from that in ACAS by inclusion of strokes
contralateral to the index carotid lesion. As with ACAS,
during the conduct of ACST (1993 to 2003), medical
therapy was scant by modern standards (see Section 7.2.6).
A summary of outcomes of randomized trials of CEA in
asymptomatic patients is given in Table 7, as well as an
analysis of the benefit of revascularization in terms of the
NNT to prevent stroke over a period of 1 year. It is
important to emphasize that selection of asymptomatic
patients for carotid revascularization should include careful
consideration of life expectancy, age, sex, and comorbidities.
The benefit of surgery may now be less than anticipated on
the basis of earlier randomized trials, and the cited 3%
complication rate should be interpreted in the context of
interim advances in medical therapy. Even when the data
from ACAS and ACST are combined to increase the
statistical power of the estimate of benefit, it remains
unclear whether women benefit as much as men from CEA
(363).
7.2.2. Factors Affecting the Outcome of
Carotid Endarterectomy
A wide range of patient- and operator-related factors, some
more tangible than others, can substantially influence both
the immediate- and long-term outcomes of CEA.
7.2.2.1. TECHNICAL CONSIDERATIONS
In the more than 50 years that CEA has been performed,
there has been considerable variation in surgical technique.
Initially, local anesthesia was advocated instead of general
anesthesia to permit observation of the patient’s level of
consciousness and motor function during temporary clamp-
ing of the carotid artery. Because only 10% of patients
undergoing CEA develop cerebral dysfunction during arte-
rial clamping, other techniques have been developed, in-
cluding electroencephalographic or other types of monitor-
ing, to assess cerebral function under anesthesia (392,393).
Advocates of local anesthesia maintain that adverse cardiac
events occur less frequently than during CEA under general
anesthesia, but retrospective analyses and data from surgical
trials have failed to demonstrate a significant difference in
outcomes based on the type of anesthesia used.
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during surgery, including measurement of residual collateral
perfusion pressure (394) or internal carotid artery back
pressure, is to select patients who may benefit from shunting
during the period of arterial clamping. Arguments for
selective as opposed to routine shunting are related to the
complications that occasionally occur during shunting, in-
cluding embolism of atheromatous debris or air through the
shunt, mechanical injury to the distal internal carotid artery
during shunt placement, and obscuring of the arterial
anatomy at the distal zone of CEA. To date, however, no
study has shown a difference in 30-day morbidity and
mortality with routine versus selective shunting during
CEA.
Variations in the technique of arterial repair after CEA
depend mainly on the length of the arteriotomy. The
advantage of primary closure is speed, but disadvantages
include higher incidences of residual and recurrent stenosis.
The advantage of patch closure is visual confirmation of
complete plaque removal, but the disadvantage is the greater
length of time required for closure. Multiple comparative
reviews have failed to demonstrate a consistent difference in
outcomes with either technique compared with the other
(395–405). One report involved a single experienced sur-
geon and a series of patients who required staged bilateral
CEA in whom 1 side was randomly allocated to primary
closure and the other side to patch angioplasty (406). Patch
angioplasty was associated with lower 30-day surgical mor-
bidity and mortality and fewer cases of residual or recurrent
stenosis as assessed by periodic duplex scanning for up to 1
year postoperatively. On the basis of these observations and
a Cochrane meta-analysis of case series (407), patch angio-
plasty after open CEA is now favored by most surgeons.
Eversion CEA is a major variation in operative technique
designed in part to avoid patch angioplasty closure and to
relocate the proximal internal carotid artery when the artery
becomes redundant after CEA. The avoidance of a longi-
tudinal arteriotomy reduces the likelihood of stricture and
the need for patching, but the technique is difficult in
patients with high carotid bifurcations or long lesions.
Furthermore, the eversion technique makes internal shunt-
ing more difficult. Randomized trials comparing the ever-
sion and direct arteriotomy techniques have found no
difference in morbidity, mortality, or rates of restenosis
(408,409).
7.2.2.2. CASE SELECTION AND OPERATOR EXPERIENCE
The relationships of perioperative mortality, neurological
morbidity, and other adverse events after CEA to surgeon
and hospital volume are complex. Hospitals in which fewer
than 100 CEA operations are performed annually typically
have poorer results than those in which larger numbers are
performed (410–421). However, the threshold criteria for
patient selection for CEA can also influence outcomes.
Perioperative results are best for asymptomatic patients,
who are more numerous than symptomatic patients. Sur-geons with higher volumes are likely to operate on more
asymptomatic cases and have better results. Surgeons who
favor selection of symptomatic patients typically have higher
30-day rates of stroke and death. In ACAS, surgeons were
selected for participation on the basis of individual experi-
ence, morbidity and mortality, and a minimum annual
caseload of 12, with the expectation that the average would
be closer to 20 operations per year. With this process, the
30-day surgical morbidity and mortality rate for CEA in
ACAS was 1.5% (389,391,415,416,422,423), but case vol-
ume did not influence results. Extrapolation of the results of
this and other carotid revascularization trials to clinical
decision making requires consideration of patient selection
and procedural results.
7.2.2.3. DEMOGRAPHIC AND CLINICAL FACTORS
The influence of patient age on surgical risk is unclear, but
advanced age does not preclude elective CEA in appropri-
ately selected patients, and several case series report neuro-
logical morbidity and mortality rates in octogenarians com-
parable to those in younger patients (424,425). Patients
older than 80 years of age were excluded from participation
in both NASCET (prior to 1991) (70) and ACAS (74),
although in NASCET, the greatest benefit of surgery
compared with medical management was observed in older
patients (up to the age of 80 years) (70). In the randomized
ACST study, no benefit accrued from CEA in patients 80
years of age or older (72). More recent results from the
SPACE (Stent-Protected Angioplasty versus Carotid End-
arterectomy) trial showed a 5.9% combined rate of stroke
and death after CEA for symptomatic patients younger than
75 years of age with carotid stenosis. The rate among those
older than 75 years of age was lower than reported for
symptomatic patients in NASCET and ECST, which
indicates either that surgical therapy has become safer with
time or that the inherent risks of these cohorts differed in
important ways. Several reports point to higher risks of
complications among older patients undergoing CEA
(426,427), but others suggest that patients 75 years of age or
older with few cardiovascular risk factors face risks of
perioperative stroke and death comparable to younger pa-
tients (428).
Women undergoing CEA face higher operative risk than
men (10.4% versus 5.8% for men in ECST) (83,429–431).
In the ACAS and NASCET studies, women had less
favorable outcomes than men in terms of surgical mortality,
neurological morbidity, and recurrent carotid stenosis and
gained little or no benefit from surgery (70,74). The reasons
for these sex-based differences are complex, and several
studies have found that patch angioplasty closure in women
materially improves results (432,433). Because the number
of minorities enrolled in randomized trials has been insuf-
ficient to permit meaningful statistical analysis, it is difficult
to evaluate differences in the results of CEA on the basis of
race beyond general observations. For example, although
Chinese populations appear to develop atherosclerosis at the
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populations (434), the immediate and long-term results of
CEA appear comparable. Black patients develop intracra-
nial disease more frequently than ECVD and may undergo
CEA less often than members of other racial groups.
Among the uncertainties is how much the perceived differ-
ences reflect biological factors as opposed to inequities in
access to diagnosis and treatment (435,436).
7.2.3. Risks Associated With Carotid Endarterectomy
The risks associated with CEA involve neurological and
nonneurological complications, including hypertension or
hypotension, hemorrhage, acute arterial occlusion, stroke,
MI, venous thromboembolism, cranial nerve palsy, infec-
tion, arterial restenosis, and death (437). The risk of stroke
or death is related mainly to the patient’s preoperative
clinical status. Symptomatic patients have a higher risk than
asymptomatic patients (OR 1.62; p0.0001), as do those
with hemispheric versus retinal symptoms (OR 2.31;
p0.001), urgent versus nonurgent operation (OR 4.9;
p0.001), and reoperation versus primary surgery (OR
1.95; p0.018) (438–440). A report of external case-by-
case reviews by nonsurgeons of a total of 1972 CEA
procedures in asymptomatic patients performed by 64 sur-
geons at 6 hospitals in 1997 and 1998 reported rates of
7.11% for stroke or death, 2.28% for stroke, and 2.93% for
TIA (441). Patients with high-risk anatomic criteria, such
as restenosis after CEA and contralateral carotid arterial
occlusion, face much higher perioperative stroke/death rates
than observed in the NASCET or ACAS patient cohorts
(74,437). Reports of perioperative stroke and death rates of
19.9% have been documented in patients undergoing reop-
erative CEA procedures (442). In NASCET, the stroke and
death rate at 30 days was 14.3% among patients with
contralateral carotid occlusion (443). The more recent
literature documents considerably lower complication rates
(444–451), although outcomes of CEA in patients at high
surgical risk are still relatively unfavorable, with the com-
bined rate of stroke, death, or MI at 7.4% for high-risk
patients compared with 2.9% among low-risk patients in 1
series (452) that did not separately report rates of stroke and
death without MI. Other rate and relative risk data for
perioperative stroke or death after CEA are listed in Table 9.
In a meta-analysis of nearly 16,000 symptomatic patients
undergoing CEA, the 30-day risk of stroke or death was
7.7% when a neurologist evaluated the patient and 2.3%
when a vascular surgeon performed the evaluation (359).
These data suggest a 3-fold increase in reported events
when independent adjudication is used and support a policy
of evaluation by a neurologist for patients undergoing CEA.
Clinical neurological assessment is crucial to the application
of recommendations for selection of patients for CEA,
which includes estimation of perioperative stroke risk.
Recent trials of CEA that included rigorous independent
neurological examination before and after CEA confirmed
low rates of perioperative stroke (1.4% in previously asymp- ctomatic patients and 3.2% in symptomatic patients in
CREST [Carotid Revascularization Endarterectomy versus
Stenting Trial] [360] and 3.3% among symptomatic pa-
tients in ICSS [International Carotid Stenting Study] [368]
based on 30-day per-protocol analysis).
Other than stroke, neurological complications include
intracerebral hemorrhage, which may occur as a conse-
quence of the hyperperfusion syndrome despite control of
blood pressure. This syndrome occurs in fewer than 1% of
patients when blood pressure has been stable preoperatively
and well managed perioperatively (461–464). Cranial nerve
injury has been reported in as many as 7% of patients
undergoing CEA but was not disabling in most studies,
resulting in permanent injury in fewer than 1% of cases
(382,465,466). In ECST, in which patients underwent
extensive preoperative and postoperative neurological as-
sessments, the incidence of cranial neuropathy was 5.1%
(465). The neuropathy that appeared early in the postoper-
ative period resolved in one fourth of the cases by the time
of discharge, leaving 3.7% of patients with residual cranial
nerve deficits. In decreasing order of frequency, these
deficits involved palsies of the hypoglossal, marginal man-
dibular, recurrent laryngeal, and spinal accessory nerves and
Horner syndrome (437,451,465,467,468). The only clinical
factor linked to cranial nerve dysfunction was duration of
the surgical procedure longer than 2 hours.
Cardiovascular instability has been reported in 20% of
patients undergoing CEA, with hypertension in 20%,
hypotension in 5%, and perioperative MI in 1%. The use
of local anesthesia or cervical block in selected patients
may lessen the likelihood of these complications (469).
Because atherosclerosis of the carotid bifurcation is commonly
associated with coronary atherosclerosis, myocardial ischemia
is a major cause of perioperative complications, including
nonfatal MI, and late mortality in patients undergoing CEA.
The risk of cardiopulmonary complications is related to ad-
vanced age, New York Heart Association class III or IV heart
failure, active angina pectoris, left main or multivessel coronary
disease, urgent cardiac surgery in the preceding 30 days, left
ventricular ejection fraction 30%, MI within 30 days, severe
hronic lung disease, and severe renal insufficiency (470–472).
n NASCET, 10% of patients experienced a complication in
he perioperative period. The majority of these were cardio-
ascular (8.1%) or pulmonary (0.8%). In NASCET (70) and
CST (83), the incidence of perioperative MI was 0.3% and
.2%, respectively. Venous thromboembolism is rare among
atients undergoing CEA (473–475); in ECST, the rate was
.1%, and no cases were reported in NASCET (377,382,
37,473–478).
Wound complications are related primarily to infection
incidence1%) (479,480) and hematoma (5%), depend-
ng in part on perioperative antiplatelet therapy (481),
uration of surgery, perioperative use of heparin and prota-
ine, and other factors. Prior ipsilateral CEA, contralateral
aryngeal nerve palsy, and permanent tracheostomy may
omplicate wound management (465).
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Trial, Year
(Reference) No. of Patients Key Features Death or Any Stroke OR (95% CI) Comments
eicester,
1998 (453)
Seventeen had
received their
allocated
treatment before
trial suspension
Single center; patients with
symptomatic carotid
stenosis 70%.
CEA: 0/10 (0%)*
CAS: 5/7 (71.4%)*
p0.0034; OR not reported Terminated prematurely
because of safety
concerns.
AVATAS-CEA,
2001 (454)
504 Multicenter; patients of any
age with symptomatic or
asymptomatic carotid
stenosis suitable for
CEA or CAS.
CEA: 25/253 (9.9%)
CAS: 25/251 (10.0%)
pNS in original article;
OR not reported
Follow-up to 3 y;
relatively low stent
use (26%) in CAS
group.
entucky, 2001
(455)
104 Single center; patients with
symptomatic carotid
stenosis 70% (events
within 3 mo of evaluation).
CEA: 1/51 (2.0%)
CAS: 0/53 (0%)
0.31 (0.01 to 7.90)
APPHIRE,
2004 (370)
334 Multicenter randomized trial
of patients with 80%
asymptomatic carotid
stenosis (70%) and
50% symptomatic
carotid stenosis (30%).
CEA: 9.3% symptomatic
patients‡*
CAS: 2.1% symptomatic
patients‡
p0.18† Terminated prematurely
because of a drop in
randomization.
VA-3S, 2006
(456)
527 Multicenter; patients with
symptomatic carotid
stenosis 60% within
120 d before enrollment
suitable for CEA or CAS.
CEA: 10/259 (3.9%)
CAS: 25/261 (9.6%)
RR 2.5 (1.2 to 5.1), p0.01 Study terminated
prematurely because
of safety and futility
issues; concerns
about operator
inexperience in the
CAS arm and
nonuniform use of
embolism protection
devices.
PACE, 2006
(457)
1,183 Multicenter; patients 50 y
old with symptomatic
carotid stenosis 70% in
the 180 d before
enrollment.
Primary endpoint of ipsilateral
ischemic stroke or death
from time of randomization
to 300 d after the
procedure:
CEA: 37/584 (6.3%)
CAS: 41/599 (6.8%)
1.19 (0.75 to 1.92) Study terminated
prematurely after
futility analysis;
concerns about
operator inexperience
in the CAS arm and
nonuniform use of
embolism protection
devices.
VA-3S 4-y
follow-up,
2008 (379)
527 Multicenter, randomized,
open, assessor-blinded,
noninferiority trial.
Compared outcome after
CAS with outcome after
CEA in 527 patients who
had carotid stenosis of at
least 60% that had
recently become
symptomatic.
Major outcome events up to
4 y for any periprocedural
stroke or death:
CEA: 6.2%
CAS: 11.1%
HR for any stroke or
periprocedural death 1.77
(1.03 to 3.02); p0.04
HR for any stroke or death
1.39 (0.96 to 2.00);
p0.08
HR for CAS versus CEA 1.97
(1.06 to 3.67); p0.03
A hazard function
analysis showed 4-y
differences in
cumulative
probabilities of
outcomes between
CAS and CEA were
largely accounted for
by the higher
periprocedural (within
30 d of the
procedure) risk of
stenting compared
with endarterectomy.
After the
periprocedural period,
the risk of ipsilateral
stroke was low and
similar in the 2
treatment groups.
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Trial, Year
(Reference) No. of Patients Key Features Death or Any Stroke OR (95% CI) Comments
PACE 2-y
follow-up,
2008 (364)
1,214 Patients with symptomatic,
severe (70%) carotid
artery stenosis were
recruited to this
noninferiority trial and
randomly assigned with a
block randomization
design to undergo CAS
or CEA.
Intention-to-treat population:
Ipsilateral ischemic strokes
within 2 y, including any
periprocedural strokes or
deaths:
CAS: 56 (9.5%)
CEA: 50 (8.8%)
Any deaths between
randomization and 2 y:
CAS: 32 (6.3%)
CEA: 28 (5.0%)
Any strokes between
randomization and 2 y:
CAS: 64 (10.9%)
CEA: 57 (10.1%)
Ipsilateral ischemic stroke
within 31 d and 2 y:
CAS: 12 (2.2%)
CEA: 10 (1.9%)
Per-protocol population:
Ipsilateral ischemic strokes
within 2 y, including any
periprocedural strokes or
deaths:
CAS: 53 (9.4%)
CEA: 43 (7.8%)
Any deaths between
randomization and 2 y:
CAS: 29 (6.2%)
CEA: 25 (4.9%)
Any strokes between
randomization and 2 y:
CAS: 61 (11.5%)
CEA: 51 (9.8%)
Ipsilateral ischemic stroke
within 31 d and 2 y:
CAS: 12 (2.3%)
CEA: 10 (2.0%)
Intention-to-treat population:
Ipsilateral ischemic strokes
within 2 y, including any
periprocedural strokes or
deaths:
HR 1.10 (0.75 to 1.61)
Any deaths between
randomization and 2 y:
HR 1.11 (0.67 to 1.85)
Any strokes between
randomization and 2 y:
HR 1.10 (0.77 to 1.57)
Ipsilateral ischemic stroke
within 31 d and 2 y:
HR 1.17 (0.51 to 2.70)
Per-protocol population:
Ipsilateral ischemic strokes
within 2 y, including any
periprocedural strokes or
deaths:
HR 1.23 (0.82 to 1.83)
Any deaths between
randomization and 2 y:
HR 1.14 (0.67 to 1.94)
Any strokes between
randomization and 2 y:
HR 1.19 (0.83 to 1.73)
Ipsilateral ischemic stroke
within 31 d and 2 y:
HR 1.18 (0.51 to 2.73)
In both the intention-to-
treat and per-protocol
populations, recurrent
stenosis of 70%
was significantly
more frequent in the
CAS group than the
CEA group, with a
life-table estimate of
10.7% versus 4.6%
(p0.0009) and
11.1% versus 4.6%
(p0.0007),
respectively.
APPHIRE 3-y
follow-up,
2008 (369)
260 Long-term data were
collected for 260
individuals; included
symptomatic carotid
artery stenosis of at least
50% of the luminal
diameter or an
asymptomatic stenosis of
at least 80%.
Stroke:
CAS: 15 (9.0%)
CEA: 15 (9.0%)
Ipsilateral stroke:
CAS: 11 (7.0%)
CEA: 9 (5.4%)
Death:
CAS: 31 (18.6%)
CEA: 35 (21%)
Note: data were calculated
using n167 for both groups
because breakdowns of CAS
and CEA for N260 were not
given.
Stroke:
p0.99 (6.1 to 6.1)
Death:
p0.68 (10.9 to 6.1)
allstent, 2005
(458)
219 Included symptomatic
angiographic carotid
stenosis 70%.
CAS: 13 (12.2%)
CEA: 5 (4.5%)
N/A Premature termination
based on futility
analysis.
SI
C
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ciated with CEA (444,452,482). Patients with pulmonary
disease, particularly those requiring supplemental oxygen,
are at risk of complications including ventilator dependence
and pneumonia (483). Renal insufficiency is an independent
risk factor for adverse outcomes of pulmonary complications
and cardiac events after CEA (484). Additionally, in a
retrospective analysis of data collected at 123 Veterans
Affairs Medical Centers as part of the National Surgical
Quality Improvement Program (n20,899), patients with
severe chronic renal insufficiency (glomerular filtration rate
30 mL/min) had significantly higher mortality rates by
both univariate and multivariate analyses. Patients with
impaired renal function, including those who required
dialysis, faced higher risks of mortality and stroke-related
morbidity in some reports, whereas in others the results
appeared to be independent of renal function (485). A study
of more than 1,000 CEA operations in nearly 900 patients
found a higher perioperative mortality rate among those
Table 9. Continued
Trial, Year
(Reference) No. of Patients Key Features
APPHIRE
(symptomatic
data), 2008
(459)
96 Included patients with
50% carotid stenosis.
CEA:
CAS
CSS, 2010
(368)
1,713 Multicenter study. In the
study, the degree of
carotid stenosis was 70%
to 99% in 89% of stent
patients and in 91% of
endarterectomy patients.
Study patients had 50%
carotid artery stenosis
measured by the NASCET
criteria.
120
on
CAS
CEA:
REST, 2010
(360)
2,502 The study included 1,321
symptomatic patients
and 1,181 asymptomatic
patients. Symptomatic
patients in the study had
50% carotid stenosis by
angiography, 70% by
ultrasound or 70% by
CTA or MRA.
Asymptomatic patients
had carotid stenosis
(patients with symptoms
beyond 180 d were
considered
asymptomatic) 60% by
angiography, 70% by
ultrasound, or 80% by
CTA or MRA.
Any
po
st
Sym
CAS
CEA:
Any
de
ip
Sym
CAS
CEA:
*Death and ipsilateral stroke. †Combined asymptomatic and symptomatic patients for death, a
CAS indicates carotid artery stent; CAVATAS, Carotid And Vertebral Artery Transluminal Angio
Endarterectomy versus Stenting Trial; CTA, computed tomography angiography; EVA-3S, Endartere
International Carotid Stenting Study; MI, myocardial infarction; MRA, magnetic resonance angiog
significant; OR, odds ratio; RR, risk reduction; SAPPHIRE, Stenting and Angioplasty with Protection
versus Carotid Endarterectomy.
Modified from Ederle et al. (460).with chronic renal insufficiency and a significant associationbetween chronic renal insufficiency and 30-day mortality
(486). In a series of 184 patients, the mortality rate was 3%
among patients with chronic renal insufficiency compared
with no deaths in a control group without renal insuffi-
ciency. Among the 23 patients with serum creatinine levels
3 mg/dL or higher, the mortality rate was 17% (p0.001)
(487).
7.2.4. Carotid Endarterectomy in Patients With
Unfavorable Anatomy
A high carotid bifurcation or an atheromatous lesion that
extends into the internal carotid artery beyond the exposed
surgical field represents a technical challenge during CEA,
and carotid lesions located at or above the level of the
second cervical vertebra are particularly problematic. High
cervical exposure increases the risk of cranial nerve injury.
Similarly, lesions below the clavicle, prior radical neck
surgery or radiation, and contralateral carotid occlusion are
each associated with higher risk (488,489). Several maneu-
or Any Stroke OR (95% CI) Comments
%) N/A Premature termination
secondary to
declining enrollment.
w-up data available
53 (8.5%)
57 (4.7%)
OR not available; HR 1.86
(1.26 to 2.74)
p0.001
Primary outcome was
3-y rate of fatal or
disabling stroke in
any territory; interim
results have been
provided for 120-d
rate of stroke, death,
or procedural MI.
cedural stroke or
edural ipsilateral
tic:
.50.9 SE)
.20.7 SE)
cedural stroke or
postprocedural
al stroke:
tic:
.00.9 SE)
.20.7 SE)
Any periprocedural stroke or
postprocedural ipsilateral
stroke:
Symptomatic: p0.04
Any periprocedural stroke or
death or postprocedural
ipsilateral stroke:
Symptomatic: p0.02
The risk of composite
primary outcome of
stroke, MI, or death
did not differ
significantly among
symptomatic and
asymptomatic
patients between CAS
and CEA.
ke. ‡Death, stroke, and MI.
Study; CEA, carotid endarterectomy; CI, confidence interval; CREST, Carotid Revascularization
ersus Angioplasty in patients with Symptomatic Severe carotid Stenosis; HR, hazard ratio; ICSS,
N/A, not available; NASCET, North American Symptomatic Carotid Endarterectomy Trial; NS, not
nts at HIgh Risk for Endarterectomy; SE, standard error; and SPACE, Stent-Protected AngioplastyDeath
3 (6.5
: 0
-d follo
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40/8
peripro
stproc
roke:
ptoma
: 37 (5
21 (3
peripro
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silater
ptoma
: 40 (6
21 (3
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raphy;
in Patievers are available to improve arterial exposure under these
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these maneuvers yield satisfactory outcomes.
Among the challenges of reoperative CEA for recurrent
stenosis is the accumulation of scar tissue after ipsilateral
CEA. Contralateral laryngeal nerve palsy is a relative
contraindication to CEA, because bilateral nerve palsies
could compromise the airway (465). Patients who have
undergone radical neck surgery or tracheostomy pose sur-
gical challenges because of the difficulty of exposing the
artery and the relatively high risk of perioperative infection.
The risk of cranial nerve injury is higher in these situations,
but the overall risks of mortality and stroke are comparable.
Patients who have undergone cervical radiation therapy
face an increased incidence of disease at the carotid bifur-
cation. Modern radiation therapy has been designed specif-
ically to avoid severe fibrotic tissue reactions. Several series
indicate that CEA can be performed successfully after neck
radiation (490), although the procedure is technically chal-
lenging. In this situation, CAS may be safer to perform, but
the rate of restenosis after CAS is high, ranging from 18%
to 80% over 3 years (373,491,492).
7.2.5. Evolution in the Safety of Carotid Surgery
Complication rates associated with CEA have improved
steadily over 2 generations. The 30-day stroke and mortality
rates of 2.3% among asymptomatic patients in ACAS
(1994) and 5.0% for symptomatic patients in the first part of
the NASCET (1999) are often cited as benchmarks against
which other forms of interventional therapy are compared.
More recent reports, however, suggest considerably lower
risks than reported in those early trials. Surgical training and
case volume are important determinants of clinical out-
comes with CEA. The experiences of individual surgeons
include a series of 442 consecutive CEAs in 391 patients
with a 0.45% cumulative 30-day rate of stroke and death
(493). A population-based study of 14,095 CEA procedures
in the state of Virginia between 1997 and 2001 reported
cumulative stroke and mortality rates of 1.0% and 0.5%,
respectively, and a progressive decline in these rates each
year (494). For 23,237 CEA procedures performed in
Maryland between 1994 and 2003, the cumulative stroke
rate was 0.73%. The stroke rate was 2.12% in 1994, 1.47%
in 1995, and from 0.29% to 0.65% between 1996 and 2003,
with a more pronounced reduction in perioperative stroke
among symptomatic patients than among asymptomatic
patients (412). Similar findings were noted in California,
where 51,231 CEA procedures performed between 1999
and 2003 were associated with a cumulative in-hospital
stroke rate of 0.54%. Methodologies varied with rates of
perioperative stroke and were generally higher when docu-
mented by a neurologist. Mortality rates in both states
remained relatively stable over the reported periods, 0.33%
to 0.58% in Maryland and 0.78% to 0.91% in California
(412), and trends were similar in other states (495) and
countries including, Australia (496), Italy (497), and Swe-
den (498).7.2.6. Evolution of Medical Therapy
Trials of carotid revascularization must be interpreted in the
context of the evolution of medical therapy for patients with
atherosclerotic disease. Although pharmacotherapy aimed
at risk reduction was incorporated in most trials, guidelines
and strategies have changed, and more effective measures
have enhanced the therapeutic armamentarium. The out-
comes of trials that use modern atherosclerotic risk factor
treatment may differ from those reported, which reduces the
generalizability of the results to contemporary practice.
Concurrently, surgical outcomes have improved with
advances in training, increased hospital and operator vol-
umes, and better perioperative medical management, in-
cluding control of blood pressure with beta blockers and
angiotensin inhibitors and the widespread use of statins
(415,422,423,499). A 1991 report indicated that 55% of
participants in NASCET were treated with antihyperten-
sive drugs. Treatment with lipid-lowering agents was used
infrequently in NASCET (20), and medical therapy was not
described in the primary report of ACAS. The evolution of
medical therapy, with which patients typically gain benefit
whether or not surgery is performed, is pertinent to the
interpretation of the results of randomized trials, most of
which were performed more than a decade ago. The ACST
investigators reported changes in medical therapies over
time for the 10-year period that began in 1993. By the last
follow-up in 2002 to 2003, 81% of patients were taking
antihypertensive medication and 70% were undergoing
lipid-lowering treatment, but the outcomes of CEA were
reported for only the first 5 years (ending in 1998), during
which concurrent use of such medical therapy was consid-
erably less frequent (60% of participants had systolic blood
pressure 160 mm Hg; 33% had total serum cholesterol
250 mg/dL; management of diabetes [20% prevalence]
was not detailed; and the proportion of participants who
were active tobacco smokers was not reported). As typically
occurs in patient care, advances that result in a decline in
adverse event rates over time must be considered in inter-
preting the safety and efficacy of interventions, and caution
is necessary with regard to assumptions about the constancy
of the response to medical therapy alone over time.
7.2.7. Recommendations for Periprocedural
Management of Patients Undergoing
Carotid Endarterectomy
CLASS I
1. Aspirin (81 to 325 mg daily) is recommended before CEA and may
be continued indefinitely postoperatively (338,500). (Level of Evi-
dence: A)
2. Beyond the first month after CEA, aspirin (75 to 325 mg daily),
clopidogrel (75 mg daily), or the combination of low-dose aspirin
plus extended-release dipyridamole (25 and 200 mg twice daily,
respectively) should be administered for long-term prophylaxis
against ischemic cardiovascular events (339,343,350). (Level ofEvidence: B)
e53JACC Vol. 57, No. 8, 2011 Brott et al.
February 22, 2011:e16–94 ECVD Guideline: Full Text3. Administration of antihypertensive medication is recommended as
needed to control blood pressure before and after CEA. (Level of
Evidence: C)
4. The findings on clinical neurological examination should be docu-
mented within 24 hours before and after CEA. (Level of Evidence: C)
CLASS IIa
1. Patch angioplasty can be beneficial for closure of the arteriotomy
after CEA (406,407). (Level of Evidence: B)
2. Administration of statin lipid-lowering medication for prevention of
ischemic events is reasonable for patients who have undergone CEA
irrespective of serum lipid levels, although the optimum agent and
dose and the efficacy for prevention of restenosis have not been
established (501). (Level of Evidence: B)
3. Noninvasive imaging of the extracranial carotid arteries is reason-
able 1 month, 6 months, and annually after CEA to assess patency
and exclude the development of new or contralateral lesions
(364,502). Once stability has been established over an extended
period, surveillance at longer intervals may be appropriate. Termi-
nation of surveillance is reasonable when the patient is no longer a
candidate for intervention. (Level of Evidence: C)
In the ACE (Acetylsalicylic Acid and Carotid Endarterec-
tomy) study, a randomized trial involving 2849 patients and
4 different daily aspirin-dose regimens, the risk of stroke,
MI, and death within 30 days and 3 months of CEA was
lower for patients assigned to the lower-dose aspirin groups
(81 mg or 325 mg daily) than for those taking 650 mg or
1300 mg of aspirin (RR 1.31 [95% CI 0.98 to 1.75], 5.4%
versus 7.0% at 30 days [p0.07] and RR 1.34 [95% CI 1.03
to 1.75], 6.2% versus 8.4% at 3 months [p0.03], respectively)
(500). The optimum duration of antithrombotic therapy after
CEA has not been established, but beyond the first month
postoperatively, it appears reasonable to use antithrombotic
therapy as recommended for long-term prevention of ischemic
events in patients with atherosclerosis.
A retrospective review of 1,566 patients undergoing CEA
by 13 surgeons at a single center between 1994 and 2004
(42% symptomatic; 8% in combination with myocardial
revascularization surgery) found lower rates of perioperative
stroke (1.2% versus 4.5%; p0.01), TIA (1.5% versus 3.6%;
p0.01), all-cause mortality (0.3% versus 2.1%; p0.01),
and length of hospital stay (2 [interquartile range 2 to 5]
versus 3 [2 to 7] days; p0.05) among the 42% of patients
who received statin medication for at least 1 week before
surgery than among those who did not (503). By multivar-
iate analysis adjusted for demographics and comorbidities,
statin use was associated with a 3-fold reduction in the risk
of stroke (OR 0.35, 95% CI 0.15 to 0.85; p0.05) and a
5-fold reduction in the risk of death (OR 0.20, 95% CI 0.04
to 0.99; p0.05).
7.3. Carotid Artery Stenting
The results of randomized trials have not shown consistent
outcome differences between CAS and CEA. CAS may be
superior to CEA in certain patient groups, such as those
exposed to previous neck surgery or radiation injury. A
summary of stroke and mortality outcomes among symp-tomatic and asymptomatic patients enrolled in major ran-
domized trials and registries is provided in Tables 9 and 10.
Although 30-day morbidity and mortality rates are im-
portant benchmarks for determining the benefit of a proce-
dure in a population with a known event rate, the confi-
dence bounds that surround estimates of event rates with
CEA and CAS often overlap. When performed in conjunc-
tion with an embolic protection device (EPD), the risks
associated with CAS may be lower than those associated
with CEA in patients at elevated risk of surgical complica-
tions. On the other hand, in a nationwide U.S. sample of
226,111 CEA procedures during 2003 and 2004, the
mortality rate was 0.44% and the rate of stroke was 0.95%,
whereas the in-hospital stroke rate for asymptomatic pa-
tients undergoing CAS was 2-fold higher than that after
CEA (504). The risks of stroke among octogenarians were
1% for CEA and 3% for CAS, whereas the mortality rates
were similar and low for both procedures. These data have
been criticized, however, because severity of illness may not
have been comparable in the 2 cohorts and because the primary
outcome measures were self-reported and not audited (505).
7.3.1. Multicenter Registry Studies
Several voluntary, nonrandomized, multicenter registries
encompassing experience in more than 17,000 patients and
large, industry-sponsored postmarket surveillance registries
have described outcomes among a broad cohort of carotid
stent operators and institutions. The results emphasized the
importance of adequate training for optimal operator per-
formance (35,362). The CASES-PMS (Carotid Artery
Stenting with Embolic Protection Surveillance) study (362)
enrolled 1493 patients at 73 sites and compared results with
the pooled results of the pivotal SAPPHIRE (Stenting and
Angioplasty with Protection in Patients at HIgh Risk for
Endarterectomy) (370) stent arms. The rate of occurrence of
the primary 30-day endpoint of major adverse events
(stroke, MI, or death) was 5.0% for the CASES-PMS
group and 6.2% in the pooled SAPPHIRE trial arms (362).
In the CAPTURE (Carotid ACCULINK/ACCUNET
Post-Approval Trial to Uncover Unanticipated or Rare
Events) registry, 2,500 high-risk patients underwent CAS
performed by more than 300 different specialty operators
with a broad range of experience. The 30-day endpoint of
MI, stroke, and death occurred in 6.3%, and the 30-day rate
of major stroke or death was 2.9% (372).
7.3.2. Risks Associated With Carotid Artery Stenting
The risks and potential complications of CAS involve
neurological deficits; injury of the vessels accessed to ap-
proach the lesion, the artery in the region of stenosis, and
the distal vessels; device malfunction; general medical and
access-site complications; restenosis; and mortality.
7.3.2.1. CARDIOVASCULAR COMPLICATIONS
Baroreflex responses such as bradycardia, hypotension, and
vasovagal reactions occur in 5% to 10% of cases but have
e
1
t
v
m
p
t
b
b
t
S
S
C
HIRE,
e54 Brott et al. JACC Vol. 57, No. 8, 2011
ECVD Guideline: Full Text February 22, 2011:e16–94been reported in as many as 33% of patients undergoing
CAS (506–508); most are transient and do not require
ongoing treatment after the procedure. With appropriate
preprocedural management, rates can be kept in the lower
range (375,507,509–513). The risk of MI is generally
reported as approximately 1% but reached 2.4% in the
ARCHeR (ACCULINK for Revascularization of Carotids
in High-Risk Patients) trial and was as low as 0.9% in the
CAPTURE registry of 3500 patients (361,446,458,508,
514–521).
The risk of arterial dissection or thrombosis in all published
series, including the ARCHeR and CAPTURE cohorts, was
1%. Target-vessel perforation occurred in1% of cases, and
xternal carotid artery stenosis or occlusion occurred in 5% to
0% of cases (361,372,446,458,508,514–539), but this event is
ypically benign and requires no further intervention. Transient
asospasm occurs in 10% to 15% of procedures related to
anipulation of the vessel with guidewires, catheters, or
rotection devices and is more common in smokers and in
hose with hypertension (540–543).
The incidence of restenosis after CAS has been reported to
e in the range of 3% to 5%. This problem can be minimized
y avoiding multiple or high-pressure balloon inflations, par-
Table 10. Trials Comparing Endarterectomy With Stenting in A
Trial, Year
(Reference)
No. of
Patients Key Features
APPHIRE,
2004 (370)
334 Multicenter randomized trial of patients
with 50% symptomatic carotid
stenosis (58%) or 80%
asymptomatic carotid stenosis (42%)
with 1 or more comorbidity criteria*
(high-surgical-risk group).
APPHIRE,
2008 (369)
334 Multicenter randomized trial of patients
with 80% asymptomatic carotid
stenosis (70%) and 50%
symptomatic carotid stenosis (30%).
REST,
2010 (360)
2,502 The study included 1,321 symptomatic
patients and 1,181 asymptomatic
patients. Symptomatic patients in
the study had 50% carotid stenosis
by angiography, 70% by
ultrasound, or 70% by CTA or MRA.
Asymptomatic patients in the study
had carotid stenosis (patients with
symptoms beyond 180 d were
considered asymptomatic) 60% by
angiography, 70% by ultrasound, or
80% by CTA or MRA.
*Criteria for high risk (at least 1 factor required): clinically significant cardiac disease (conges
contralateral carotid occlusion; contralateral laryngeal nerve palsy; previous radical neck surgery
is defined by age 80 years, New York Heart Association class III/IV heart failure, chronic obstru
artery bypass graft surgery. †Death, stroke, and MI.
CAS indicates carotid artery stent; CEA, carotid endarterectomy; CREST, Carotid Revascularizat
device; MI, myocardial infarction; MRA, magnetic resonance angiography; OR, odds ratio; SAPP
standard error.icularly in heavily calcified arteries (425,491,544–560).7.3.2.2. NEUROLOGICAL COMPLICATIONS
The incidence of TIA has been reported as 1% to 2% in
patients undergoing CAS. In the ARCHeR trial, the overall
incidence of stroke was 5.5%, with disabling stroke occur-
ring in 1.5% and relatively minor events occurring in 4.0%
of cases (361,458,514,515,517,518,520,521). In the CAP-
TURE registry, the rate of disabling stroke was 2% and that
of nondisabling stroke was 2.9% (372,524–529,531,533,
534). Intracranial hemorrhage and the hyperperfusion syn-
drome related to hypertension and anticoagulation have
been reported as complications in 1% of CAS procedures.
Seizures are related predominantly to hypoperfusion and
also occur in 1% of cases (561–569). Subclinical ischemic
injury has also been detected by MRI (380,570,571). In a
recent randomized trial (ICSS), comparisons were possible
between patients with CAS and CEA; these injuries, which
presumably resulted from microembolism, were more fre-
quent after CAS (368).
Device malfunction that results in deployment failure,
stent malformation, and migration after deployment is rare,
occurring in 1% of procedures (540,541,572–576). If
properly deployed, EPDs can reduce the neurological risks
associated with CAS, but these devices may also be associ-
tomatic Patients With Carotid Stenosis
Death or Any Stroke p Comments
symptomatic:
EA: 10.2%†
AS: 5.4%†
ombined:
EA: 9.8%†
AS: 4.8%†
0.20
0.09
Terminated prematurely
because of a drop in
randomization.
APPHIRE 3-y data,
troke:
EA: 15/167
AS: 15/197
eath:
EA: 35/167
AS: 31/167
Stroke: 0.99
Death: 0.68 (OR not
reported)
No significant difference
could be shown in
long-term outcomes
between patients who
underwent CAS with
an EPD and those
who underwent CEA.
ny periprocedural
stroke or
postprocedural
ipsilateral stroke:
symptomatic:
AS: 15 (2.50.6 SE)
EA: 8 (1.40.5 SE)
ny periprocedural
stroke or death or
postprocedural
ipsilateral stroke:
symptomatic:
AS: 15 (2.50.6 SE)
EA: 8 (1.40.5 SE)
Any periprocedural
stroke or
postprocedural
ipsilateral stroke:
Asymptomatic: 0.15
Any periprocedural
stroke or death or
postprocedural
ipsilateral stroke:
Asymptomatic: 0.15
The risk of the
composite primary
outcome of stroke,
MI, or death did not
differ significantly
among symptomatic
and asymptomatic
patients between
CAS and CEA.
art failure, abnormal stress test, or need for open heart surgery); severe pulmonary disease;
tion therapy to the neck; recurrent stenosis after endarterectomy; and age 80 years. High risk
lmonary disease, contralateral carotid stenosis 50% or more, prior CEA or CAS, or prior coronary
arterectomy versus Stent Trial; CTA, computed tomography angiography; EPD, embolic protection
Stenting and Angioplasty with Protection in Patients at HIgh Risk for Endarterectomy; and SE,symp
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a large profile and reduced steerability and ischemia if the
device becomes overloaded with embolic material during
deployment. Sizing of the EPD is important, because
undersizing allows passage of debris into the distal circula-
tion and oversizing can cause endothelial damage or provoke
vasospasm.
Among the general risks is access-site injury, which
complicates 5% of cases, but most such injuries involve pain
and hematoma formation and are self-limited (584–587).
The risk of groin infection is 1% and that of pseudoan-
eurysm is 1% to 2%. Blood transfusion is required in 2% to
3% of cases because of bleeding from the catheter insertion
site or retroperitoneal hematoma (588–591). Contrast-
induced nephropathy has been reported in 1% of cases,
because CAS is generally avoided in patients with severe
renal dysfunction (592).
7.3.3. Prevention of Cerebral Embolism in Patients
Undergoing Catheter-Based Carotid Intervention
Designed to prevent cerebral atheroembolism during
catheter-based interventions, EPDs are effective in aorto-
coronary saphenous vein graft angioplasty, in which there is
typically a relatively large burden of thrombus (593,594),
but no randomized studies have compared rates of ischemic
stroke in patients undergoing CAS with and without these
devices. The results of several observational studies suggest
that EPDs reduce rates of adverse events during CAS
(595–597) when operators are experienced with the appa-
ratus (35); in unfamiliar hands, the devices are associated
with worse clinical outcomes (454,456,457) and a higher
rate of ischemic abnormalities on postprocedural brain
imaging (598). Two postmarketing studies (362,372,375)
found similar outcomes when physicians trained in different
specialties with various levels of initial experience received
training in CAS with EPD techniques. In an international
survey of 12,392 CAS procedures performed by experienced
operators in 11,243 patients at 53 sites, technical success was
achieved in 98.9%, with rates of stroke and death of 2.8% when
the devices were used and 6.2% when they were not (595).
Although there was no difference in outcomes when experi-
enced operators used the devices with a single CAS system in
the ARCHeR trial (361), other studies have found that EPDs
improved outcomes (366,369,370,376,580).
7.3.4. Intravascular Ultrasound Imaging in
Conjunction With Catheter-Based
Carotid Intervention
Intravascular ultrasound (IVUS) is an adjunctive imaging
technique that can provide detailed information about the
diameter of the vascular lumen, extent of atherosclerosis,
and degree of calcification. IVUS has been used in coronary
and peripheral arteries to verify complete deployment of
intravascular stents, to measure plaque protrusion, and to
detect arterial dissection after angioplasty. Identification of
these complications during the procedure may permit mod-ification of technique or suggest supplementary interven-
tions to improve outcomes (599,600). Additionally, limited
studies suggest that IVUS may be useful to assess plaque
burden and composition.
Studies of IVUS in patients with ECVD have focused
mainly on the safety of the technique and its potential
contribution to the success of carotid revascularization
(601,602). Experience to date suggests that IVUS can safely
yield imaging information complementary to contrast an-
giography (603,604), and although incomplete stent expan-
sion or small postprocedural stent diameter may be associ-
ated with a greater risk of restenosis (605), the use of IVUS
has not been proven to improve outcomes, reduce peripro-
cedural stroke rates, or prevent restenosis. Although the
technique has been used safely in a small series of patients
undergoing carotid intervention, the additional catheter
manipulation required to traverse stenotic lesions carries
risk, and more evidence demonstrating benefit is needed
before the incremental risk associated with IVUS can be
justified as the basis for recommendations regarding routine
use of this technology in patients undergoing endovascular
evaluation and treatment of ECVD.
7.3.5. Management of Patients Undergoing
Endovascular Carotid Artery Stenting
7.3.5.1. RECOMMENDATIONS FOR MANAGEMENT OF PATIENTS UNDERGOING
CAROTID ARTERY STENTING
CLASS I
1. Before and for a minimum of 30 days after CAS, dual-antiplatelet
therapy with aspirin (81 to 325 mg daily) plus clopidogrel (75 mg
daily) is recommended. For patients intolerant of clopidogrel, ticlo-
pidine (250 mg twice daily) may be substituted. (Level of Evidence: C)
2. Administration of antihypertensive medication is recommended to
control blood pressure before and after CAS. (Level of Evidence: C)
3. The findings on clinical neurological examination should be docu-
mented within 24 hours before and after CAS. (Level of Evidence: C)
CLASS IIa
1. EPD deployment during CAS can be beneficial to reduce the risk of
stroke when the risk of vascular injury is low (456,606). (Level of
Evidence: C)
2. Noninvasive imaging of the extracranial carotid arteries is reason-
able 1 month, 6 months, and annually after revascularization to
assess patency and exclude the development of new or contralat-
eral lesions (364). Once stability has been established over an
extended period, surveillance at extended intervals may be appro-
priate. Termination of surveillance is reasonable when the patient is
no longer a candidate for intervention. (Level of Evidence: C)
The periprocedural management of patients undergoing
CAS can be organized according to distinct time frames.
First is the preprocedural evaluation, which includes careful
documentation of neurological status and identification of
comorbidities that impact the patient’s candidacy for endo-
vascular intervention, such as peripheral arterial obstructive
disease that limits catheter access, renal insufficiency, and
contraindications to intensive platelet-inhibitor therapy.
Second is the intraprocedural component, which involves
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supportive care. Third is the immediate postprocedure
period, when continued in-hospital support and monitoring
are required with control of blood pressure, prevention of
bleeding and access-site complications, and neurological
reassessment. The fourth and final stage involves long-term
postprocedural care, which is generally accomplished in the
outpatient setting, aimed at preservation of neurological
health and secondary prevention of complications of sys-
temic atherosclerosis.
Intraprocedural management includes adequate anti-
coagulation, continuous assessment of neurological and
hemodynamic parameters, and successful technical handling
of the CAS procedure. Adequate anticoagulation can be
achieved with unfractionated heparin given in sufficient
dosage to maintain the activated clotting time between 250
and 300 seconds. Bivalirudin may have advantages over
heparin, including obviating the need for monitoring of
activated clotting time (607,608).
CAS is associated with a number of periprocedural
events, including hypotension and vasovagal and vasode-
pressor reactions. For this reason, continuous electrocardio-
gram and blood pressure monitoring has become routine.
Several pharmacological agents have been used to correct
hemodynamic derangements during CAS. Atropine, 0.5 to
1 mg given intravenously, may be administered prophylac-
tically before the angioplasty or stent portion of the proce-
dure to avoid or attenuate bradycardia. Infrequently, persis-
tent bradycardia may require insertion of a temporary
transvenous pacemaker. Sustained hypotension is not rare,
and it may be helpful to ensure adequate hydration and
careful adjustment of antihypertensive medication immedi-
ately before the procedure. In the event of persistent
hypotension, intravenous phenylephrine (1 to 10 mcg/kg/
min) or dopamine (5 to 15 mcg/kg/min) should be available.
Hypertension occasionally develops immediately before,
during, or after the procedure, and maintenance of systolic
blood pressure below 180 mm Hg is advised to minimize
the risk of intracranial hemorrhage or the hyperperfusion
syndrome.
The patient’s neurological status, particularly level of
consciousness, speech, and motor function, should be mon-
itored throughout the stent procedure by the physician or
circulating nurse. It is important to avoid excessive sedation
to facilitate this ongoing assessment. When neurological
dysfunction develops, management is complex and governed
by the likely cause and the stage of the procedure at which
it becomes manifest. If a neurological event occurs early in
the procedure, such as during placement of the guidewire, it
may be prudent to abort the procedure and reassess the
patient for later intervention, if appropriate. If the event
occurs near the completion of the procedure, it may be best
to finish as quickly as possible and immediately assess the
patient clinically and angiographically for correctable causes.
A determination must then be made regarding neurological
rescue or alternative management techniques (609).Immediate postprocedural management includes care of
the access site and monitoring of neurological and hemo-
dynamic function. Formal neurological assessment should
be documented within 24 hours after intervention. Patients
who are stable and neurologically intact may be discharged
on the first postprocedural day. In addition to aspirin (81 to
325 mg daily), it is conventional to administer clopidogrel
(75 mg daily) for at least 4 weeks, mainly on the basis of
experience gained in patients undergoing CAS. Smoking
cessation and medications for control of hypertension,
hyperlipidemia, and diabetes should be resumed or initiated.
For neurologically intact patients with persistent hypoten-
sion, an additional period of in-hospital observation may
be required. The use of the oral adrenergic agent ephedrine
(25 to 50 mg orally, 3 or 4 times daily) may be useful in
managing persistent hypotension.
Longer-term postprocedural management includes phar-
macotherapy with antiplatelet medication and serial nonin-
vasive imaging to assess stent patency and exclude the
development of new areas of stenosis. Atherosclerotic risk
factor modification is an ongoing task. The role of risk
factor–modifying therapies, including smoking cessation
and lipid-lowering and antihypertensive agents, was dis-
cussed in Sections 6.1 and 6.3.
Serial follow-up assessment most commonly involves
duplex ultrasound imaging. By recent trial convention,
surveillance should be performed at 1 month, 6 months, and
annually to assess for restenosis. Imaging by CTA or MRA
may also be helpful for surveillance after CAS, particularly
when Doppler interrogation is difficult because of a superior
anatomic location of the region of interest.
7.4. Comparative Assessment of Carotid
Endarterectomy and Stenting
7.4.1. Nonrandomized Comparison of Carotid
Endarterectomy With Carotid Artery Stenting
The CaRESS (Carotid Revascularization Using Endarter-
ectomy or Stenting Systems) feasibility trial compared CAS
and CEA in a broad population of patients with symptom-
atic carotid stenosis (50%) or asymptomatic carotid ste-
nosis (75%) (610,611). To reflect the spectrum of patient
characteristics encountered in clinical practice, enrollment
was not limited to high-risk surgical candidates. The pri-
mary endpoint was the combined incidence of death and
stroke within 30 days after the procedure. Treatment was
not randomized but was determined on the basis of the
recommendation of the treating physicians. A total of 397
patients underwent either CEA or CAS in a ratio of 2:1.
Despite the lack of randomization, patient characteristics
were reasonably balanced across treatment arms; 87% of
patients undergoing CEA and 84% of those treated by CAS
were considered high-risk surgical cases, as defined by age
80 years, New York Heart Association class III or IV
heart failure, chronic obstructive pulmonary disease, 50%
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CABG surgery (610,611).
Kaplan-Meier estimates of event rates at 30 and 365 days
after the procedure are provided in Table 11, along with
observed rates of restenosis and carotid revascularization.
There were no significant differences between the CEA and
CAS groups for any outcome. Although these results may
suggest similar outcomes with CEA and CAS in the first
year, the nonrandomized design is an important limitation.
7.4.2. Meta-Analyses Comparing Carotid
Endarterectomy and Stenting
A meta-analysis of 5 randomized trials comparing CAS
with CEA disclosed no difference in stroke or death rates at
30 days (8.1% versus 6.3%); in MI, stroke, or death rates at
30 days (8.1% versus 7.8%); or in stroke or death rates at 1
year (13.5% versus 13.3%) (458). Another analysis of 6 trials
involving 1,177 patients found no difference between CAS
and CEA in 30-day or 1-year rates of stroke and death
(612). The studies included both symptomatic and asymp-
tomatic patients across a range of surgical risk, as well as
stenting with and without EPDs. The authors noted that
CAS was associated with a lower rate of MI (RR 0.3, 95%
CI 0.1 to 0.8; p0.02) and procedural morbidity such as
cranial nerve injury (RR 0.05, 95% CI 0.01 to 0.3; p0.001)
(458). Other meta-analyses found CAS to be inferior to
CEA or associated with higher rates of periprocedural
stroke (613–615). In another meta-analysis of 11 trials that
included 4,796 patients (10 of which reported on short-term
outcomes [n4,709] and 9 of which reported on
intermediate-term outcomes, or 1 to 4 years), the risk of
periprocedural mortality or stroke was lower with CEA than
with CAS (OR 0.67, 95% CI 0.47 to 0.95; p0.025). This
was based mainly on a lower risk of stroke (OR 0.65, 95%
CI 0.43 to 1.00; p0.049), because the risk of death (OR
1.14, 95% CI 0.56 to 2.31; p0.727) and the composite
endpoint of mortality or disabling stroke (OR 0.74, 95% CI
0.53 to 1.05; p0.088) did not differ significantly. The odds
of periprocedural MI (2.69, 95% CI 1.06 to 6.79; p0.036)
Table 11. Kaplan-Meier Estimates of Event Rates in the
CaRESS Trial
<30 Days (%) <365 Days (%)
Event CEA CAS CEA CAS
eath 0.40 0.00 6.60 6.30
troke 3.60 2.10 9.80 5.50
I 0.80 0.00 2.40 1.70
eath/stroke 3.60 2.10 13.60 10.00
eath/stroke/MI 4.40 2.10 14.30 10.90
estenosis N/A N/A 3.60 6.30
arotid revascularization N/A N/A 1.00 1.80
CaRESS indicates Carotid Revascularization Using Endarterectomy or Stenting Systems; CAS,
carotid artery stenting; CEA, carotid endarterectomy; MI, myocardial infarction; and N/A, not
available.
Modified from CaRESS Steering Committee (611).or cranial nerve injury (10.2, 95% CI 4.0 to 26.1; p0.001)were higher with CEA than with CAS. In the intermediate
term, the treatments did not differ significantly for stroke or
death (HR 0.90, 95% CI 0.74 to 1.1; p0.314) (616).
7.4.3. Randomized Trials Comparing Carotid
Endarterectomy and Carotid Artery Stenting
7.4.3.1. HIGH-RISK PATIENTS
The SAPPHIRE study (370,371) is the only randomized
trial that specifically enrolled high-risk patients to compare
CEA to CAS with an EPD. The inclusion criteria included
symptomatic stenosis 50% or asymptomatic stenosis
80%, plus at least 1 high-risk criterion. The trial was
stopped prematurely because of slow enrollment after 334
patients were randomized, and many potential participants
were excluded because they were considered to be at
exceedingly high risk for complications if randomized to
undergo CEA. Enrollment in the randomized portion of
the trial diminished sharply 12 months after the study was
initiated in 2000 (369). Technical success was achieved in
95.6% of patients who underwent CAS. The 30-day inci-
dence of MI, stroke, or death was 4.8% after CAS and 9.8%
after CEA (p0.09). The primary endpoint (the composite
of MI, stroke, or death within 30 days plus death because of
neurological causes or ipsilateral stroke between 31 days and
1 year) occurred in 12.2% of patients assigned to CAS and
20.1% of those assigned to CEA (p0.004 for noninferi-
ority and p0.053 for superiority). The protocol required
the collection of cardiac serum biomarker data as the basis
for diagnosis of periprocedural MI, the majority of which
were asymptomatic events. This was not the approach taken
in earlier studies of revascularization, and the higher re-
ported incidence of MI should be interpreted accordingly.
In patients with symptomatic stenosis, the occurrence of
the primary endpoint was similar after CAS and CEA
(16.8% versus 16.5%, respectively). In asymptomatic pa-
tients, fewer primary endpoints occurred after CAS (9.9%
versus 21.5%). At 1 year, CEA was associated with more
cranial nerve palsy (4.9% versus none; p0.004) and target-
vessel revascularization (4.3% versus 0.6%; p0.04). The
3-year incidence of stroke (7.1% versus 6.7%; p0.945) and
target-vessel revascularization (3% versus 7.1%; p0.084)
was similar for CAS and CEA (35,370,371).
7.4.3.2. CONVENTIONAL-RISK PATIENTS
The CAVATAS (Carotid And Vertebral Artery Translu-
minal Angioplasty Study) international randomized trial of
endovascular versus medical therapy involved 504 patients
(454). Although the combined stroke or death rate at 30
days was 10% in both groups, the angioplasty and CAS
group experienced less cranial neuropathy, major hema-
toma, MI, and pulmonary embolism and more restenosis at
1 year (14% versus 4%; p0.001), which reflects a relatively
low rate of stent use (22%) in the endovascular intervention
arm. Stroke or death at 3 years was similar in the 2 groups
(14.2%) (454).
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CAS would be noninferior to CEA in symptomatic patients
with high-grade carotid artery stenosis (Table 12) (457).
Patients were required to have 70% carotid stenosis
determined by duplex ultrasound, TIA or stroke within the
previous 180 days, and a Modified Rankin Scale score 4.
Surgical risk status was not a determinant of eligibility. The
primary outcome was a composite of ipsilateral stroke or
death within 30 days of the procedure. Subjects were
randomized between 2001 and 2006 to CEA (n595) or
CAS (n605). The surgeons were required to have per-
formed at least 25 CEA procedures with acceptable rates of
mortality and morbidity in the prior year, and CAS opera-
tors were required to have performed at least 25 successful
angioplasty or stent procedures, not necessarily involving
carotid arteries. The use of shunting during CEA and the
use of an EPD during CAS were optional. The 1,200-
patient enrollment fell short of the planned sample size of
1,900 when the study was terminated because of inability to
enroll the intended number of patients. Patient demograph-
ics and lesion characteristics were similar in the 2 groups,
and there was no significant difference in outcomes between
CAS and CEA at 30 days. Among the limitations of the
SPACE trial were the unequal training and experience of
surgeons performing CEA (617) and nonuniform use of
EPDs during CAS procedures (618).
Table 12. SPACE Trial Results at 30 Days After
the Procedure
Study Arm
CEA
(N584),
n (%)
CAS
(N599),
n (%)
Absolute Difference
(CASCEA)
Primary response events 37 (6.3) 41 (6.8) 0.51%
(1.89% to 2.91%)*
Death 5 (0.9) 4 (0.7)
All stroke 36 (6.2) 45 (7.5)
Ischemic stroke 30 (5.1) 39 (6.5)
Ipsilateral
Hemorrhagic stroke 5 (0.9) 1 (0.2)
Stroke
Disabling stroke† 17 (2.9) 24 (4.0)
*90% confidence interval. †Stroke resulting in a Modified Rankin Scale score of 3.
CAS indicates carotid artery stenting; CEA, carotid endarterectomy; and SPACE, Stent-
Protected Angioplasty versus Carotid Endarterectomy.
Table 13. Result of the EVA-3S Trial at 30 Days After the Proc
CEA (N259),
n (%)
Primary response events 10 (3.9)
Death 3 (1.2)
All stroke 9 (3.5)
Fatal stroke 2 (0.8)
Nonfatal stroke 7 (2.7)
Disabling stroke* 1 (0.4)
*Stroke resulting in a Modified Rankin Scale score of 3 with an increase of 2 over the scor
CAS indicates carotid artery stenting; CEA, carotid endarterectomy; CI, confidence interval; EVA-3S,
Adapted from Ringleb et al. (457) and Mas et al. (456).The EVA-3S (Endarterectomy Versus Angioplasty in
Patients with Symptomatic Severe Carotid Stenosis) trial
randomized patients within 120 days of TIA or completed
stroke who had 60% ipsilateral carotid stenosis deter-
mined by duplex ultrasound and angiography (456). Pa-
tients were excluded if they had experienced a disabling
stroke (Modified Rankin Scale score 3), but surgical risk
tatus was not a specified exclusion criterion. The primary
utcome was the composite of stroke or death within 30
ays of the procedure. Surgeons were required to have
erformed at least 25 CEA procedures during the previous
ear, and operators performing CAS were required to have
erformed at least 12 CAS procedures or 35 stenting
rocedures in other vessels. Trainees with little stenting
xperience were eligible to perform CAS if proctored by
ualified operators. The use of EPDs was limited. After 520
atients were randomized, enrollment was stopped in 2005
ecause of higher 30-day rates of stroke and other adverse
vents in the CAS arm (Table 13). More patients assigned
o CAS had occlusions of the contralateral carotid artery
5% versus 1.2%), a high-risk anatomic feature.
As with the SPACE trial (457), an important criticism of
he EVA-3S trial (619) centers on inadequate training
equirements for operators performing CAS and the non-
niform requirement to use an EPD, which may have
ompromised the results of CAS. The single-antiplatelet
edication regimen used in some subjects has also been
uestioned. Although dual-antiplatelet therapy has been the
tandard in North American carotid stent trials, compara-
ive outcome data from randomized clinical trials are avail-
ble only for stents deployed in other (mainly coronary)
ascular beds. Hence, the optimum dosing, timing, and
uration of dual-antiplatelet therapy for patients undergo-
ng CAS have not been established.
At least 4 additional randomized clinical trials have been
eported, are in progress, or are under consideration to
ompare CEA to CAS with EPD in conventional-risk
atients. The ICSS is an ongoing randomized trial designed
o compare the safety and effectiveness of CEA versus CAS
n symptomatic patients with 50% carotid stenosis (368).
articipating centers were classified as either experienced or
upervised. Experience required that at least 1 surgeon at the
enter had performed at least 50 CEA procedures (mini-
e
N261),
(%) OR (95% CI) p
(9.6) 0.38 (0.16 to 0.84) 0.0133
(0.8) 0.66 (0.17 to 18.30) 0.6851
(9.2) 0.36 (0.14 to 0.81) 0.0108
(0.4) 2.02 (0.10 to 119.82) 0.6228
(8.8) 0.29 (0.10 to 0.71) 0.0041
(2.7) 0.14 (0.0031 to 1.11) 0.0682
e the stroke.edur
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performed at least 50 stenting procedures and a minimum of
10 carotid stents. Supervised centers were designated as
experienced after randomization and treatment of 20 cases
by CEA or CAS if the results were acceptable to a proctor
and credentialing committee. Under this classification, 88%
of patients were treated at experienced centers. The primary
endpoint is the 3-year rate of fatal or disabling stroke, but
only an interim safety analysis has been reported. Among
1713 randomized patients, the 120-day composite rate of
stroke, death, or procedural MI was 8.5% in the CAS group
versus 5.2% in the CEA group (HR 1.69, 95% CI 1.16 to
2.45). Although the investigators suggested at that point
that CEA should be preferred over CAS in similar patients,
firm conclusions await completion of longer-term follow-up
of the cohort.
CREST is a randomized multicenter trial comparing
CAS to CEA in both symptomatic and asymptomatic
patients (620–622). The primary endpoint is the occurrence
of stroke, death, or MI during the periprocedural period and
ipsilateral stroke thereafter up to 4 years. CREST is unique
among the reported randomized trials comparing CAS and
CEA in conventional-risk patients because it included both
symptomatic patients with 50% carotid stenosis and
asymptomatic patients with 60% stenosis. Among 2502
patients followed up for a mean of 2.5 years, there was no
significant difference in primary events between the 2
methods of revascularization (7.2% with CAS versus 6.8%
with CEA; HR 1.11, 95% CI 0.81 to 1.51). Despite the
similarity in primary outcome, there were differences in rates
of the component periprocedural events. Stroke was signif-
icantly more frequent with CAS (4.1% versus 2.3%;
p0.01), and MI was more likely after CEA (2.3% versus
1.1%; p0.03), although the absolute rates of either were
low. Questions have arisen regarding the comparative im-
pact of periprocedural stroke and MI on the patient. In
CREST at 1 year, quality of life was impacted significantly
by major and minor stroke but not by MI. The lack of a
detectable impact of MI on quality of life may relate to
sensitive ascertainment techniques, including biomarker
assessments, such that the rate of MI in CREST was higher
than that reported in other randomized trials. The compar-
ative primary results between treatment groups did not vary
by sex or symptom status, although event rates were higher
among symptomatic patients in both groups than among
asymptomatic patients. For both symptomatic and asymp-
tomatic patients, the periprocedural stroke and death rates at
the 117 centers in CREST were at or below the recommended
safety requirements in current guideline statements (111).
Consistent with reports from the SPACE trial, there was a
differential outcome based on patient age: For patients younger
than 70 years of age, the primary results favored CAS, whereas
in those older than 70 years of age, results favored CEA (360).
lso, as in previous randomized trials, cranial nerve palsy was
ore common after CEA (360).ACST-2 and ACT-1 (Asymptomatic Carotid Trial)
compare CEA with CAS in patients with asymptomatic
carotid stenosis (http://www.ClinicalTrials.gov and http://
www.controlled-trials.com), but no outcome data have yet
been reported.
7.4.4. Selection of Carotid Endarterectomy or
Carotid Artery Stenting for Individual Patients
With Carotid Stenosis
Table 14 summarizes recommendations for the selection of
revascularization techniques for patients with carotid artery
stenosis. Although no adequate studies have validated the
specific high-risk criteria that might warrant preferential
selection of CAS rather than CEA for individual patients,
generally accepted anatomic features are listed in Table 10.
In addition to these are comorbid medical conditions
associated with increased surgical risk, such as advanced
cardiopulmonary disease that might complicate surgical
anesthesia.
Recent large trials like CREST make it clear that with
adequate training, physicians can perform CAS and CEA
with low complication rates. Taken together with the results
of previous trials, it appears that CAS is associated with a
higher periprocedural risk of stroke or death. Although this
difference remained significant in CREST for up to 4 years,
a meta-analysis of studies that preceded CREST found
CEA to be superior to CAS with regard to short-term but
not longer-term outcomes (616). Hence, additional long-
term data are needed before clear conclusions can be drawn
regarding the relative risks and benefits of the 2 procedures
(623). Although the increased risk of nonfatal stroke with
CAS is statistically offset by an increased risk of nonfatal MI
with CEA, stroke appears to have more detrimental health
consequences. Similarly, local complications, particularly
cranial nerve palsies, are more frequently associated with
CEA, whereas microembolic cerebral injury after CAS may
have implications for cognitive function. Although the
reasons remain speculative, the interaction of patient age
with the outcomes of CAS and CEA must also be consid-
ered carefully by clinicians, with CEA favored for elderly
patients. Finally, the benefit of revascularization by either
Table 14. Summary of Recommendations Regarding the
Selection of Revascularization Techniques for Patients
With Carotid Artery Stenosis
Symptomatic Patients Asymptomatic
Patients:
70% to 99%
Stenosis*
50% to 69%
Stenosis
70% to 99%
Stenosis*
Endarterectomy Class I
LOE: B
Class I
LOE: A
Class IIa
LOE: A
Stenting Class I
LOE: B
Class I
LOE: B
Class IIb
LOE: B
The severity of stenosis is defined according to angiographic criteria by the method used in
NASCET (70) but generally corresponds as well to assessment by sonography (136) and other
accepted methods of measurement. See Sections 7.2 to 7.4.4 for details.
LOE indicates level of evidence.method versus modern aggressive medical therapy has not
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stenosis.
7.5. Durability of Carotid Revascularization
7.5.1. Recommendations for Management of Patients
Experiencing Restenosis After Carotid Endarterectomy
or Stenting
CLASS IIa
1. In patients with symptomatic cerebral ischemia and recurrent ca-
rotid stenosis due to intimal hyperplasia or atherosclerosis, it is
reasonable to repeat CEA or perform CAS using the same criteria as
recommended for initial revascularization (see Sections 7.5.2 and
7.5.3). (Level of Evidence: C)
2. Reoperative CEA or CAS after initial revascularization is reasonable
when duplex ultrasound and another confirmatory imaging method
identify rapidly progressive restenosis that indicates a threat of
complete occlusion. (Level of Evidence: C)
CLASS IIb
1. In asymptomatic patients who develop recurrent carotid stenosis
due to intimal hyperplasia or atherosclerosis, reoperative CEA or
CAS may be considered using the same criteria as recommended
for initial revascularization. (Level of Evidence: C)
CLASS III: HARM
1. Reoperative CEA or CAS should not be performed in asymptomatic
patients with less than 70% carotid stenosis that has remained
stable over time. (Level of Evidence: C)
7.5.2. Clinical Durability of Carotid Surgery and
Carotid Stenting
Clinical durability refers to the sustained efficacy of CEA
and CAS in preventing stroke, as discussed for CEA in
Section 7.2. In the large randomized clinical trials, the
ipsilateral stroke rates after the first 30 days were approxi-
mately 1% to 2% per year for symptomatic patients (ECST,
NASCET) and approximately 0.5% to 0.8% per year for
asymptomatic patients (ACAS, ACST). For clinical dura-
bility of CEA compared with CAS, longer-term results
from EVA-3S and SPACE are now available and show
promising results for both procedures. EVA-3S outcomes
projected to 4 years showed ipsilateral stroke rates beyond
30 days of 1% per year for both CEA and CAS. In
PACE, at 2 years, the ipsilateral stroke rate was approxi-
ately 1% per year for CEA and CAS when periprocedural
vents were excluded. The clinical durability of CEA and
AS beyond 5 years cannot be clearly determined from
vailable studies (364,379).
The mechanism responsible for arterial restenosis after
EA is related to the postoperative interval. Early restenosis
within 2 years) typically involves intimal hyperplasia,
hereas later restenosis usually reflects progression of ath-
rosclerotic disease. Outcomes are similar regardless of
hether the patch material is vein, polyethylene terephtha-
ate, polytetrafluoroethylene, or bovine pericardium (624–
27). The role of CAS as an alternative to reoperative CEA
n patients who experience restenosis after initial CEA is
iscussed in Section 7.3. b.5.3. Anatomic Durability of Carotid Surgery and
arotid Stenting
he incidence of recurrent carotid stenosis depends on the
ethod used for detection. Restenosis after CEA has been
eported in 5% to 10% of cases when assessed by postoper-
tive ultrasonography, but the rate has been consistently
elow 5% when patching was used in more recent series
407,440,468,624,625,628–630). When periodic duplex
canning is used, hemodynamically significant recurrent
tenosis rates of 5% to 7% have been reported in multicenter
rials in which the quality of surgery is monitored carefully
396,403,404,406,440,628,631–645).
Recurrent carotid stenosis after CEA is a trimodal phe-
omenon. The first event is not really recurrence but instead
epresents an unsatisfactory or incomplete CEA. This is
sually detected when the first postoperative duplex ultra-
ound scan identifies residual stenosis, and its occurrence
an be minimized by intraoperative completion angiography
r duplex ultrasound imaging. Because the quality of CEA
as improved, this phenomenon occurs in 1% of cases.
he second peak of recurrent carotid stenosis, occurring
ithin 18 months and usually within 6 months after
peration, is due to intimal hyperplasia. This is usually
enign, seldom requires reoperation, and has been reduced
hrough the routine incorporation of patch angioplasty
losure into the operative procedure. The third form of
ecurrent stenosis usually develops 5 years or longer after
peration and reflects progressive atherosclerotic disease
ither at the site of CEA or in proximal or distal arterial
egments.
For both CEA and CAS, comparative data on restenosis
re becoming available but should be interpreted with
aution. A minority of patients in contemporary studies
ave undergone follow-up ultrasound scanning, which in-
roduces potential important selection bias. For CAS, the
ole of stent-generated artifacts in ultrasound velocity mea-
urements has yet to be resolved with angiographic com-
arisons. In the CAVATAS study, a stent was used in only
2% of the angioplasty patients, and carotid ultrasound at 1
ear detected 70% to 99% stenosis in 4% of the CEA
atients and in 14% of the patients managed by CAS
p0.001). In SAPPHIRE, all CAS patients received a
tent; 96 of the CEA patients and 122 of the CAS patients
nderwent carotid ultrasound at 1 year. Four CEA patients
4.2%) and 1 CAS patient (0.8%) had 70% recurrent
tenosis (p0.17). After 1 year of follow-up in the SPACE
rial, 4.6% of patients who underwent CEA and 10.7% of
hose who underwent CAS had developed 70% recurrent
tenosis as assessed by ultrasound (p0.0009). Comparative
estenosis rates for CEA and CAS are also available from
ase series (646–649), but inference is limited by potential
election bias.
In patients who develop restenosis after CEA, CAS is an
lternative to reoperative CEA (see Section 7.2.4) and may
e appropriate in asymptomatic patients with restenosis that
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patients with 50% recurrent stenosis. Contralateral occlu-
sion arguably increases the risk associated with CAS,
because the procedure does not provide an option to use a
shunt, and little collateral circulation is available in the event
of thrombosis or occlusion of an EPD. On the other hand,
3 studies (ARCHeR, a nonrandomized prospective study
[361]; SAPPHIRE, a randomized comparison [370]; and
CAPTURE, a multicenter registry [372]) specifically ad-
dressed the use of CAS in patients with carotid stenosis and
contralateral carotid occlusion. The prevalence of contralat-
eral carotid occlusion was 16.5% in ARCHeR, 24.5% in
SAPPHIRE, and 8.2% in CAPTURE. Although the over-
all results of these limited studies suggested that CAS was
noninferior to CEA in patients with various comorbidities
(including but not limited to contralateral occlusion), the
available data are insufficient to justify a recommendation
favoring one procedure over the other in patients with
carotid stenosis and occlusion of the contralateral carotid
artery. Restenosis is generally a benign condition that does
not require revascularization except in selected circum-
stances, such as when restenosis leads to recurrent ischemic
symptoms or progresses to preocclusive severity. Under
these circumstances, it may be justifiable to repeat revascu-
larization, either by CEA in the hands of an experienced
surgeon or by CAS as in the general approach to patients
with unsuitable neck anatomy.
8. Vertebral Artery Disease
Symptomatic obstructive disease of the vertebral arteries is
encountered less commonly in clinical practice than carotid
stenosis, and the volume of evidence available to guide its
evaluation and management is less substantial. The preva-
lence, pathophysiology, and natural history of vertebral
artery disease are not as well understood as disease of the
extracranial carotid circulation. Like patients with carotid
atherosclerosis, however, those with vertebral artery disease
face an increased risk of other cardiovascular ischemic
events, including MI, PAD, and vascular death.
8.1. Anatomy of the Vertebrobasilar
Arterial Circulation
The left and right vertebral arteries are typically described as
having 4 segments each (V1 through V4), the first 3 of
which are extracranial. The first segments (V1) extend
cephalad and posteriorly from the origin of the vertebral
arteries between the longus colli and scalenus anterior
muscles to the level of the transverse foramina, typically
adjacent to the sixth cervical vertebra. The second segments
(V2) extend cephalad from the point at which the arteries
enter the most inferior transverse portion of the foramina to
their exits from the transverse foramina at the level of the
second cervical vertebra. These segments of the left and
right vertebral arteries therefore have an alternating in-traosseous and interosseous course, a unique anatomic
environment that exposes the V2 segments to the possibility
of extrinsic compression from spondylotic exostosis of the
spine. Small branches from the V2 segments supply the
vertebrae and adjacent musculature and, most importantly,
may anastomose with the spinal arteries. The third seg-
ments (V3) extend laterally from the points at which the
arteries exit the C2 transverse foramina, cephalad and
posterior to the superior articular process of C2, cephalad
and medially across the posterior arch of C1, and then
continue into the foramen magnum. Branches of the V3
segments typically anastomose with branches of the occip-
ital artery at the levels of the first and second cervical
vertebrae. The fourth segments (V4) of each vertebral artery
extend from the point at which the arteries enter the dura to
the termination of these arteries at the vertebrobasilar
junction. Important branches of the V4 segments include
the anterior and posterior spinal arteries, the posterior
meningeal artery, small medullary branches, and the poste-
rior inferior cerebellar artery.
Anatomic variants of vertebral artery anatomy are much
more common than variants of the carotid circulation. The
vertebral arteries typically arise from the subclavian arteries;
in approximately 5% of individuals, however, the left verte-
bral artery arises directly from the aortic arch. The diameter
of the left vertebral artery diameter is larger than (in 50% of
individuals) or equal to (in 25% of individuals) that of the
right vertebral artery. In approximately 10% of people, 1
vertebral artery is markedly smaller than the other. When
this is the case, the smaller vertebral artery may terminate in
the posterior inferior cerebellar artery or have a hypoplastic
segment that extends beyond the posterior inferior cerebel-
lar artery to the basilar artery, contributing little to basilar
artery blood flow. These important anatomic variations
must be considered in clinical assessment and treatment.
8.2. Epidemiology of Vertebral Artery Disease
Because it may be difficult to visualize the origins of the
vertebral arteries by ultrasound imaging, the incidence of
posterior circulation strokes may be underestimated (650),
but vertebral artery atherosclerosis may be the causative
basis for approximately 20% of posterior circulation strokes
(650–653). In the New England Medical Center Posterior
Circulation Registry, 82 of 407 patients with ischemia
affecting the posterior circulation had 50% stenosis of the
extracranial vertebral artery (654). Annual stroke rates for
patients with symptomatic intracranial vertebral and basilar
artery stenosis are 8% and 11%, respectively (655–657). A
study using contrast-enhanced MRA in consecutive patients
with posterior circulation TIA or minor stroke found a
greater prevalence of 50% vertebral and basilar arterial
stenosis than of 50% carotid stenosis in patients with
carotid territory events, and vertebrobasilar arterial stenosis
was more often associated with multiple ischemic episodes
and a higher risk of early recurrent stroke (658).
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Vertebrobasilar Arterial Insufficiency
Atherosclerotic stenosis most commonly affects the first
portion of the vertebral arteries or extends from plaques that
compromise the origin of the vertebral arteries as they arise
from the brachiocephalic and subclavian arteries. Lesions at
the midportion of the vertebral arteries can occur when
overgrowth of the transverse process of a vertebra impinges
on the artery as it passes through the bony canal. In such
cases, symptoms are commonly provoked by head turning,
during which an osteophyte obstructs the vertebral artery.
Symptoms associated with vertebral artery occlusive dis-
ease include dizziness, vertigo, diplopia, perioral numbness,
blurred vision, tinnitus, ataxia, bilateral sensory deficits, and
syncope, all of which can be caused by other disease entities,
including cardiac arrhythmias, orthostatic hypotension, and
vestibular disorders.
8.4. Evaluation of Patients With
Vertebral Artery Disease
Evaluation of a patient with presumed vertebrobasilar in-
sufficiency should begin with a thorough clinical history and
examination followed by noninvasive imaging as for patients
with carotid artery disease (659).
8.5. Vertebral Artery Imaging
8.5.1. Recommendations for Vascular Imaging in
Patients With Vertebral Artery Disease
CLASS I
1. Noninvasive imaging by CTA or MRA for detection of vertebral artery
disease should be part of the initial evaluation of patients with
neurological symptoms referable to the posterior circulation and
those with subclavian steal syndrome. (Level of Evidence: C)
2. Patients with asymptomatic bilateral carotid occlusions or unilat-
eral carotid artery occlusion and incomplete circle of Willis should
undergo noninvasive imaging for detection of vertebral artery ob-
structive disease. (Level of Evidence: C)
3. In patients whose symptoms suggest posterior cerebral or cerebel-
lar ischemia, MRA or CTA is recommended rather than ultrasound
imaging for evaluation of the vertebral arteries. (Level of Evidence: C)
CLASS IIa
1. In patients with symptoms of posterior cerebral or cerebellar isch-
emia, serial noninvasive imaging of the extracranial vertebral arter-
ies is reasonable to assess the progression of atherosclerotic dis-
ease and exclude the development of new lesions. (Level of
Evidence: C)
2. In patients with posterior cerebral or cerebellar ischemic symptoms
who may be candidates for revascularization, catheter-based con-
trast angiography can be useful to define vertebral artery patho-
anatomy when noninvasive imaging fails to define the location or
severity of stenosis. (Level of Evidence: C)
3. In patients who have undergone vertebral artery revascularization,
serial noninvasive imaging of the extracranial vertebral arteries is
reasonable at intervals similar to those for carotid revascularization.
(Level of Evidence: C)In contrast to the wealth of literature on carotid arterial
imaging, published data on noninvasive imaging of the
vertebrobasilar arterial system are relatively sparse. A sys-
tematic review found 11 studies that evaluated noninvasive
imaging methods compared with catheter-based angiogra-
phy for detection of vertebral artery stenosis. CTA and
contrast-enhanced MRA were associated with higher sen-
sitivity (94%) and specificity (95%) than duplex ultrasonog-
raphy (sensitivity 70%), and CTA had slightly superior
accuracy (167). The relative insensitivity of ultrasound
reflects the technical difficulty involved in sonographic
interrogation and makes this method less suitable for
detection of disease in this anatomic region. Local expertise
and availability of imaging techniques must also be consid-
ered in the selection of noninvasive modalities in a given
clinical situation. Because neither MRA nor CTA reliably
delineates the origins of the vertebral arteries, catheter-
based contrast angiography is typically required before
revascularization for patients with symptomatic posterior
cerebral ischemia. Digital subtraction arteriography with
intravenous contrast administration is sometimes used when
selective catheterization of the vertebral arteries cannot be
achieved, but the accuracy of this method compared with
CTA has not been established.
8.6. Medical Therapy of Patients With
Vertebral Artery Disease
8.6.1. Recommendations for Management of
Atherosclerotic Risk Factors in Patients With
Vertebral Artery Disease
CLASS I
1. Medical therapy and lifestyle modification to reduce atherosclerotic
risk are recommended in patients with vertebral atherosclerosis
according to the standards recommended for those with extracra-
nial carotid atherosclerosis (261,660). (Level of Evidence: B)
2. In the absence of contraindications, patients with atherosclerosis
involving the vertebral arteries should receive antiplatelet therapy
with aspirin (75 to 325 mg daily) to prevent MI and other ischemic
events (305,661). (Level of Evidence: B)
3. Antiplatelet drug therapy is recommended as part of the initial
management for patients who sustain ischemic stroke or TIA asso-
ciated with extracranial vertebral atherosclerosis. Aspirin (81 to 325
mg daily), the combination of aspirin plus extended-release dipyrid-
amole (25 and 200 mg twice daily, respectively), and clopidogrel
(75 mg daily) are acceptable options. Selection of an antiplatelet
regimen should be individualized on the basis of patient risk factor
profiles, cost, tolerance, and other clinical characteristics, as well as
guidance from regulatory agencies (260,305,339–342). (Level of
Evidence: B)
CLASS IIa
1. For patients with atherosclerosis of the extracranial vertebral arter-
ies in whom aspirin is contraindicated by factors other than active
bleeding, including those with allergy to aspirin, either clopidogrel
(75 mg daily) or ticlopidine (250 mg twice daily) is a reasonablealternative. (Level of Evidence: C)
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tebral artery stenosis is not as well established as that for
patients with carotid stenosis. Although various medical,
interventional, and surgical approaches have been developed
for treatment of patients with vertebral artery disease, none
have been evaluated in randomized trials. In fact, few trials
involving ischemic stroke have distinguished between ante-
rior or posterior circulatory disease. In general, despite the
relative paucity of evidence specifically applicable to patients
with vertebral artery disease, we recommend that medical
management follow the guidelines set forth for those with
disease of the carotid arteries. This is particularly true of
measures directed at reduction of systemic atherosclerotic
risk and the prevention of ischemic complications in other
vascular beds.
For patients with acute ischemic syndromes that in-
volve the vertebral artery territory, studies of intravenous
thrombolytic therapy have reported variable outcomes
(650,662,663). When there is angiographic evidence of
thrombus at the origin or extracranial portion of the
vertebral artery, anticoagulation is generally recommended
for at least 3 months, whether or not thrombolytic therapy
is used initially (662,664–666). The WASID (Warfarin
versus Aspirin for Symptomatic Intracranial Disease) trial
found aspirin and warfarin to be equally efficacious after
initial noncardioembolic ischemic stroke (656,667). Ticlo-
pidine was superior to aspirin for secondary prevention of
ischemic events in patients with symptomatic posterior
circulation disease (668). In ESPS-2, vertebrobasilar terri-
tory stroke or TIA occurred in 5.7% of 255 patients treated
with a combination of low-dose aspirin and sustained-
release dipyridamole twice daily compared with 10.8% of
those given a placebo (669).
8.7. Vertebral Artery Revascularization
8.7.1. Surgical Management of
Vertebral Artery Disease
Compared with CEA, operations are rarely performed to
treat vertebral artery occlusive disease. Although no random-
ized trials have addressed operative procedures for posterior
cerebral circulation disease, reports of surgical treatment of
patients with extracranial vertebral artery stenosis have dem-
onstrated the feasibility of endarterectomy and vessel recon-
struction with favorable outcomes (670–677). For proximal
vertebral artery reconstruction, early complication rates of 2.5%
to 25% and perioperative mortality rates of 0% to 4% have been
reported (671,672). For distal vertebral artery reconstruction,
mortality rates have ranged from 2% to 8% (670,673,674,
676,677). Intracranial bypass surgery is associated with mor-
tality rates of 3% to 12% and neurological and systemic
complication rates of 22% to 55% (673–677).
When symptoms can be clearly attributed to occlusive
disease of the vertebral arteries, corrective surgery may be
effective. Indications for surgery on the first portion of the
vertebral artery are relatively rare. When both vertebralarteries are patent and 1 has a significant stenotic lesion, the
contralateral vertebral artery usually supplies sufficient blood
flow to the basilar artery, provided there is anatomic
continuity. This is particularly true if the uninvolved verte-
bral artery is the larger (dominant) vessel. Compromised
vertebrobasilar perfusion is not the only mechanism of
symptoms, however, because atheroembolism from lesions
at the origin of the vertebral artery may be the source of
brainstem or cerebellar infarction.
The surgical approach to atherosclerotic lesions at the
origin of the vertebral artery includes trans-subclavian ver-
tebral endarterectomy, transposition of the vertebral artery
to the ipsilateral common carotid artery, and reimplantation
of the vertebral artery with vein graft extension to the
subclavian artery. Distal reconstruction of the vertebral
artery, necessitated by total occlusion of the midportion,
may be accomplished by anastomosis of the principal trunk
of the external carotid artery to the vertebral artery at the
level of the second cervical vertebra (678). Such operations,
although rare, can relieve symptoms, with low rates of
morbidity and mortality in appropriately selected patients
(670,679–686).
8.7.2. Catheter-Based Endovascular Interventions for
Vertebral Artery Disease
Although angioplasty and stenting of the vertebral vessels
are technically feasible, as for high-risk patients with carotid
disease, there is insufficient evidence from randomized trials
to demonstrate that endovascular management is superior to
best medical management. In a review of 300 interventions
for proximal vertebral artery stenosis, the risk of death was
0.3%, the risk of periprocedural neurological complications
was 5.5%, and risk of posterior stroke was 0.7% at a mean
follow-up of 14.2 months. Restenosis occurred in 26% of
cases (range 0% to 43%) after a mean of 12 months (range
3 to 25 months), although restenosis was not consistently
correlated with recurrent symptoms (687). Among 170
angioplasty procedures in patients with distal vertebrobasilar
disease, neurological complications developed in 24%, but
the rate approached 80% in cases of urgent vertebrobasilar
revascularization. Restenosis developed in 10% after a mean
follow-up interval of 12.6 months (687). When data from
14 case series were combined, the annual stroke risk after
angioplasty for distal vertebrobasilar disease was approxi-
mately 3% (687), and rates of stroke and restenosis appeared
to be related to ascending (more distal) location and the
anatomic complexity of the offending lesion.
CAVATAS (688), the only randomized study to date to
compare outcomes after endovascular and medical treat-
ment for patients with vertebral artery stenosis, included
only 16 such patients (454,688,689), in contrast to 504
patients with carotid stenosis, and because no patient in
either arm had recurrent vertebral basilar territory stroke by
8 years after randomization, there was no difference in
outcomes among those treated by stenting or medical
therapy. The lower rate of diagnosis of symptomatic verte-
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the inherent difficulty in demonstrating a benefit of vertebral
artery revascularization.
9. Diseases of the Subclavian and
Brachiocephalic Arteries
9.1. Recommendations for the Management
of Patients With Occlusive Disease of the
Subclavian and Brachiocephalic Arteries
CLASS IIa
1. Extra-anatomic carotid-subclavian bypass is reasonable for patients
with symptomatic posterior cerebral or cerebellar ischemia caused
by subclavian artery stenosis or occlusion (subclavian steal syn-
drome) in the absence of clinical factors predisposing to surgical
morbidity or mortality (690–692). (Level of Evidence: B)
2. Percutaneous endovascular angioplasty and stenting is reasonable
for patients with symptomatic posterior cerebral or cerebellar isch-
emia caused by subclavian artery stenosis (subclavian steal syn-
drome) who are at high risk of surgical complications. (Level of
Evidence: C)
3. Revascularization by percutaneous angioplasty and stenting, direct
arterial reconstruction, or extra-anatomic bypass surgery is reason-
able for patients with symptomatic ischemia involving the anterior
cerebral circulation caused by common carotid or brachiocephalic
artery occlusive disease. (Level of Evidence: C)
4. Revascularization by percutaneous angioplasty and stenting, direct
arterial reconstruction, or extra-anatomic bypass surgery is reason-
able for patients with symptomatic ischemia involving upper-
extremity claudication caused by subclavian or brachiocephalic
arterial occlusive disease. (Level of Evidence: C)
5. Revascularization by either extra-anatomic bypass surgery or sub-
clavian angioplasty and stenting is reasonable for asymptomatic
patients with subclavian artery stenosis when the ipsilateral internal
mammary artery is required as a conduit for myocardial revascular-
ization. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Asymptomatic patients with asymmetrical upper-limb blood pres-
sure, periclavicular bruit, or flow reversal in a vertebral artery caused
by subclavian artery stenosis should not undergo revascularization
unless the internal mammary artery is required for myocardial
revascularization. (Level of Evidence: C)
9.2. Occlusive Disease of the Subclavian and
Brachiocephalic Arteries
Occlusive disease that involves the subclavian and brachio-
cephalic arteries is relatively uncommon. Causes include
atherosclerosis, Takayasu arteritis, giant cell arteritis, FMD,
and radiation-induced arteriopathy; of these, atherosclerosis
is the most frequent cause. The clinical presentation de-
pends on the vessel involved and severity of disease. Symp-
toms may reflect upper-extremity ischemia, such as arm or
hand claudication, paresthesia, or rest pain.
Subclavian artery stenosis is generally associated with a
favorable prognosis. Some patients with high-grade stenosis
and mild upper-extremity claudication become asymptom-atic as collateral blood supply develops. In asymptomatic
patients, subclavian intervention may be performed in prep-
aration for coronary revascularization surgery that requires
use of the ipsilateral internal mammary artery as a bypass
conduit or to preserve blood flow to the internal mammary
artery in patients who require myocardial revascularization.
To our knowledge, no randomized trials of subclavian artery
or brachiocephalic revascularization have been published.
9.3. Subclavian Steal Syndrome
When the proximal subclavian artery becomes stenotic or
occluded, branches distal to the obstruction become sources
of collateral circulation to the arm by flow reversal in the
vertebral artery and internal mammary arteries. Usually, this
does not cause symptoms except for muscular fatigue in the
affected arm, akin to claudication. Because 2 vertebral
arteries normally supply blood to the basilar artery, ante-
grade flow through 1 is usually sufficient to maintain
posterior cerebral circulation. When the dominant vertebral
artery is subtended by subclavian obstruction, reversal of
flow in the vertebral artery may reduce basilar artery
perfusion and cause posterior cerebrovascular insufficiency.
Symptoms are typically aggravated by exercising the ipsilat-
eral arm, which amplifies the flow reversal as a source of
collateral circulation to the subclavian artery and its
branches. The same phenomenon affects the internal mam-
mary artery, compromising its utility as a conduit for CABG
surgery.
Detection of a periclavicular or infraclavicular bruit sug-
gests the possibility of subclavian stenosis, but subclavian
arterial occlusive disease is most readily recognized on the
basis of asymmetry between left and right arm blood
pressure measurements. The side with the lower pressure is
suspect for subclavian artery stenosis or occlusion, and blood
pressure tends to fall further in the affected limb after arm
exercise. Blood pressure measurements may not be asym-
metrical when bilateral subclavian disease or aortic arch
syndrome compromises perfusion of both upper limbs
equally.
The diagnosis of subclavian steal syndrome should be
considered in patients with symptoms of posterior cerebral
circulatory insufficiency aggravated by upper-limb exercise.
In the vertebral ischemic form of subclavian steal syndrome,
upper-extremity exertion leads to retrograde flow in the
ipsilateral vertebral artery, and symptoms of posterior cere-
bral or cerebellar hypoperfusion, including lightheadedness,
syncope, vertigo, ataxia, diplopia, and motor deficits may
occur; the patient may also develop upper-limb claudication.
In the less common coronary ischemic form of subclavian
steal syndrome, blood is diverted from the coronary arteries
to the upper limb through an internal mammary artery graft
during arm exercise, producing angina pectoris. Involve-
ment of the brachiocephalic or common carotid artery can
lead to symptomatic cerebral hypoperfusion. Duplex ultra-
sonography may identify reversal of flow in a vertebral
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stenosis of the subclavian artery.
Asymptomatic patients with asymmetrical upper-limb
blood pressure, reversal of flow in a vertebral artery, or other
manifestations of subclavian steal syndrome need no specific
intervention other than strategies directed at the secondary
prevention of ischemic events related to systemic atheroscle-
rosis, unless the ipsilateral internal mammary artery is
required for myocardial revascularization. Symptomatic pa-
tients should be considered for subclavian revascularization
with endovascular or surgical techniques.
9.4. Revascularization of the Brachiocephalic
and Subclavian Arteries
The main surgical approach to revascularization involves
prosthetic extra-anatomic bypass grafting from the ipsilat-
eral carotid artery to the subclavian artery, which is highly
effective in delivering blood to the subclavian artery and
restoring antegrade vertebral artery flow to the basilar artery.
In addition to carotid-subclavian bypass, commonly used
extra-anatomic methods of subclavian artery revasculariza-
tion include carotid-axillary or axilloaxillary bypass with
polytetrafluoroethylene or Dacron grafts and subclavian-
carotid arterial transposition. Surgical repair is associated
with low morbidity and mortality and excellent long-term
patency (690,693).
Subclavian artery stenosis is also amenable to balloon
angioplasty, atherectomy, and stenting. No randomized
trials have compared these methods with surgical revascu-
larization, but numerous reports from single institutions
have provided data about early and long-term results, and 2
reports compared results of catheter-based and surgical
revascularization in patients with symptomatic obstructive
subclavian artery disease (692,694,695). In a series of 110
patients reported in 2005, the procedure was considered
initially successful in 93% of cases (694). In 6% of cases,
total occlusion of the subclavian artery precluded cannula-
tion. Of the cases in which the artery was initially opened,
the median obstruction-free interval was 23 months, and
89% maintained patency at 5 years. Four recurrent stenoses
were treated successfully by percutaneous angioplasty, and 4
required surgical revascularization. In a nonrandomized
comparison of endovascular revascularization with extra-
anatomic bypass surgery for subclavian stenosis, all bypass
grafts remained patent except 1 that occluded 19 years after
operation (692). In contrast, 6 of 46 attempted subclavian
artery angioplasties could not be completed because of
occlusive lesions. Among the arteries successfully opened,
the 4-year patency rate was 82%.
In a report that compared 121 patients undergoing
stenting and 51 undergoing carotid-subclavian bypass, ini-
tial success rates were 98% and 100% for the endovascular
and surgical approaches, respectively, whereas periproce-
dural complication rates were 15.1% and 5.9%, being lower
in the surgical group (695). There were no cases of periop-erative stroke or mortality in those selected for bypass
surgery, whereas complications in the stent group included
thromboembolism, heart failure, arm edema after reperfu-
sion, arterial pseudoaneurysm, and 1 death. Primary patency
after surgical bypass was 100% at 1 year and 96% at 5 years.
Among patients managed by endovascular therapy, patency
was 93% at 1 year and 70% at 5 years. Freedom from
recurrent symptoms was greater in the surgical bypass group
(p0.0001) (695). Whether the use of drug-eluting stents
for this application will reduce the need for subsequent
revascularization has not been determined.
Balloon angioplasty and stenting are associated with
high rates of success and better outcomes than balloon
angioplasty alone (694,696 –700), which makes endovas-
cular stenting an alternative to open surgery in patients
with obstructive disease of the subclavian or brachioce-
phalic arteries. Few studies have compared these ap-
proaches, but 1 demonstrated equal effectiveness and
fewer complications with stenting (697). Numerous re-
ports have suggested that angioplasty and stenting of the
subclavian and brachiocephalic arteries can be performed
with a high degree of technical success and safety, but
long-term follow-up data are scant (695,701–704). A
retrospective comparison of percutaneous revasculariza-
tion with carotid-subclavian bypass surgery in patients
with isolated subclavian artery disease described excellent
technical success with both methods, but the primary
patency rates at 1, 3, and 5 years were higher with bypass
surgery. Although the currently prevailing view favors
bypass surgery for good surgical candidates and percuta-
neous stenting of the subclavian artery for patients at
high risk of surgical complications, physicians experi-
enced with both techniques may prefer to take a percu-
taneous catheter-based approach initially when the anat-
omy is suitable and reserve surgery for patients with total
arterial occlusion or stenotic lesions that are anatomically
unsuited to catheter intervention.
Brachiocephalic artery occlusive disease is often ac-
companied by carotid or subclavian artery stenosis (705),
but the natural history is less well understood. Patients
may present with an asymptomatic blood pressure dis-
parity between arms or with upper-extremity claudica-
tion, subclavian steal, TIA, or stroke. Transthoracic
surgical revascularization involves aorta-innominate or
aorta-carotid bypass with subclavian artery reimplanta-
tion; brachiocephalic endarterectomy is less commonly
used. Transthoracic revascularization is preferred in pa-
tients with embolism when the source can be excluded
concurrent with distal brachiocephalic artery revascular-
ization. Graft patency is excellent, but the combined rate
of perioperative stroke and death is as high as 16%
(705,706). Survival after transthoracic arterial reconstruc-
tion has been reported as 73% and 52% at 5 and 10 years,
respectively (705).
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10.1. Neurological Risk Reduction in Patients
With Carotid Artery Disease Undergoing
Cardiac or Noncardiac Surgery
10.1.1. Recommendations for Carotid Artery
Evaluation and Revascularization Before
Cardiac Surgery
CLASS IIa
1. Carotid duplex ultrasound screening is reasonable before elective
CABG surgery in patients older than 65 years of age and in those
with left main coronary stenosis, PAD, a history of cigarette smok-
ing, a history of stroke or TIA, or carotid bruit. (Level of Evidence: C)
2. Carotid revascularization by CEA or CAS with embolic protection
before or concurrent with myocardial revascularization surgery is
reasonable in patients with greater than 80% carotid stenosis who
have experienced ipsilateral retinal or hemispheric cerebral isch-
emic symptoms within 6 months. (Level of Evidence: C)
CLASS IIb
1. In patients with asymptomatic carotid stenosis, even if severe, the
safety and efficacy of carotid revascularization before or concurrent
with myocardial revascularization are not well established. (Level of
Evidence: C)
10.1.2. Neurological Risk Reduction in Patients
With Carotid Artery Disease Undergoing
Coronary Bypass Surgery
Whether or not symptomatic of carotid atherosclerosis,
patients with high-grade carotid artery stenosis undergoing
CABG surgery face a higher risk of stroke than patients
without carotid disease, but most strokes are mechanistically
unrelated to carotid disease. Considerable evidence suggests
that patients undergoing combined CABG surgery plus
CEA are at high risk of stroke, but there is no convincing
evidence that such intervention in a patient with asymp-
tomatic stenosis undergoing CABG surgery produces ben-
efit in the majority of cases (707). In patients with symp-
tomatic carotid stenosis, published reports indicate that the
performance of CEA before CABG surgery is associated
with a lower stroke rate but a higher rate of fatal and
nonfatal MI. Combined CEA and CABG surgery has been
associated with a lower rate of MI, stroke, and death than
staged surgery in some reports, but this strategy has not
been tested in prospective trials. Other studies suggest that
the combination of CEA with CABG surgery is associated
with a higher risk of stroke and death than CABG surgery
alone (495,708). Proof is lacking that carotid revasculariza-
tion reduces adverse events in patients with asymptomatic
carotid stenosis who are undergoing myocardial revascular-
ization surgery (709), so clinical practice must follow a
patient-specific approach.
Although carotid angioplasty and stenting would appear
to be a logical alternative to CEA in this situation, catheter-
based carotid interventions require periprocedural treatment
with potent platelet-inhibitor drugs such as clopidogrel,which greatly increases the risk of major bleeding associated
with CABG surgery, and delaying antiplatelet therapy raises
the risk of stent thrombosis and stroke. Another strategy is
to perform carotid intervention immediately before coronary
surgery and administer intravenous heparin between the
procedures, but this approach and the optimum revascular-
ization strategy in general for patients with combined
carotid artery disease and CAD that requires intervention
have not been evaluated properly (707,708,710–714). The
Nationwide Inpatient Sample included 27,084 patients
discharged after undergoing CAS before CABG surgery or
combined CEA and CABG surgery during the 5 years from
2000 to 2004 (715). Of these, 96.7% underwent CEA plus
CABG surgery versus 3.3% (887 patients) who had CAS
plus CABG surgery. Fewer major adverse events were
reported among patients undergoing CAS plus CABG
surgery than among those undergoing CEA plus CABG
surgery. Patients who had CAS plus CABG surgery also
had a lower incidence of postoperative stroke (2.4% versus
3.9%) and of combined stroke and death (6.9% versus 8.6%)
than those managed by the combination of CEA with
CABG surgery (p0.001), although rates of in-hospital
mortality were similar with the 2 approaches (5.2% versus
5.4%). In this nonrandomized cohort, patients undergoing
CEA plus CABG surgery faced a 62% greater risk of
postoperative stroke than patients undergoing CAS before
CABG surgery (OR 1.62, 95% CI 1.1 to 2.5; p0.02).
There was no difference in the combined risk of stroke and
death according to treatment strategy (OR 1.26, 95% CI 0.9
to 1.6; pNS) (715). Whether the lower rate of complica-
tions with CAS than with CEA in this population under-
going CABG surgery reflects case-selection bias or an
intrinsic safety advantage remains uncertain, and the find-
ings justify the conduct of properly designed prospective
studies to compare these approaches.
10.1.3. Neurological Risk Reduction in Patients
Undergoing Noncoronary Cardiac or
Noncardiac Surgery
For guidance about the management of patients undergoing
other types of cardiac and noncardiac surgery, the reader is
referred to the 2009 ACCF/AHA Focused Update on
Perioperative Beta Blockade Incorporated Into the ACC/
AHA 2007 Guidelines on Perioperative Cardiovascular
Evaluation and Care for Noncardiac Surgery (716).
11. Nonatherosclerotic Carotid
and Vertebral Artery Diseases
Compared with atherosclerosis, nonatherosclerotic diseases
of the extracranial carotid arteries are relatively uncommon.
Among these, FMD and cervical artery dissection are the
most common.
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11.1.1. Recommendations for Management of
Patients With Fibromuscular Dysplasia of the
Extracranial Carotid Arteries
CLASS IIa
1. Annual noninvasive imaging of the carotid arteries is reasonable
initially for patients with FMD to detect changes in the extent or
severity of disease, although the effect on outcomes is unclear.
Studies may be repeated less frequently once stability has been
confirmed. (Level of Evidence: C)
2. Administration of platelet-inhibitor medication can be beneficial in
patients with FMD of the carotid arteries to prevent thromboembo-
lism, but the optimum drug and dosing regimen have not been
established. (Level of Evidence: C)
3. Carotid angioplasty with or without stenting is reasonable for pa-
tients with retinal or hemispheric cerebral ischemic symptoms
related to FMD of the ipsilateral carotid artery, but comparative data
addressing these methods of revascularization are not available.
(Level of Evidence: C)
CLASS III: NO BENEFIT
1. Revascularization is not recommended for patients with asymptom-
atic FMD of a carotid artery, regardless of the severity of stenosis.
(Level of Evidence: C)
FMD is a nonatherosclerotic, noninflammatory vascular
disease characterized by either focal stenosis or multiple
constrictions due to thickening of a layer of the arterial wall.
Multiple histological subtypes have been defined (717),
most commonly medial fibroplasia, which imparts a beaded
appearance to the carotid artery. Intimal fibroplasia, which
causes a focal, concentric, or tubular stenosis similar to
atherosclerotic narrowing, is much less common. The dis-
ease can affect any portion of the cervical or intracranial
arteries but most frequently involves the internal carotid
arteries bilaterally. The incidence of carotid FMD is low; it
is most commonly encountered in middle-aged women,
who may be symptomatic or asymptomatic. When symp-
tomatic, clinical manifestations of FMD depend on the
location and the extent of arterial obstruction. Stroke,
TIA, carotid dissection, Horner syndrome, cranial nerve
palsies, and subarachnoid hemorrhage have been de-
scribed (717–720).
The pathophysiology and natural history of FMD are
unknown. Gross pathological manifestations include
elongation, kinking, and coiling of the carotid artery.
Web-like lesions may obstruct flow, and aneurysmal
dilation of the carotid artery has been described (721).
Symptoms are thought to result from reduced blood flow
or thromboembolism. The relationship of FMD to ca-
rotid arterial dissection is poorly understood, but spon-
taneous dissection and aneurysmal degeneration are ad-
ditional causes of symptomatic events in patients with
carotid FMD.
Treatment of carotid FMD depends on whether the
patient is symptomatic. Antiplatelet therapy and sequentialimaging to monitor changes in the extent of disease over
time are generally recommended even for asymptomatic
patients. Both surgical revascularization (722) and endovas-
cular approaches have been successful in alleviating ischemic
symptoms in patients with FMD of the carotid arteries, and
percutaneous angioplasty with or without stenting increas-
ingly has been advocated on the basis of case reports and
series of limited scope (723,724).
11.2. Cervical Artery Dissection
11.2.1. Recommendations for Management of Patients
With Cervical Artery Dissection
CLASS I
1. Contrast-enhanced CTA, MRA, and catheter-based contrast angiog-
raphy are useful for diagnosis of cervical artery dissection. (Level of
Evidence: C)
CLASS IIa
1. Antithrombotic treatment with either an anticoagulant (heparin, low
molecular weight heparin, or warfarin*) or a platelet inhibitor
(aspirin, clopidogrel, or the combination of extended-release dipy-
ridamole plus aspirin*) for at least 3 to 6 months is reasonable for
patients with extracranial carotid or vertebral arterial dissection
associated with ischemic stroke or TIA (724a–724d). (Level of
Evidence: B)
CLASS IIb
1. Carotid angioplasty and stenting might be considered when isch-
emic neurological symptoms have not responded to antithrombotic
therapy after acute carotid dissection. (Level of Evidence: C)
2. The safety and effectiveness of pharmacological therapy with a
beta-adrenergic antagonist, angiotensin inhibitor, or nondihydro-
pyridine calcium channel antagonist (verapamil or diltiazem) to
lower blood pressure to the normal range and reduce arterial wall
stress are not well established. (Level of Evidence: C)
Carotid or vertebral artery dissection is an uncommon but
sometimes dramatic cause of acute or progressive neurolog-
ical ischemic symptoms. Carotid artery dissection may occur
spontaneously, unheralded by symptoms. Minor trauma
such as hyperflexion or hyperextension of the neck (the
so-called beauty parlor stroke), chiropractic manipulation,
coughing, and nose blowing have been associated with
carotid dissection (725).
Dissection results from an intimal tear that initiates an
intramural hematoma. Subintimal dissection tends to cause
stenosis, whereas subadventitial dissection can result in
aneurysmal degeneration. The underlying structural defect
of the arterial wall remains unknown, but a number of
pathological associations have been described. Specific con-
nective tissue disorders thought to form an etiologic basis
for carotid dissection include the Ehlers-Danlos syndrome
type IV, Marfan syndrome, autosomal dominant polycystic
kidney disease, hyperhomocysteinemia, and osteogenesis
imperfecta. There may also be an association with bicuspid
aortic valve, but carotid dissection is observed in only 1% to*Drugs are not listed in order of preference.
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dissection with FMD is greater, at approximately 15%, but
the mechanistic relation between these disorders is not well
understood.
Community-based studies suggest that the annual inci-
dence of spontaneous carotid artery dissection is approxi-
mately 2.5 to 3 per 100,000 population and that carotid
artery dissection accounts for approximately 2% of ischemic
strokes. The proportion is greater among younger patients,
in whom carotid dissection may account for 10% to 15% of
ischemic strokes (726). The incidence of vertebral artery
dissection has not been well defined. One of the 4 segments
of the vertebral artery (V3) is connected to highly mobile
cervical vertebrae, and this mechanical vulnerability under-
lies the presumption that sudden or excessive neck move-
ment might increase the risk of vertebral artery dissection
(727). Other suspected risk factors for cervical arterial
dissection include penetrating trauma (728) and amphet-
amine abuse (729). A structured review found that the
incidence of vertebral artery dissection or occlusion attrib-
utable to cervical manipulation in patients 45 years of age
was approximately 1.3 per 100,000 within 1 week of
manipulative therapy (730).
The clinical presentation of cervical artery dissection is
variable. Some patients develop sudden catastrophic neuro-
logical events, but the typical presentation involves pain on
one side of the head or neck, accompanied by the Horner
syndrome of asymmetrical ptosis, meiosis, and anhidrosis.
After these warning symptoms occur, cerebral or retinal
ischemia develops in 50% to 95% of cases of carotid artery
dissection. Patients with vertebral artery dissection may
present with headache, neck pain, vertigo, nausea, visual
disturbances, or syncope.
The diagnostic algorithm begins with clinical exami-
nation and brain imaging, followed by vascular imaging
when an ischemic cause is suspected. Carotid duplex
ultrasonography may identify a dissection flap and differ-
ential flow in the true and false lumens, but CTA or MRA
is increasingly used to establish the diagnosis of carotid
artery dissection, largely supplanting catheter-based and
digital subtraction angiography. Selective catheterization of
the arteries that supply the posterior cerebral circulation is
sometimes the only way to delineate collateral filling via the
circle of Willis, which may be important in guiding man-
agement. Dissection that begins cephalad of the angle of the
mandible may not be detected by ultrasound, and in these
cases contrast-enhanced CTA and MRA are superior mo-
dalities.
Treatment is usually conservative, involving anticoagula-
tion with heparin followed by warfarin; with this approach,
the prognosis is usually favorable (731–733). There have
been no placebo-controlled trials of anticoagulant or anti-
platelet agents or randomized trials comparing anticoagu-
lant and antiplatelet therapy (734). In a small observational
study of patients with cervical artery dissection conducted by
the Canadian Stroke Consortium, the annual rate of recur-rent stroke, TIA, or death was 12.4% among patients
treated with aspirin versus 8.3% in those given anticoagu-
lants (735). Anticoagulation may adversely influence the
outcome of subarachnoid hemorrhage in the event of
intracranial extension of cervical artery dissection. Regard-
less of initial antithrombotic therapy during the acute phase,
antiplatelet therapy may replace anticoagulation once symp-
toms resolve, but no uniform approach has been developed
regarding the timing of this transition, and no antithrom-
botic regimen has been established as superior to another.
Surgical or endovascular revascularization is reserved for
patients with persistent or recurrent symptoms that fail to
respond to anticoagulation. Surgical revascularization tech-
niques include direct carotid repair and resection with vein
graft replacement (736,737). Endovascular stent angioplasty
has been successful in a small number of patients but has
been associated with complications in others (738–748).
12. Future Research
As evident from the number of recommendations in this
document that are based on consensus in a void of definitive
evidence, there are vast opportunities for future research.
These begin with the need to define more precisely the
scope of clinical carotid artery disease as a cause of stroke in
major segments of the population through well-designed
population studies of ischemic stroke in which ECVD and
intracranial vascular disease are separately and objectively
classified to provide accurate estimates of disease prevalence.
A major hurdle to overcome is the lack of sound evidence
with which to target asymptomatic patients above specific
risk thresholds for detection of hemodynamically significant
carotid stenosis and, more pertinent, to identify those who
may benefit from therapeutic intervention. To date, no
screening program for detection of carotid stenosis has
demonstrated the capacity to reduce stroke risk for any
defined cohort, and as a result, no solid consensus can be
developed concerning which patients should undergo diag-
nostic screening. More work is also needed to gauge the
value of measuring the IMT of the carotid artery wall as a
way of directing preventive therapies to those at risk of
progressive carotid atherosclerosis. Outcome-based valida-
tion of the value of IMT measurements to guide treatment
interventions for individual patients would help overcome
an important impediment to proper application of this
imaging technology and improve understanding of the
pathogenesis of the most common cause of ECVD.
Despite considerable progress in understanding the
pathophysiology of atherosclerosis, the practical utility of
these morphological and biochemical assessments in pre-
dicting stroke due to ECVD requires validation by prospec-
tive studies. Given the imperfect correlation between the
severity of carotid stenosis and ischemic brain events, the
search for other indexes of plaque vulnerability linked to
stroke risk must advance. The most promising currently
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in the vessel wall in the region of carotid plaques by PET
imaging. Whether the tracers should optimally target the
intensity of local inflammation, macrophage activity, angio-
genesis, or some combination of these variables has not been
clarified. Opportunities exist for combined assessment by
PET/CT or PET/MRI to identify carotid plaque instability
and enhance the value of biomarkers of inflammation,
cytokine activation, and matrix metalloproteinase accumu-
lation as predictors of clinical events.
Advancements in noninvasive imaging technology have
accelerated the acquisition of data, overcome motion-based
artifacts, and greatly improved diagnostic accuracy to rival
that of conventional angiography for evaluation of patients
with ECVD. Ever-higher field-strength systems, more
powerful magnetic gradients, and simplification of sophis-
ticated software promise to expand the availability of CT
and MRA to broader segments of the patient population,
but there is an urgent need to overcome limitations that lead
to overestimation of stenosis severity and reliably distinguish
subtotal from complete arterial occlusion. We must develop
intravascular contrast materials free of the nephrotoxicity,
osmotic effects, allergic reactions, and other toxicity of
agents currently used for catheter angiography, CTA, and
MRA to allow application of these technologies across a
wider range of patient comorbidities. As these challenges
are met, however, it will become more essential to clarify
which imaging methods can reliably identify patients at
significantly increased risk of stroke, because data of this
type ultimately represent the only foundation on which to
recommend broad application of techniques for evaluation
of patients with cervical arterial disease.
The value of specific therapies to prevent stroke, even in
symptomatic patients with severe carotid artery stenosis,
largely lacks validation. An example involves antihyperten-
sive therapy in those with impaired cerebral perfusion due to
arterial obstructive disease. Clinical trials evaluating treat-
ment of hypertension in patients with ECVD could sub-
stantiate specific approaches and better inform future clin-
ical practice guidelines. Similarly, the relationship between
cholesterol and ischemic stroke should be buttressed by
stronger evidence than currently exists, because findings
from population-based studies have been inconsistent.
There are multiple causes of ischemic stroke, and available
studies have not specifically established a benefit of statins
(or other lipid-lowering strategies) to reduce the frequency
or severity of stroke in patients with ECVD, so our
recommendations are based on inference. Statins not only
decrease cholesterol but also stabilize the endothelial cell
layer, increase the bioavailability of nitric oxide, reduce
oxidative stress, and decrease inflammation in the vascular
wall and in the atheromatous plaque itself, and studies
focused on these specific mechanisms in patients with
ECVD would not only shed light on the optimum timing
and intensity of drug therapy but would also provide
important clues to other methods of stroke prevention. Thesame can be said of interventions to manage blood glucose
homeostasis in patients with diabetes, even though the risk
of ischemic stroke in patients with diabetes mellitus is
manifold higher than in those without this prevalent con-
dition. Finally, among the roster of risk factors, it is not even
clear whether regular exercise reduces the risk of first or
recurrent stroke independent of beneficial effects on other
risk factors, and this plays out daily as an unanswered
question faced by thousands of patients with ECVD.
Although antiplatelet drugs reduce the risk of stroke
compared with placebo in patients with TIA or previous
stroke, no adequately powered studies have demonstrated
their efficacy for stroke prevention in asymptomatic patients
with ECVD. Further studies are needed to evaluate the
safety and efficacy of newer antiplatelet agents, particularly
those in the thienopyridine class, relative to aspirin in
patients with asymptomatic ECVD. It is critical to define
optimum antithrombotic therapy for patients who experi-
ence recurrent cerebral ischemia during antiplatelet therapy,
which requires not only studies of comparative effectiveness
but careful genetic profiling with respect to the factors that
contribute to drug resistance. Parallel work is needed to
establish the optimum method to assess platelet function as
a guide to assessment of drug resistance, to establish
whether resistance to platelet inhibitors is associated with a
greater risk of stroke, and to clarify whether testing for or
treatment of drug resistance leads to improved clinical
outcomes.
Few studies have investigated the role of anticoagulant
drugs in the management of patients with ECVD who
develop acute ischemic stroke, especially after administra-
tion of thrombolytic therapy. If parallels to the management
of patients with acute MI continue to expand in the care of
acute stroke victims, then earlier catheter-based revascular-
ization will be tested, but such studies must be advanced
carefully because of the high risk of exacerbating irreversible
ischemic injury and functional deficit. The judicious use of
thrombin inhibitors, factor Xa inhibitors, and other anti-
thrombotic agents in conjunction with antiplatelet agents is
fertile ground for future investigation but one equally
fraught with risk.
In the days and weeks after the acute phase of ischemic
stroke, it remains unclear whether women benefit as much
as men from CEA, and further studies must aim to recruit
sufficient numbers of women and older patients to address
these important demographic subsets of patients with symp-
tomatic ECVD. This begs the question of how to address
differences in the results of CEA based on race, ethnicity,
and other clinical features. Such studies must consider not
only the differential rates at which patients develop ECVD
but also address uncertainties about how these differences
reflect biological factors as opposed to inequities in access to
diagnosis and treatment. The outcomes of trials that eval-
uate revascularization in these subjects must incorporate
comprehensive atherosclerotic risk factor management to
ensure accurate assessment of treatment effects and their
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ful attention should be paid to determining the optimum
duration and intensity of antithrombotic therapy after re-
vascularization, because women, older patients, and mem-
bers of other ethnic groups may not respond the same way
as middle-aged white males. This applies during the
periprocedural period as well as over the longer term, and it
is important to define when in the course of longitudinal
care it becomes reasonable for such therapy to merge into
the regimen recommended for long-term prevention of
ischemic events in patients with atherosclerosis. The reasons
for differences in outcomes based on these demographic
variables have not been investigated, and there may be a
need for both extravascular and intravascular imaging to
provide more detailed information about the vascular lu-
men, pathobiology of atherosclerosis, plaque composition,
and calcification, any or all of which could provide useful
clues to the myriad clinical manifestations of ECVD.
CREST has answered important questions about the
value of CAS relative to CEA but raised several others.
Rigorous training and credentialing of the operators con-
tributed to the low absolute rates of stroke, MI, and death
during the CREST study, but delivering this level of success
in clinical practice outside the rubric of a controlled clinical
trial will both raise practical challenges and hopefully
stimulate objective studies of which physicians to train, how
to train them, and for what period of time. The event rates
reported by the CREST investigators were generally low
with either method of revascularization among symptomatic
patients of either sex, but there was an important difference
related to patient age, the explanation for which is un-
known. More research is needed to validate this observation
and uncover the conditions responsible for the differential
advantage of CEA over CAS among older patients. The
most pressing question, however, is how either technique of
revascularization compares with intensive contemporary
medical therapy, particularly among asymptomatic patients,
and a direct comparative trial of both methods of revascu-
larization versus modern medical management should be
initiated as quickly as feasible and include a sufficiently
broad range of patients to permit meaningful analysis of
subgroups based on age, gender, ethnicity, and risk status.
Beyond these many issues involving carotid atherosclero-
sis lie still deeper challenges involving less common forms of
ECVD. In this uncharted territory of future research are
questions about the pathophysiology and clinical outcomes
of patients with FMD of the cervical arteries, including its
relationship to carotid arterial dissection and ischemic brain
events. The management of dissection itself is fodder for
fresh investigation, beginning with placebo-controlled trials
of anticoagulant or antiplatelet drug regimens, with or
without CAS. Huge gaps in knowledge of vertebral arterial
disease will be more difficult to address because of its relative
infrequency compared with carotid stenosis. This circum-
stance requires well-designed collaborative registries that
capture in a structured format data about prevalence, patho-physiology, natural history, and prognosis. Before conclu-
sions can be drawn about which findings on noninvasive
imaging are relevant to clinical decision making, the accu-
racy of each method compared with catheter-based angiog-
raphy must be established more clearly. Given the plethora
of medical, interventional, and surgical approaches available
for treatment of patients with vertebral artery disease, clarity
about comparative effectiveness can come only from well-
designed randomized trials that involve a large number of
practitioners and that are conducted across a broad range of
clinical sites. Our recommendations that medical manage-
ment follow guidelines set forth for patients with disease of
the carotid arteries are largely extrapolative, awaiting con-
firmation or refutation through soundly designed prospec-
tive studies, but the lower rate of diagnosis of vertebral
artery stenosis than carotid artery disease is a root cause of
the inherent difficulty in demonstrating therapeutic benefit.
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APPENDIX 3. ABBREVIATION LIST
CABG  coronary artery bypass graft IVUS  intravascular ultrasound
CAD  coronary artery disease LDL  low-density lipoprotein
CAS  carotid artery stenting MI  myocardial infarction
CEA  carotid endarterectomy MRA  magnetic resonance angiography
CT  computed tomography MRI  magnetic resonance imaging
CTA  computed tomography angiography NSAID  nonsteroidal anti-inflammatory drugs
ECVD  extracranial carotid and vertebral artery disease PAD  peripheral arterial disease
EPD  embolic protection device PET  positron emission tomography
FMD  fibromuscular dysplasia TIA  transient ischemic attack
IMT  intima-media thickness
